Document:

EX-10.5

 Exhibit 10.5 

FIBROGEN, INC. 
 2014
EMPLOYEE STOCK PURCHASE PLAN 
 ADOPTED BY THE
BOARD OF DIRECTORS: SEPTEMBER 09, 2014 
 APPROVED
BY THE STOCKHOLDERS: SEPTEMBER 30, 2014 
  

	1.	 GENERAL; PURPOSE. 

(a)      The Plan provides a means by which Eligible Employees of the Company and certain
designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. 

(b)      The Company, by means of the Plan, seeks to retain the services of such
Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. 

 

	2.	 ADMINISTRATION. 

(a)      The Board will administer the Plan unless and until the Board delegates
administration of the Plan to a Committee or Committees, as provided in Section 2(c). 

(b)      The Board will have the power, subject to, and within the limitations of, the
express provisions of the Plan: 
 (i)       To determine how and when
Purchase Rights will be granted and the provisions of each Offering (which need not be identical). 

(ii)      To designate from time to time which Related Corporations of the Company will
be eligible to participate in the Plan. 
 (iii)     To construe and interpret the Plan and
Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems
necessary or expedient to make the Plan fully effective. 
 (iv)     To settle all
controversies regarding the Plan and Purchase Rights granted under the Plan. 

(v)      To suspend or terminate the Plan at any time as provided in Section 12. 

(vi)     To amend the Plan at any time as provided in Section 12. 

(vii)    Generally, to exercise such powers and to perform such acts as it deems necessary or
expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. 

  
 1 

 (viii)         To adopt such
procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States. 

(c)      The Board may delegate some or all of the administration of the Plan to a
Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including
the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions,
not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of
the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the
Plan. 
 (d)      All determinations, interpretations and constructions made by
the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
  

	3.	 SHARES OF COMMON STOCK SUBJECT TO THE
PLAN. 

 (a)      Subject to the provisions of
Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 1,600,0001 shares of Common Stock, plus
the number of shares of Common Stock that are automatically added on January 1 of each year, commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to the lesser of
(i) 1.0% of the total number of shares of Capital Stock outstanding on December 31 of the preceding fiscal year, and (ii) 1,200,0002 shares of Common Stock. Notwithstanding the
foregoing, the Board may act prior to the first day of any fiscal year to provide that there will be no January 1 increase in the share reserve for such fiscal year or that the increase in the share reserve for such fiscal year will be a lesser
number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. 

(b)      If any Purchase Right granted under the Plan terminates without having been
exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.  

(c)      The stock purchasable under the Plan will be shares of authorized but unissued
or reacquired Common Stock, including shares repurchased by the Company on the open market.  
  

	1 	 The share limit was adjusted from 4,000,000 to 1,600,000 pursuant to the 1-for-2.5 reverse split of the Company’s Common Stock, effective
November 10, 2014. 

	2 	 The share limit was adjusted from 3,000,000 to 1,200,000 pursuant to the 1-for-2.5 reverse split of the Company’s Common Stock, effective
November 10, 2014. 

  
 2 

2014 EMPLOYEE STOCK PURCHASE PLAN 

	4.	 GRANT OF PURCHASE RIGHTS; OFFERING. 

(a)       The Board may from time to time grant or provide for the grant of Purchase
Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will
deem appropriate, and will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by
reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the
Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive. 

(b)       If a Participant has more than one Purchase Right outstanding under the Plan,
unless he or she otherwise indicates in forms delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase
Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical
exercise prices) will be exercised. 
 (c)       The Board will have the
discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the
Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first
Trading Day of such new Purchase Period.  
  

	5.	 ELIGIBILITY. 

(a)       Purchase Rights may be granted only to Employees of the Company or, as the
Board may designate in accordance with Section 2(b), to Employees of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has
been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or
greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company or the Related
Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.  

(b)       The Board may provide that each person who, during the course of an Offering,
first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs  

  
 3 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 
thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as
any Purchase Rights originally granted under that Offering, as described herein, except that: 

(i)      the date on which such Purchase Right is granted will be the “Offering
Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; 

(ii)     the period of the Offering with respect to such Purchase Right will begin on its
Offering Date and end coincident with the end of such Offering; and 
 (iii)    the Board may
provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering. 

(c)    No Employee will be eligible for the grant of any Purchase Rights if, immediately after any
such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the
rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.

 (d)    As specified by Section 423(b)(8) of the Code, an Eligible Employee may be
granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of
the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective
Offering Dates) for each calendar year in which such rights are outstanding at any time. 

(e)    Officers of the Company and any designated Related Corporation, if they are otherwise
Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D)
of the Code will not be eligible to participate. 
  

	6.	 PURCHASE RIGHTS; PURCHASE PRICE. 

(a)    On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan,
will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee’s
earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later
than the end of the Offering. 

  
 4 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 (b)    The Board will establish one or more Purchase
Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. 

(c)    In connection with each Offering made under the Plan, the Board may specify (i) a
maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such
Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase
Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock
available will be made in as nearly a uniform manner as will be practicable and equitable. 

(d)    The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be
not less than the lesser of: 
 (i)      an amount equal to 85% of the Fair
Market Value of the shares of Common Stock on the Offering Date; and 
 (ii)     an amount
equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. 
  

	7.	 PARTICIPATION; WITHDRAWAL; TERMINATION. 

(a)    An Eligible Employee may elect to authorize payroll deductions as the means of making
Contributions by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified
by the Board. Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be
deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering
but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions.
If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date. 

(b)    During an Offering, a Participant may cease making Contributions and withdraw from the
Offering by delivering to the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately
terminate and the Company will distribute to such Participant all of his or her accumulated but unused  

  
 5 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 
Contributions and such Participant’s Purchase Right in that Offering shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or her
eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. 

(c)    Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately
if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company will
distribute to such individual all of his or her accumulated but unused Contributions.  

(d)    During a Participant’s lifetime, Purchase Rights will be exercisable only by such
Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10.  

(e)    Unless otherwise specified in the Offering, the Company will have no obligation to pay
interest on Contributions. 
  

	8.	 EXERCISE OF PURCHASE RIGHTS. 

(a)    On each Purchase Date, each Participant’s accumulated Contributions will be applied to
the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically
provided for in the Offering. 
 (b)    If any amount of accumulated Contributions remains
in a Participant’s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will
be held in such Participant’s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will
be distributed to such Participant after the final Purchase Date, without interest. If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Common Stock is at least equal to the amount required to
purchase one whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such
Offering without interest. 
 (c)    No Purchase Rights may be exercised to any extent
unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and
other securities and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date
will be delayed until the shares of Common Stock are subject to such an effective registration  

  
 6 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 
statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum
extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the
Participants without interest. 
  

	9.	 COVENANTS OF THE COMPANY. 

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction
over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company
deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to
issue and sell Common Stock upon exercise of such Purchase Rights. 
  

	10.	 DESIGNATION OF BENEFICIARY. 

(a)    The Company may, but is not obligated to, permit a Participant to submit a form designating
a beneficiary who will receive any shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but
is not obligated to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. 

(b)    If a Participant dies, in the absence of a valid beneficiary designation, the Company will
deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If, to the knowledge of the Company, no executor or administrator has been appointed, the Company, in its sole discretion, may
deliver such shares of Common Stock and/or Contributions to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. 

 

	11.	 ADJUSTMENTS UPON CHANGES IN COMMON STOCK;
CORPORATE TRANSACTIONS. 

 (a)    In the
event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of
securities by which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights,
and (iv) the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive.  

(b)    In the event of a Corporate Transaction, then: (i) any surviving corporation or
acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to 

  
 7 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 
acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent
company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common Stock within ten business days
prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. 
  

	12.	 AMENDMENT, TERMINATION OR SUSPENSION OF THE
PLAN. 

 (a)    The Board may amend the Plan at any time in
any respect the Board deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is
required by applicable law or listing requirements, including any amendment that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals
eligible to become Participants and receive Purchase Rights, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan,
(iv) materially extends the term of the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or
listing requirements. 
 (b)    The Board may suspend or terminate the Plan at any time.
No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated. 

(c)    Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights
granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted,
(ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder
relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable
tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements
of Section 423 of the Code. 
  

	13.	 EFFECTIVE DATE OF PLAN. 

The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised
unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board.

  
 8 

2014 EMPLOYEE STOCK PURCHASE PLAN 

	14.	 MISCELLANEOUS PROVISIONS. 

(a)      Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights
will constitute general funds of the Company. 
 (b)      A Participant will not be
deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are
recorded in the books of the Company (or its transfer agent). 
 (c)      The Plan and
Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or be deemed to create in any way whatsoever any obligation on the part of any
Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant. 

(d)      The provisions of the Plan will be governed by the laws of the State of
California without resort to that state’s conflicts of laws rules. 
  

	15.	 DEFINITIONS. 

As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

(a)      “Board” means the Board of
Directors of the Company. 

(b)      “Capital Stock” means each
and every class of common stock of the Company, regardless of the number of votes per share. 

(c)      “Capitalization Adjustment”
means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company
through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares,
change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. 

(d)      “Code” means the Internal
Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. 

(e)      “Committee” means a
committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c). 

(f)      “Common Stock” means, as of
the IPO Date, the common stock of the Company. 

  
 9 

2014 EMPLOYEE STOCK PURCHASE PLAN 

(g)      “Company” means FibroGen,
Inc., a Delaware corporation. 

(h)      “Contributions” means the payroll
deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided
for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. 

(i)      “Corporate Transaction”
means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i)      a sale or other disposition of all or substantially all, as determined by the
Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii)      a sale or other disposition of at least 90% of the outstanding securities of
the Company; 
 (iii)      a merger, consolidation or similar transaction following
which the Company is not the surviving corporation; or 
 (iv)      a merger,
consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of
the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. 

(j)      “Director” means a member of
the Board. 
 (k)      “Eligible
Employee” means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to
participate set forth in the Plan. 

(l)      “Employee” means any person,
including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a
Director to be considered an “Employee” for purposes of the Plan.  

(m)      “Employee Stock Purchase
Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code. 

(n)      “Exchange Act” means the
Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder. 

(o)      “Fair Market Value” means,
as of any date, the value of the Common Stock determined as follows: 

  
 10 

2014 EMPLOYEE STOCK PURCHASE PLAN 

 (i)      If the Common Stock is listed on
any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest
volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of
determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. 

(ii)      In the absence of such markets for the Common Stock, the Fair Market Value
will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code. 

(iii)      Notwithstanding the foregoing, for any Offering that commences on the IPO
Date, the Fair Market Value of the shares of Common Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified in the final prospectus for that
initial public offering. 
 (p)      “IPO
Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.

 (q)      “Offering”
means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the
“Offering Document” approved by the Board for that Offering. 

(r)       “Offering Date” means a
date selected by the Board for an Offering to commence. 

(s)      “Officer” means a person who
is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act. 

(t)      “Participant” means an
Eligible Employee who holds an outstanding Purchase Right. 

(u)      “Plan” means this FibroGen,
Inc. 2014 Employee Stock Purchase Plan. 

(v)      “Purchase Date” means one or
more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. 

(w)      “Purchase Period” means a
period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. 

(x)      “Purchase Right” means an
option to purchase shares of Common Stock granted pursuant to the Plan. 

  
 11 

2014 EMPLOYEE STOCK PURCHASE PLAN 

(y)      “Related Corporation” means
any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. 

(z)      “Securities Act” means the
Securities Act of 1933, as amended. 

(aa)      “Trading Day” means any day
on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for
trading. 

  
 12 

2014 EMPLOYEE STOCK PURCHASE PLANEX-10.18

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.18 
 AMENDED AND RESTATED 

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

(for the US and Certain Other Territories) 
  

between 
  

FIBROGEN, INC. 
  

and 
  

ASTRAZENECA AB 

 TABLE OF CONTENTS 
  

					
	 ARTICLE 1 DEFINITIONS
	  	 	2	  
		
	 ARTICLE 2 COLLABORATION; GOVERNANCE
	  	 	16	  
		
	 ARTICLE 3 DEVELOPMENT
	  	 	25	  
		
	 ARTICLE 4 REGULATORY MATTERS
	  	 	33	  
		
	 ARTICLE 5 COMMERCIALIZATION
	  	 	36	  
		
	 ARTICLE 6 MANUFACTURE AND SUPPLY
	  	 	41	  
		
	 ARTICLE 7 LICENSES AND EXCLUSIVITY
	  	 	44	  
		
	 ARTICLE 8 FINANCIALS
	  	 	50	  
		
	 ARTICLE 9 INTELLECTUAL PROPERTY
	  	 	62	  
		
	 ARTICLE 10 REPRESENTATIONS AND WARRANTIES
	  	 	70	  
		
	 ARTICLE 11 INDEMNIFICATION
	  	 	75	  
		
	 ARTICLE 12 CONFIDENTIALITY
	  	 	77	  
		
	 ARTICLE 13 TERM AND TERMINATION
	  	 	81	  
		
	 ARTICLE 14 DISPUTE RESOLUTION AND GOVERNING LAW
	  	 	86	  
		
	 ARTICLE 15 MISCELLANEOUS
	  	 	88	  
		
	 EXHIBIT A – TERRITORY – EXCLUDED COUNTRIES
	  	 	1	  
		
	 EXHIBIT B – DFCI AGREEMENT
	  	 	1	  
		
	 EXHIBIT C – CHEMICAL STRUCTURE OF FG-4592
	  	 	1	  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	 EXHIBIT D – FIELD INDICATIONS
	  	 	1	  
		
	 EXHIBIT E – LISTED PATENTS
	  	 	1	  
		
	 EXHIBIT F – ASTRAZENECA’S ANTI-CORRUPTION RULES AND POLICIES
	  	 	1	  
		
	 EXHIBIT G – INITIAL MEMBERS OF THE JSC
	  	 	1	  
		
	 EXHIBIT H – INITIAL DEVELOPMENT PLAN
	  	 	1	  
		
	 EXHIBIT I – U.S. CO-COMMERCIALIZATION TERMS
	  	 	1	  
		
	 EXHIBIT J – DEVELOPMENT SUPPLY TERMS
	  	 	1	  
		
	 EXHIBIT K – COMMERCIAL SUPPLY TERMS
	  	 	1	  
		
	 EXHIBIT L – INVOICING REQUIREMENTS
	  	 	1	  
		
	 EXHIBIT M – PATENTS THAT MAY BE EXTENDED
	  	 	1	  
		
	 EXHIBIT N – JOINT PRESS RELEASE
	  	 	1	  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 AMENDED AND RESTATED 

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

THIS AMENDED AND RESTATED LICENSE,
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of October 16, 2014 (the “Execution Date”), and
effective as of July 30, 2013 (the “Effective Date”) by and between FIBROGEN, INC., a Delaware corporation having its principal place of business at 409 Illinois St.,
San Francisco, California 94158, United States (“FibroGen”) and ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with offices at Pepparedsleden 1, 431 83
Mölndal, Gothenburg, Sweden (“AstraZeneca”). FibroGen and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

BACKGROUND 

A.        AstraZeneca is a fully-integrated, global pharmaceutical company with
expertise in the research, development, manufacture and commercialization of human therapeutic products. 

B.        FibroGen is a biotechnology company with expertise in the discovery,
research, development and manufacture of small molecule prolyl hydroxylase inhibitors that modulate hypoxia-inducible factor for the treatment of anemia. 

C.        FibroGen is developing certain of such compounds in collaboration
with Astellas Pharma Inc. (“Astellas”), its exclusive licensee for Japan, Europe, the Commonwealth of Independent States (CIS), the Middle East and South Africa pursuant to certain collaboration agreements between FibroGen
and Astellas (collectively, the “Astellas Collaboration”). 

D.        AstraZeneca and FibroGen desire to establish as of Effective Date a
collaboration for the joint continued development, including regulatory submission, and, if successful, commercialization of certain of such compounds in the U.S. and all countries of the world other than those subject to the existing Astellas
Collaboration. 
 E.        With respect to the collaboration between the
Parties in China, the development and commercialization activities are governed by that certain License, Development and Commercialization Agreement (China) by and between FibroGen China Anemia Holdings, Ltd., Beijing FibroGen Medical Technology
Development Co., Ltd., and FibroGen International (Hong Kong) Limited, Affiliates of FibroGen, and AstraZeneca, of even date herewith (the “China Agreement”), except that a portion of the governance structure for China shall
be as set forth in this Agreement, and the Parties’ activities with respect to all other countries not licensed to Astellas are governed by this Agreement. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
promises, covenants and conditions contained in this Agreement, the Parties agree as follows: 

  
 1. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 1 

DEFINITIONS 

As used in this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have
the meanings set forth in this Article 1. Except where the context otherwise requires, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a
number of days, unless otherwise specified, such number refers to calendar days. In addition, the terms “includes,” “including,” “include” and derivative forms of them shall be deemed followed by the phrase
“without limitation” (regardless of whether it is actually written there (and drawing no implication from the actual inclusion of such phrase in some instances after such terms but not others)). 

1.1        “Acquiror” has the meaning set forth in
Section 15.5. 
 1.2        “Affiliate” means,
with respect to a particular Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word “control” (including, with
correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and
policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 

1.3        “Alliance Manager” has the meaning set forth
in Section 2.7. 
 1.4        “Annual Net Sales”
means the Net Sales made during any given Calendar Year. 

1.5        “Anti-Corruption Laws” means the U.S.
Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

1.6        “Astellas” has the meaning set forth in
Section C on the first page. 
 1.7        “Astellas
Agreements” means the Astellas EU Agreement and the Astellas Japan Agreement. 

1.8        “Astellas Collaboration” has the meaning set
forth in Section C on the first page. 
 1.9        “Astellas EU
Agreement” means the Anemia License and Collaboration Agreement between FibroGen and Astellas with respect to the countries listed on Exhibit A (other than Japan) effective April 28, 2006, as amended from time to time. 

1.10      “Astellas Japan Agreement” means the Collaboration
Agreement between FibroGen and Astellas with respect to Japan effective June 1, 2005, as amended from time to time. 

1.11      “AstraZeneca Inventions” has the meaning set forth in
Section 7.8(d). 

  
 2. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.12      “AstraZeneca
Know-How” means all Information Controlled as of the Effective Date or thereafter during the Term by AstraZeneca and/or its Affiliate(s) that is reasonably necessary or useful for the research, development, manufacture, use, importation
or sale of Products in the Field. For clarity, the use of “Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s acquisition of or by AstraZeneca, except as provided in
Section 15.5. For additional clarity, AstraZeneca Know-How shall exclude rights under any AstraZeneca Patents and AstraZeneca’s interest in the Joint Patents and Joint Inventions. 

1.13      “AstraZeneca Patents” means all Patents that are
Controlled as of the Effective Date or thereafter during the Term by AstraZeneca and/or its Affiliate(s) and that claim the composition of matter, manufacture or use of one or more Collaboration Compounds or Products or that would otherwise be
infringed (or with respect to patent applications, would be infringed if issued or granted with the then-currently pending claims), absent a license, by the manufacture, use or sale of any Collaboration Compounds or Product. For clarity, the use of
“Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s acquisition of or by, AstraZeneca except as provided in Section 15.5. 

1.14      “AstraZeneca Anti-Corruption Rules and Policies” means
the key principles from AstraZeneca’s ABAC and External Interactions Policies regarding anti-bribery and corruption issues, attached as Exhibit F to this Agreement, as the same may be amended, modified or supplemented from time to time
as notified by AstraZeneca to FibroGen. 
 1.15      “AstraZeneca
Technology” means the AstraZeneca Patents, AstraZeneca Know-How, and AstraZeneca’s interest in Joint Patents and Joint Inventions. 

1.16      “Bankrupt Party” has the meaning set forth in Section
13.9(b). 
 1.17      “Business Day” means a day other than a
Saturday, Sunday or bank or other public holiday in San Francisco, California, the UK or Sweden. 

1.18      “Calendar Quarter” means each successive period of
three (3) calendar months commencing on January 1, April 1, July 1 and October 1. 

1.19      “Calendar Year” means each successive period of twelve
(12) calendar months commencing on January 1. 

1.20      “Carcinogenicity Studies” means the following
carcinogenicity studies in rats and mice: (1) [*]. 
 1.21      “China
Agreement” has the meaning set forth in Section E on the first page. 

1.22      “China Committee” means the governing committee
established under the China Agreement, and any successor or other committee or governing body that serves the same functions under the China Agreement. 

  
 3. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.23      “CKD
Indications” means (a) treatment of anemia in patients with chronic kidney disease undergoing dialysis, and (b) treatment of anemia in patients with chronic kidney disease not undergoing dialysis. 

1.24      “Clinical Trial” means any human clinical trial of a
Product. 
 1.25      “Co-Commercialization Agreement” has the
meaning set forth in Section 5.10. 
 1.26      “Collaboration”
has the meaning set forth in Section 2.1. 
 1.27      “Collaboration
Compound” means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and
amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)). 

1.28      “Collaboration Inventions” has the meaning set forth in
Section 9.2. 
 1.29      “Combination Product” means a Product
that is comprised of or contains a Collaboration Compound as an active ingredient together with one (1) or more other active ingredients and is sold either as a fixed dose/unit or as separate doses/units in a single package. 

1.30      “Commercialization” means the commercial manufacture,
marketing, promotion, sale and/or distribution of Products in the Territory. Commercialization includes commercial activities conducted in preparation for Product launch in each indication. “Commercialize” has a correlative
meaning. 
 1.31      “Commercialization Costs” means all costs
incurred by or on behalf of FibroGen that are directly and reasonably allocable to the conduct of activities allocated to FibroGen under the U.S. Commercialization Plan or Co-Commercialization Agreement for the Commercialization of Products in the
U.S. 
 1.32      “Commercially Reasonable Efforts” means, with
respect to a Party’s obligations under this Agreement to Develop or Commercialize a Product, the carrying out of such obligations or tasks with a level of efforts and resources consistent with the commercially reasonable practices of
(a) in the case of AstraZeneca, a pharmaceutical company the size and geographical scope of AstraZeneca and (b) in the case of FibroGen, a biotechnology company the size and geographical scope of FibroGen, in each case (a) and
(b) for the development or commercialization of similarly situated pharmaceutical products as such Product and at a similar stage of development or commercialization, taking into consideration their safety and efficacy, their cost to develop,
the nature and extent of their market exclusivity (including patent coverage and regulatory exclusivity), the likelihood of Regulatory Approval, their expected profitability, including the amounts of marketing and promotional expenditures with
respect to such products and generic products, and the competitiveness of alternative compounds and products. Commercially Reasonable Efforts requires that the Party: (a) promptly assign responsibility for such obligations or tasks to specific
employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (b) set and consistently seek to achieve specific and meaningful objectives for carrying out such obligations, and (c) consistently make and
implement decisions and allocate 

  
 4. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
resources designed to advance progress with respect to such objectives. For the avoidance of doubt, the commitment to use “Commercially Reasonable Efforts” shall not preclude the
suspension or discontinuance by AstraZeneca of any Product, if appropriate, based on the foregoing considerations. 

1.33      “Committee” means the Joint Steering Committee, Joint
Development Committee, Joint Commercialization Committee or IP Committee, or any other subcommittee established under Article 2, as applicable. 

1.34      “Compliance Audit” has the meaning set forth in Section
10.3(e). 
 1.35      “Confidential Information” means, with
respect to a Party, all Information of such Party that is disclosed to the other Party under this Agreement, which may include, without limitation, specifications, know-how, trade secrets, technical information, models, business information,
inventions, discoveries, methods, procedures, formulae, protocols, techniques, data, and unpublished patent applications, whether disclosed in oral, written, graphic, or electronic form. All confidential Information disclosed by either Party
pursuant to the Existing Confidentiality Agreement shall be deemed to be Confidential Information of the disclosing Party hereunder (with the mutual understanding and agreement that any use or disclosure thereof that is authorized under Article 12
shall not be restricted by, or be deemed a violation of, such Existing Confidentiality Agreement). 

1.36      “Control” means, with respect to any material,
Information, or intellectual property right, that a Party (a) owns such material, Information, or intellectual property right, or (b) has a license or right to use to such material, Information, or intellectual property right, in each case
with the ability to grant to the other Party access, a right to use, or a license, or a sublicense (as applicable) to such material, Information, or intellectual property right on the terms and conditions set forth herein, without violating the
terms of any agreement or other arrangement with any Third Party. 

1.37      “Core Indication” means any of the following:
(a) treatment of anemia in patients with chronic kidney disease undergoing dialysis, (b) treatment of anemia in patients with chronic kidney disease not undergoing dialysis, (c) [*]). 

1.38      “Covenant Period 1” has the meaning set forth in
Section 7.4(a)(ii). 
 1.39      “Covenant Period 2” has the
meaning set forth in Section 7.4(a)(iii). 
 1.40      “CPI-U”
means the Consumer Price Index for All Urban Consumers (All Items), or any successor to such published measure, not seasonally adjusted, as published by the U.S. Department of Labor Bureau of Labor Statistics. 

1.41      “Designated Indication” has the meaning set forth in
Section 3.5(a). 
 1.42      “Designated Product” has the
meaning set forth in Section 8.4(a). 
 1.43      “Development”
means all activities that relate to (a) obtaining, maintaining or expanding Regulatory Approval of a Product for one or more indications or (b) developing the 

  
 5. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
process for the manufacture of clinical and commercial quantities of drug substance or drug Product. This includes: (i) preclinical testing, toxicology and Clinical Trials;
(ii) preparation, submission, review, statistical analysis, report writing and development of data or information for the purpose of submission to a governmental authority to obtain, maintain and/or expand Regulatory Approval of a Product, and
outside counsel regulatory legal services related thereto; and (iii) manufacturing process development and scale-up for drug substance and drug product, test method development, packaging development, stability testing, qualification and
validation, production of drug substance and drug product, in bulk for preclinical and clinical studies, and related quality assurance technical support activities; provided, however, that Development shall exclude Commercialization. For clarity,
Development shall include those Phase 4 Clinical Trials that are included in clause (b) of the definition of Phase 4 Clinical Trials. “Develop” has a correlative meaning. 

1.44      “Development Budget” means the budget associated with
the activities conducted under the Development Plan for the U.S., detailing the anticipated Development Costs. 

1.45      “Development Costs” means all costs incurred by or on
behalf of FibroGen or AstraZeneca that are reasonably allocable to the Development of Products for the U.S. in accordance with the Development Plan, which shall equal the sum of (a) Personnel Costs, (b) the Fully Burdened Cost of
Collaboration Compound or Product or comparator drug, concomitant drug, placebo or other materials used in any Clinical Trial or Nonclinical Studies, and (c) all other out-of-pocket costs, in each case for activities for the U.S. 

1.46      “Development Data” has the meaning set forth in Section
3.10(a). 
 1.47      “Development Plan” means the plan for
conducting collaborative Development of Products for approval and use in the U.S. and RoW, as set forth in Section 3.2(a). 

1.48      “Development Sharing Period” means the time period
commencing on August 1, 2013 and ending on the date on which the Parties have incurred two hundred thirty-three million Dollars ($233,000,000) in Development Costs. 

1.49      “Development Strategy” has the meaning set forth in
Section 3.2(c). 
 1.50      “DFCI Agreement” means the License
Agreement between FibroGen and the Dana-Farber Cancer Institute, Inc. (“DFCI”), dated March 29, 2006, a redacted copy of which is attached hereto as Exhibit B. 

1.51      “Distributor” has the meaning set forth in Section
7.3(c). 
 1.52      “Dollar” or “$”
means United States dollar. 
 1.53      “ESA Approved
Indications” means the following indications: (a) treatment of anemia in patients with chronic kidney disease undergoing dialysis, (b) treatment of anemia in patients with chronic kidney disease not undergoing dialysis, (c)
[*]. 
 1.54      “EU” means all of the European Union member
states as of the applicable time during the Term. 

  
 6. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.55      “Executive
Officer” means, in the case of AstraZeneca, AstraZeneca’s Chief Executive Officer or any senior executive designated by and who reports directly to the Chief Executive Officer of AstraZeneca, and in the case of FibroGen,
FibroGen’s Chief Executive Officer. 
 1.56      “Existing
Confidentiality Agreement” means, collectively, the Non-Disclosure Agreement between FibroGen and AstraZeneca dated June 21, 2012, as amended February 7, 2013, and May 23, 2013, and the Non-Disclosure Agreement between
FibroGen and AstraZeneca dated April 1, 2013. 

1.57      “FCPA” means the U.S. Foreign Corrupt Practices Act of
1977, as amended, including the rules and regulations thereunder. 

1.58      “FDA” means the United States Food and Drug
Administration or its successor. 
 1.59      “FD&C Act”
means the United States Federal Food, Drug and Cosmetic Act, as amended. 

1.60      “FG-4592” means the molecule with the chemical
structure set forth on Exhibit C. 
 1.61      “FibroGen
IPO” means the initial public offering of its securities by FibroGen in any of the U.S., United Kingdom, Spain, France, Italy, Germany, Japan, China or Hong Kong. 

1.62      “FibroGen Know-How” means all Information Controlled as
of the Effective Date or thereafter during the Term by FibroGen and/or its Affiliate(s) and reasonably necessary or useful for the development, manufacture, use, importation or sale of Collaboration Compounds or Products in the Field; including,
without limitation, any such Information made or generated by or on behalf of FibroGen or its Affiliate in the course of performing FibroGen’s obligations or exercising FibroGen’s rights under this Agreement. The use of
“Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s acquisition of FibroGen, except as provided in Section 15.5. FibroGen Know-How shall exclude (a) rights under
any FibroGen Patents and FibroGen’s interest in the Joint Patents and Joint Inventions and (b) any Third Party Information that is not included pursuant to Section 8.8(d). 

1.63      “FibroGen Patents” means (i) the Listed Patents
and (ii) all other Patents (excluding any Joint Patents) that are Controlled as of the Effective Date or thereafter during the Term by FibroGen and/or its Affiliate(s) and that claim the composition of matter, manufacture or use of one or more
Collaboration Compounds or Products in the Field or that would otherwise be infringed (or with respect to patent applications, would be infringed if issued or granted with the then-currently pending claims), absent a license, by the manufacture, use
or sale of any Collaboration Compound or Product in the Field. The use of “Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s acquisition of FibroGen except as provided in
Section 15.5. FibroGen Patents does not include Third Party Patents that are not included pursuant to Section 8.8(d). 

1.64      “FibroGen Technology” means the FibroGen Patents,
FibroGen Know-How, and FibroGen’s interest in Joint Patents and Joint Inventions. 

  
 7. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.65      “Field”
means (a) the treatment of anemia in humans and non-human animals, which means any treatment intended to increase hemoglobin levels or utilization or to increase hematocrit, as measured by acceptable clinical parameters, including unit volume
concentrations of hemoglobin, red blood cell volume, or red blood cell count, and (b) any Designated Indication added to the Field pursuant to Section 3.5. For the avoidance of doubt, the Core Indications, the ESA Approved Indications as
well as the indications listed on Exhibit D are all included in clause (a) of the preceding sentence. 

1.66      “First Commercial Sale” means, with respect to a
Product and country in the Territory, the first arm’s length sale for monetary value by AstraZeneca, its Affiliates or its Sublicensees to a Third Party intended for end use or consumption by the general public (regardless of when actual
consumption occurs) of such Product in such country after Regulatory Approval (and any pricing or reimbursement approvals, if reasonably necessary to commence regular commercial sales) has been obtained in such country. For the avoidance of doubt,
sales prior to receipt of Regulatory Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”, “named patient sales” or “compassionate use sales”, shall not be construed as a
First Commercial Sale. 
 1.67      “Fully Burdened Cost”
means, with respect to a Product, all costs actually incurred by FibroGen or its Affiliates attributable and fairly allocable to produce, package and distribute the Product to AstraZeneca or its carrier [*]) for the acquisition or sale of such
Product, which costs to produce and package the Product will include the direct material and labor and indirect costs (fairly allocated) that are incurred by FibroGen or its Affiliates associated with the manufacture, filling, packaging, labeling,
and preparation of product for shipment and/or other preparation of such Product, as applicable, including non-refundable and non-creditable Indirect Taxes, customs fees and customs duties. Fully Burdened Cost will be determined in accordance with
U.S. GAAP and will include the attributable and fairly allocable costs of facilities, labor, purchasing, depreciation of equipment, materials, payments to Third Parties for any necessary contract work for the manufacture or testing of the Product,
quality assurance, quality control and other testing (including validation studies), storage (if requested by AstraZeneca), shipping and costs for distribution, and a reasonable allocation of general and administrative overhead for the manufacturing
operations attributable to Product distribution to AstraZeneca. These costs shall include capacity reservation charges paid to a Third Party, and the proportion of fixed overhead allocated to total available capacity reasonably reserved for the
production of a Product, less the amount included in budgeted cost of goods (budgeted capacity); provided, that FibroGen shall use good faith efforts to utilize any such reserved but unused capacity. By way of example, if fifteen percent
(15%) of the total site capacity is reasonably reserved for the production of the Product and for the same period budgeted capacity is planned for only ten percent (10%) of the site, the fixed overhead related to the remaining five percent
(5%) dedicated capacity shall be included in Fully Burdened Cost as reserve capacity. Costs for distribution consist of the labor, materials and reasonably allocated overhead necessary to prepare and package the final product for shipment to
AstraZeneca. 
 1.68      “GCP” means the current standards for
clinical trials for pharmaceuticals, as set forth in the U.S. Code of Federal Regulations, ICH guidelines and applicable regulations, laws or rules as promulgated thereunder, as amended from time to time, and such standards of good clinical practice
as are required in other countries than the U.S. in which a Product is intended to be sold to the extent such standards are not less stringent than U.S. GCP. 

  
 8. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.69      “Generic
Product” means, with respect to a Product and a particular country, any pharmaceutical product (a) that is sold in such country by a Third Party that is not a Sublicensee or Distributor selling such product under authorization from
AstraZeneca or its Affiliates, (b) that contains the same Collaboration Compound as the relevant Product and that is in the same dosage form as such Product and for the same route of administration as such Product and is approved by the
Regulatory Authority for such country for an indication for which such Product obtained Regulatory Approval in such country and (c) that is approved in reliance on the prior approval of such Product as determined by the applicable Regulatory
Authority. 
 1.70      “Governmental Authority” means any
multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.71      “Government Official” means (i) any individual or
entity employed by or acting on behalf of a government, government-controlled agency or entity or public international organization, (ii) any political party, party official or candidate, (iii) any individual or entity that holds or
performs the duties of an appointment, office or position created by custom or convention or (iv) any individual or entity that holds himself, herself or itself out to be the authorized intermediary of any of the foregoing. 

1.72      “HICP” means, with respect to a country, the Harmonised
Index of Consumer Prices for such country published by Eurostat. 

1.73      “HIF Compound” means any compound that stabilizes
hypoxia-inducible factor (“HIF”) or that modulates HIF prolyl hydroxylase activity. 

1.74      “Hourly Rate” means, as of the Effective Date, $[*],
which is the blended hourly fully burdened rate for FibroGen’s employees and agents conducting Development activities. The Hourly Rate will be adjusted annually as of each January 1 (commencing 2014) to reflect the percentage increase or
decrease (as the case may be) from the preceding year in the average consumer price, calculated as the average of (i) the annual percentage change of US CPI-U and (ii) the average of the annual percentage changes of HICP for the 5 major EU
countries (UK, France, Germany, Italy, and Spain) for such annual period, except as otherwise mutually agreed by the Parties. The Hourly Rate includes, without limitation, the following general expense categories: salaries and wages (including
bonuses, moving expenses, and payroll taxes), benefits provided (including health benefits, defined contribution, defined benefit plans, vacations, etc.), direct employee costs (including recruitment costs, internal and external training costs,
computer charges, automobile leases, subscriptions and reference materials, telephone, fax, cellular phone, and copy machines and related costs), and allocation of other overhead costs (including rent, insurance, and utilities). 

1.75      “IND” means (a) an Investigational New Drug
Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) the equivalent 

  
 9. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
application to the equivalent Regulatory Authority in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in
humans in such jurisdiction. 
 1.76      “Indirect Taxes”
means VAT, sales taxes, consumption taxes and other similar taxes required by law to be disclosed on the invoice. 

1.77      “Information” means any data, results and information
of any type whatsoever, in any tangible or intangible form, including, without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, compositions of matter
of any type or kind, software, algorithms, marketing reports, clinical and non-clinical study reports, regulatory submission documents and summaries, expertise, stability, technology, test data including pharmacological, biological, chemical,
biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, in all cases, patentable or otherwise. 

1.78      “Initial Development Plan” has the meaning set forth in
Section 3.2(b). 
 1.79      “Inventions” has the meaning
set forth in Section 9.2. 
 1.80      “IP Committee” has
the meaning set forth in Section 9.1. 
 1.81      “Joint
Commercialization Committee” or “JCC” means the committee formed by the Parties as described in Section 2.4. 

1.82      “Joint Development Committee” or
“JDC” means the committee formed by the Parties as described in Section 2.3. 

1.83      “Joint Inventions” has the meaning set forth in
Section 9.2. 
 1.84      “Joint Patents” has the meaning
set forth in Section 9.2. 
 1.85      “Joint Project Team” or
“JPT” has the meaning set forth in Section 2.9. 

1.86      “Joint Steering Committee” or
“JSC” means the committee formed by the Parties as described in Section 2.2. 

1.87      “Large Dialysis Organization” or
“LDO” means (a) an organization that operates out-patient dialysis centers and that has at least twenty-five percent (25%) of the market share (measured by number of patients as determined by USRDS or any successor)
of dialysis centers in the U.S. and (b) Dialysis Clinic Inc. Examples of Large Dialysis Organizations as of the Effective Date in clause (a) are Fresenius Medical Care and DaVita HealthCare Partners Inc. 

1.88      “Listed Patents” means the Patents listed on Exhibit
E. The Parties may update such exhibit from time to time upon mutual written agreement, e.g., to update the status of the listed Patents, to add newly filed FibroGen Patents, or to make other agreed revisions. 

  
 10. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.89      “Marketing
Authorization Application” or “MAA” means an application for Regulatory Approval in a country, territory or possession other than the U.S. 

1.90      “Marks” has the meaning set forth in Section 9.11. 

1.91      “Material Anti-Corruption Law Violation” means a
violation of an Anti-Corruption Law relating to the subject matter of this Agreement which [*] a material adverse effect on either Party or on the reputation of either Party because of its relationship with the other Party. 

1.92      “Medical Scientific Liaison” or
“MSL” means a field-based professional with scientific, medical and clinical expertise who provides medical and scientific support for marketed products, new indications and compounds in development or registration. An MSL
engages in scientific exchange with medical and scientific experts including investigators, key opinion leaders, physicians and other medical professionals and customers. 

1.93      “NDA” means a New Drug Application, as defined in the
FD&C Act and applicable regulations promulgated thereunder by the FDA. 

1.94      “Net Sales” means the gross invoiced amount on sales of
a Product by AstraZeneca, its Affiliates or its or their Sublicensees to Third Parties (including Distributors but excluding Sublicensees) in the Territory, after deduction of the following amounts: 

(a)        normal and customary trade, quantity or prompt settlement discounts
(including chargebacks and allowances) actually allowed; 

(b)        amounts repaid or credited by reason of rejection, returns or
recalls of goods, rebates or bona fide price reductions determined by AstraZeneca, its Affiliates or its or their Sublicensees in good faith; 

(c)        rebates and similar payments made with respect to sales paid for by
managed care organizations, hospitals, other buying groups or any governmental or regulatory authority such as, by way of illustration and not in limitation of the Parties’ rights under this Agreement, federal or state Medicaid, Medicare or
similar state program in the U.S. or equivalent governmental program in any other country; 

(d)        any invoiced amounts that are not collected by AstraZeneca, its
Affiliates or its or their Sublicensees, including bad debts (provided that such amounts will be added to Net Sales if and when recovered), up to an amount not to exceed [*]) of Net Sales; 

(e)        excise taxes, Indirect Taxes, customs duties, customs levies and
import fees imposed on the sale, importation, use or distribution of the Products; 

(f)        [*]; and 

(g)        as an allowance for transportation costs, distribution expenses,
special packaging and related insurance charges, [*]. 

  
 11. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 For clarity, any deduction made pursuant to one subsection above, shall not be additionally
deducted in the event that such deduction may also apply in a separate subsection (i.e., no double-counting). 
 In the event that a Product
is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by multiplying actual Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition of
“Net Sales” by the fraction A/(A+B), where A is the average invoice price in such country of any Product that contains the same Collaboration Compound(s) as such Combination Product as its sole active ingredient(s), if sold separately in
such country, and B is the average invoice price in such country of each product that contains active ingredient(s) other than the Collaboration Compound(s) contained in such Combination Product as its sole active ingredient(s), if sold separately
in such country; provided that the invoice price in a country for each Product that contains only the Collaboration Compound(s) and each product that contains solely active ingredient(s) other than the Collaboration Compound(s) included in
the Combination Product shall be for a quantity comparable to that used in such Combination Product and of substantially the same class, purity and potency or functionality, as applicable. If either such Product that contains the Collaboration
Compound(s) as its sole active ingredient or a product that contains the active ingredient(s) (other than the Product) in the Combination Product as its sole active ingredient(s) is not sold separately in a particular country, the Parties shall
negotiate in good faith a reasonable adjustment to Net Sales in such country that takes into account the medical contribution to the Combination Product of and all other factors, including patent coverage, reasonably relevant to the relative value
of the Collaboration Compound(s) on the one hand and all of the other active ingredient(s), collectively, on the other hand. 
 In the case
of pharmacy incentive programs, hospital performance incentive programs, chargebacks, disease management programs, similar programs or discounts on portfolio product offerings, all rebates, discounts and other forms of reimbursements shall be
allocated among products on the basis on which such rebates, discounts and other forms of reimbursements were actually granted or, if such basis cannot be determined, in accordance with AstraZeneca’s, its Affiliates’ or its or their
Sublicensees’ existing allocation method; provided that any such allocation shall be done in accordance with applicable law, including any price reporting laws, rules and regulations. 

Net Sales will be calculated using AstraZeneca’s internal audited systems consistently applied to report such sales as adjusted for any
of the deductions set forth above not taken into account in such systems. Deductions pursuant to item (d) above will be taken in the Calendar Quarter in which such sales are no longer recorded as a receivable. 

Any free of charge disposition or use of reasonable quantities of a Product, up to the amount determined by the JCC, for regulatory or
marketing purposes (it being understood and agreed that neither Party shall have the right to distribute the Product as samples except pursuant to Section 5.7) such as compassionate use or indigent patient programs, will not be deemed a sale or
disposition for calculating Net Sales. Sales and other transfer of Product between any of AstraZeneca, its Affiliates and Sublicensees will not give rise to Net Sales except if the purchaser is an end user. 

  
 12. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.95      “Nonclinical
Studies” means all in vivo and in vitro non-human studies of Collaboration Compounds and Products, including non-clinical pharmacology, toxicology, tumor and teratogenicity studies. 

1.96      “Patent” means (i) all national, regional and
international patents and patent applications, including provisional patent applications, (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from
any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (iii) any and all patents that have issued or in the future issue from the foregoing patent
applications ((i) and (ii)), including utility models, petty patents and design patents and certificates of invention, (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including
revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((i), (ii) and (iii)), and (v) any similar rights, including
so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents. 

1.97      “Personnel Costs” means, with respect to a reporting
period, the total number of hours FibroGen employees and consultants or AstraZeneca employees and consultants, as applicable, actually spent in such reporting period conducting activities under the Development Plan multiplied by the Hourly Rate.
Such activities may include, without limitation, clinical development, research activities directly in support of the Development program, management of clinical research organizations and other vendors, regulatory, supply chain, medical monitoring,
biostatistics, safety data collection, monitoring and exchange, and clinical and nonclinical finance and contracting. 

1.98      “Pharmacovigilance Agreement” has the meaning set forth
in Section 4.3. 
 1.99      “Phase 2 Clinical Trial” means a
Clinical Trial of a Product that would satisfy the requirements of 21 CFR 312.21(b) or its foreign equivalents. 

1.100    “Phase 3 Clinical Trial” means a Clinical Trial of a Product that
would satisfy the requirements of 21 CFR 312.21(c) or its foreign equivalents. 

1.101    “Phase 4 Clinical Trial” means a Clinical Trial of a Product
conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or
(b) conducted due to a request or requirement of a Regulatory Authority. 

1.102    “Product” means any pharmaceutical product (including all forms,
presentations, dosage strengths and formulations) containing as an active ingredient a Collaboration Compound alone or in combination with one or more other therapeutically active ingredients. 

1.103    “Product Information” has the meaning set forth in Section 12.1.

 1.104    “Product Infringement” has the meaning set forth in Section
9.5(a)(i). 

  
 13. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.105    “Promotional
Materials” means all sales representative training materials and all written, printed, graphic, electronic, audio or video matter, including, without limitation, journal advertisements, sales visual aids, formulary binders, reprints,
direct mail, direct-to-consumer advertising, internet postings and sites and broadcast advertisements intended for use or used by either Party or its Affiliates or sublicensees in connection with any promotion of a Product. 

1.106    “Publication” has the meaning set forth in Section 12.5(b). 

1.107    “Regulatory Approval” means all approvals necessary for the
manufacture, marketing, importation and sale of a Product for one or more indications in the Field and in a country or regulatory jurisdiction, which may include, without limitation, satisfaction of all applicable regulatory and notification
requirements, but which shall exclude any pricing and reimbursement approvals. 

1.108    “Regulatory Authority” means, in a particular country or
regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement approval of a Product in such country or
regulatory jurisdiction. 
 1.109    “Regulatory Materials” means
regulatory applications, submissions, notifications, registrations, Regulatory Approvals and/or other material filings or correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to
any communications with any Regulatory Authority), or other approvals granted by, a Regulatory Authority that are necessary or reasonably desirable in order to Develop, manufacture, market, sell or otherwise Commercialize a Product in a particular
country or regulatory jurisdiction. Regulatory Materials include, without limitation, INDs, MAAs, and NDAs. 

1.110    “Representatives” has the meaning set forth in Section 10.3(a).

 1.111    “RoW” means all countries of the Territory other than the
U.S. For clarity, except as expressly set forth in Article 2, the territories licensed under the China Agreement are not included in RoW. 

1.112    “SEC” means the U.S. Securities and Exchange Commission. 

1.113    “Sublicense Agreement” has the meaning set forth in Section
7.3(b). 
 1.114    “Sublicensee” means any Third Party granted a
sublicense by AstraZeneca or any of its Affiliates under the rights licensed to AstraZeneca pursuant to Article 7. 

1.115    “Subsequent Agreement” has the meaning set forth in Section
7.4(c). 
 1.116    “Subsequent Licensee” has the meaning set forth in
Section 7.4(c). 
 1.117    “Supply and Quality Agreement” has the
meaning set forth in Section 6.5. 

  
 14. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.118    “Tax and Taxation”
means any form of tax or taxation, levy, duty, charge, social security charge, contribution, or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority. 

1.119    “Tax Authority” or “Tax Authorities” means
any government, state or municipality, or any local, state, federal or other fiscal, revenue, customs, or excise authority, body or official anywhere in the world, authorized to levy Tax. 

1.120    “Technical Product Failure” means (a) a [*] of a
Collaboration Compound or Product under Development or Commercialization under this Agreement, as determined (including following a review of the Carcinogenicity Studies) (i) by a consensus decision by the JSC or (ii), following referral of the
matter to the Executive Officers pursuant to Section 2.6(c), by a consensus decision by the Executive Officers, or (iii), in the event that a consensus decision by the Executive Officers has not been attained within twenty (20) Business
Days after the JSC’s submission of the matter to them, by expedited resolution in accordance with Section 14.8; or (b) a Regulatory Authority action or decision [*]. 

1.121    “Term” has the meaning set forth in Section 13.1. 

1.122    “Territory” means all countries of the world other than
(a) the countries listed on Exhibit A and (b) China (including Hong Kong SAR and Macau SAR, but excluding Taiwan region). The Territory consists of the U.S. and RoW. 

1.123    “Third Party” means any entity other than FibroGen or AstraZeneca
or an Affiliate of either of them. 
 1.124    “Transatlantic Clinical Development
Plan” or “TCDP” has the meaning set forth in Section 3.2(b). 

1.125    “U.S.” means the United States of America (including all
possessions and territories thereof). 
 1.126    “U.S. Commercialization
Budget” has the meaning set forth in Section 5.2. 
 1.127    “U.S.
Commercialization Plan” has the meaning set forth in Section 5.2. 

1.128    “U.S. GAAP” means generally accepted accounting principles in the
U.S. 
 1.129    “Valid Claim” means, with respect to a Product in a
particular country, any claim of a FibroGen Patent that specifically or generically claims (i) the Collaboration Compound included in such Product as a composition of matter, (ii) a method of manufacture of such Collaboration Compound, or
(iii) a method of treatment or other use of such Collaboration Compound [*] and either: 

(a)        with respect to a granted and unexpired Patent in such country,
that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, and
(ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; or 

  
 15. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b)        with respect to a
pending Patent application, that was filed and is being prosecuted in good faith and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application. For purposes hereof, a claim in a patent application
that has not been granted within [*]) years from the priority date for such claim (or, with respect to [*]) shall not be considered to be a Valid Claim, unless and until such claim thereafter issues such that it is included in subsection
(a) above. 
 ARTICLE 2 

COLLABORATION; GOVERNANCE 

2.1        Collaboration Overview. The Parties desire and intend to collaborate
with respect to the Development and Commercialization of Products in the Field in the Territory, as and to the extent set forth in this Agreement (the “Collaboration”). It is intended that the Collaboration utilize
AstraZeneca’s position as a large, fully-integrated pharmaceutical company, while recognizing FibroGen’s current experience and expertise in, and aspirations to further develop its clinical development and commercialization capabilities
with respect to, HIF Compounds. 
 2.2        Joint Steering Committee. 

(a)        Purpose; Formation. The Parties hereby establish a joint steering
committee (the “JSC”) that will monitor and oversee their activities under this Agreement in the Territory and under the China Agreement in China, resolve disputes within subcommittees and facilitate communications between
the Parties with respect to the Development and Commercialization of Products in the Territory and in China (under the China Agreement), all in accordance with this Section 2.2. 

(b)        Composition. Each Party shall initially appoint five
(5) representatives of such Party or its applicable Affiliates to the JSC. Each representative appointed to the JSC shall have sufficient seniority within the applicable Party or its Affiliate to make decisions arising within the scope of the
JSC’s responsibilities. The Parties’ initial representatives to the JSC are set forth on Exhibit G. The JSC may change its size from time to time by mutual consent of its members, provided that the JSC shall at all times consist of
an equal number of representatives of each of FibroGen and AstraZeneca. Each Party may replace its JSC representatives at any time upon written notice to the other Party. The JSC may invite non-members (including consultants and advisors of a Party
who are under an obligation of confidentiality consistent with this Agreement) to participate in the discussions and meetings of the JSC, provided that such participants shall have no voting authority at the JSC. Each Party shall appoint a
secretariat to the JSC who is not a member of the JSC. 
 (c)        Specific
Responsibilities. In addition to its overall responsibility for monitoring and providing a forum to discuss and coordinate the Parties’ activities under this Agreement, the JSC shall in particular: 

(i)        oversee the collaborative activities of the Parties under this
Agreement and the China Agreement, including overseeing the China Committee; 

  
 16. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (ii)       oversee and delegate
responsibility for the use of any information arising under the Astellas Agreements, to the extent that (A) [*] such information; and (B) such information [*] this Agreement; 

(iii)      review and fully discuss the Development and Commercialization of Products
and any other ongoing activities; 
 (iv)      receive and discuss reports from the
JDC and JCC and provide guidance thereto, and approve the Development Plan (and associated Development Budget) and U.S. Commercialization Plan and amendments thereto; 

(v)       receive and discuss reports from the China Committee and provide guidance
thereto, and approve the applicable Development and Commercialization plans and budgets; 

(vi)      receive and discuss reports from the IP Committee, provide guidance thereto
and review strategies for obtaining, maintaining, defending and enforcing patent and trademark protection for Products within the Territory; 

(vii)     attempt to resolve issues presented to it by, and disputes within, the JDC, JCC and
China Committee or any other subcommittee; 
 (viii)    at least annually, discuss and determine
indications for Development of Products; 
 (ix)      review and approve the filing of
an NDA for a Product in the U.S. prior to submission; 
 (x)       establish such
additional joint subcommittees as it deems necessary to achieve the objectives and intent of this Agreement; 

(xi)      review and approve the JPT Charter and any subsequent amendments thereto,
including the composition and responsibilities of the Core JPT; and 
 (xii)     perform
such other functions as appropriate to further the purposes of this Agreement as allocated to it in writing by the Parties. 

The JSC shall further – until the date when the JDC or the JCC has been formed – assume the responsibilities of the
JDC and the JCC, as applicable, and delegate certain responsibilities to the Core JPT as set forth in Schedule G(a) for the JDC and Schedule G(b) for the JCC. 

  
 17. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d)        Delegation or Assumption
of Responsibilities by the JSC. The JSC may by mutual consent of its members: 

(i)        delegate any of its responsibilities set out in this
Section 2.2 or in Schedule G(a) or G(b) to any of its subcommittees or the Core JPT; or 

(ii)       assume any responsibilities assigned to any of its subcommittees. 

(e)        Meetings.  The JSC shall hold its first meeting within
thirty (30) days after the Effective Date. The JSC shall meet at least one (1) time per Calendar Quarter during the Term unless the Parties mutually agree in writing to a different frequency for such meetings. Either Party may also call a
special meeting of the JSC (by videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the
next scheduled meeting, and such Party shall provide the JSC no later than ten (10) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision; provided, however, that where a special meeting is
called for on shorter notice with regard to a matter that does not admit delay, such notice and such materials shall be provided as early as possible in advance of such meeting. No later than ten (10) Business Days (or such shorter period as
may be necessary in the event of a special meeting called for on shorter notice in accordance with the foregoing) prior to any meeting of the JSC, the secretariats of the JSC shall jointly prepare and circulate an agenda for such meeting. The JSC
may meet in person, by videoconference or by teleconference. Notwithstanding the foregoing, at least two (2) meetings per Calendar Year shall be in person unless the Parties mutually agree in writing to waive such requirement in lieu of a
videoconference or teleconference. In-person JSC meetings will be held at locations alternately selected and hosted by FibroGen and by AstraZeneca. The host Party shall be responsible for the costs and expenses of the JSC meeting hosted, provided
that each Party will bear the expense of its respective JSC members’ and other attendees’ participation in JSC meetings, including travel costs. Meetings of the JSC shall be effective only if at least one (1) representative of each
Party is present or participating in such meeting. The JSC secretariat of the host Party will be responsible for keeping reasonably detailed written minutes of all JSC meetings that reflect, without limitation, material decisions made at such
meetings. The JSC secretariat of the host Party shall send draft meeting minutes to the other Party’s JSC secretariat, and each secretariat shall seek and obtain review and approval of such minutes from its respective Party’s members of
the JSC within ten (10) Business Days after each JSC meeting. Such minutes will be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within ten (10) Business Days of receipt. 

(f)        Decision-Making.  In addition to resolving issues
specifically delegated to it, the JSC shall have the authority to resolve any disputes within the Collaboration not resolved by the JDC, JCC, China Committee and any other committees that the Parties may subsequently create to assist in governance
of the Collaboration, except where expressly specified elsewhere in this Agreement. The representatives from each Party will have, collectively, one (1) vote on behalf of that Party, and all decision making shall be by consensus. Disputes at
the JSC shall be handled in accordance with Section 2.6. 
 2.3        Joint
Development Committee. 
 (a)        Formation;
Composition.   At a time determined by the JSC, the Parties shall establish a committee to oversee Development of Product(s) in the Territory and in China in 

  
 18. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
accordance with the Development Plan(s) for such Product(s) and to coordinate the Development activities of the Parties (the “JDC”) and prior thereto, the JSC will be
responsible for all JDC responsibilities except for the specific responsibilities it delegates to the Core JPT as set out in Schedule G(a). 

Each Party shall appoint three (3) representatives of such Party or its Affiliates to the JDC at its inception. Each representative
appointed to the JDC shall have knowledge and expertise in relevant aspects of the development of small molecule pharmaceutical products, including in the area of chronic kidney disease or cardiovascular or metabolic disorders and having sufficient
seniority within the applicable Party or Affiliate to make decisions arising within the scope of the JDC’s responsibilities. The JDC may change its size from time to time by mutual consent of its members, provided that the JDC shall consist at
all times of an equal number of representatives of each of FibroGen and AstraZeneca. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members (including consultants and
advisors of a Party who are under an obligation of confidentiality consistent with this Agreement) to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC shall
have two (2) co-chairmen, one selected by FibroGen and one selected by AstraZeneca. The role of the co-chairmen shall be to convene and preside at meetings of the JDC, but they shall have no additional
powers or rights beyond those held by the other JDC representatives. Each Party shall appoint a secretariat to the JDC. 

(b)        Specific Responsibilities of the
JDC.      In addition to its general responsibilities, the JDC (or the JSC until the JDC is formed, with certain delegations as set forth in this Section 2.3 and Schedule G(a)) shall in particular: 

(i)        provide regular reports to the JSC regarding the development of the
Product, and discuss, prepare and submit to the JSC for approval annual and interim amendments to the Development Plan (and the Development Budget) for each Product; 

(ii)       discuss and manage the implementation of the Initial Development Plan;

 (iii)      oversee the conduct of Development; 

(iv)      discuss the audited final report from the Carcinogenicity Studies, including
whether or not a Technical Product Failure has occurred, and provide input thereon to the JSC; 

(v)       propose to the JSC particular studies to be conducted; 

(vi)      create, implement and review the Development Strategy for Development in the
Territory and the design of all Clinical Trials and Nonclinical Studies conducted under each Development Plan, including Phase 4 Clinical Trials; 

(vii)     oversee any CMC related development activities, e.g. stability studies or packaging
development, as well as other activities to prepare for supply of drug substance and finished Product for Commercialization, including to oversee the selection process for, and select (pursuant to Section 6.4), a contract manufacturer to be
used by FibroGen for commercial supplies; 

  
 19. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (viii)    decide whether and when to initiate or
discontinue any Clinical Trial and any Nonclinical Study under each Development Plan, including Phase 4 Clinical Trials; 

(ix)      allocate budgeted resources and determine priorities for each Clinical Trial
and Nonclinical Study under each Development Plan, including Phase 4 Clinical Trials; 

(x)       oversee the conduct of all Clinical Trials and Nonclinical Studies under
each Development Plan, including Phase 4 Clinical Trials; 
 (xi)      select Third
Party contractors to conduct Clinical Trials of Products; 
 (xii)     facilitate the flow
of Information between the Parties with respect to the Development of Products, including Development Data [*] under this Agreement; 

(xiii)    discuss whether to Develop Products for other indications and propose any such
indications to the JSC; 
 (xiv)    allocate primary responsibility as between the Parties for
tasks relating to Development of Products where not already specified in the Development Plan; 

(xv)     discuss the requirements for Regulatory Approval in the Territory and oversee and
coordinate regulatory matters with respect to Products in the Territory, including to review and approve material regulatory filings (other than the filing of an NDA in the U.S., which shall be approved by the JSC) prior to submission thereof; 

(xvi)    establish a publication strategy for publications and presentations related to Products
in the Territory and review and approve all such publications in accordance with Section 12.5; 

(xvii)   facilitate the flow of Information between the Parties with respect to obtaining Regulatory
Approval for Products; and 
 (xviii)  perform such other functions as may be appropriate to further the
purposes of this Agreement, as directed by the JSC. 

(c)        Meetings.  Following its inception, the JDC shall meet at
least one (1) time per Calendar Quarter (or more frequently when necessary), spaced at regular intervals, unless the Parties mutually agree in writing to a different frequency. Either Party may also call a special meeting of the JDC (by
videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, and such
Party shall provide the JDC no later than ten (10) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision; provided, however, that where a special meeting is called for on shorter notice
with regard to a matter that does not admit delay, such notice and such 

  
 20. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
materials shall be provided as early as possible in advance of such meeting. No later than ten (10) Business Days (or such shorter period as may be necessary in the event of a special
meeting called for on shorter notice in accordance with the foregoing) prior to any meeting of the JDC, the secretariats shall jointly prepare and circulate an agenda for such meeting; provided, however, that either Party shall be free to propose
additional topics to be included on such agenda, either prior to or, subject to the consent of the other Party, in the course of such meeting. The JDC may meet in person, or at the request of either Party, by videoconference or teleconference.
In-person JDC meetings will be held at locations alternately selected and hosted by FibroGen and by AstraZeneca. Each Party shall report to the JDC on all material issues relating to the Development of Products for and in the Territory at the JDC
meeting occurring after such issues arise. The host Party shall be responsible for the costs and expenses of the JDC meeting hosted, provided that each Party will bear the expense of its respective JDC members’ and other attendees’
participation in JDC meetings, including travel costs. Meetings of the JDC shall be effective only if at least one (1) representative of each Party is present or participating in such meeting. The secretariat of the host Party shall be
responsible for keeping reasonably detailed written minutes of all JDC meetings that reflect all decisions made at such meetings. The secretariat of the host Party shall send meeting minutes to the other Party’s secretariat, and each
secretariat shall seek and obtain review and approval of such minutes from its respective Party’s members of the JDC within ten (10) Business Days after each JDC meeting. Minutes will be deemed approved unless one or more members of the
JDC objects to the accuracy of such minutes within ten (10) Business Days of receipt. 

(d)        Decision-Making.    The JDC shall act by
consensus. The representatives from each Party will have, collectively, one (1) vote on behalf of that Party. If the JDC cannot reach consensus on an issue that comes before the JDC and over which the JDC has oversight, then the Parties shall
refer such matter to the JSC for resolution in accordance with Sections 2.2(e) and 2.6(b). 

2.4        Joint Commercialization Committee. 

(a)        Formation; Composition.  At a time determined by the JSC,
but no later than the earlier of (i) eighteen (18) months prior to the date of the expected First Commercial Sale of the Product in the U.S. and (ii) six (6) months prior to the projected date of submission of the first NDA for
the Product in the U.S., the Parties shall establish a committee to oversee Commercialization of Products in the Territory and in China (the “JCC”), and prior thereto, the JSC will be responsible for all JCC responsibilities
except for the specific responsibilities it delegates to the Core JPT as set out in Schedule G(b). 
 Each Party shall appoint three
(3) representatives of such Party or its Affiliate to the JCC at its inception. Each representative appointed to the JCC shall have knowledge and expertise in relevant aspects of the commercialization of small molecule pharmaceutical products,
including in the area of chronic kidney disease or cardiovascular or metabolic disorders and having sufficient seniority within the applicable Party or its Affiliate to make decisions arising with the scope of the JCC’s responsibilities. The
JCC may change its size from time to time by mutual consent of its members, provided that the JCC shall consist at all times of an equal number of representatives of each of FibroGen and AstraZeneca. Each Party may replace its JCC representatives at
any time upon written notice to the other Party. The JCC may invite non-members (including consultants and advisors of a Party who are under an obligation of confidentiality consistent with this 

  
 21. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Agreement) to participate in the discussions and meetings of the JCC, provided that such participants shall have no voting authority at the JCC. The JCC shall have a chairman, who shall be
selected by AstraZeneca. The role of the chairman shall be to convene and preside at meetings of the JCC, but the chairman shall have no additional powers or rights beyond those held by the other JCC representatives. 

(b)        Specific Responsibilities of the Joint Commercialization
Committee.  In addition to its general responsibilities, the Joint Commercialization Committee (or the JSC until the JCC is formed, with certain delegations as set forth in this Section 2.4 and Schedule G(b)) shall in particular:

 (i)        oversee Commercialization in the Territory and (as set out in
more detail in the China Agreement) China; 
 (ii)        regularly report
to the JSC regarding the Commercialization of the Products, and discuss, prepare and submit for approval to the JSC the U.S. Commercialization Plan for each Product in the U.S., including any amendments thereto; 

(iii)       review and approve each commercialization plan for the RoW prepared by
AstraZeneca; 
 (iv)       oversee implementation of each U.S. Commercialization
Plan; 
 (v)        coordinate the Commercialization activities of FibroGen
and AstraZeneca with respect to Products, including pre-launch and post-launch activities; 

(vi)       allocate primary responsibility as between the Parties for tasks
relating to Commercialization of Products in the U.S.; 
 (vii)      determine the
amount of Product to be distributed free of charge annually for regulatory or marketing purposes or investigator-initiated trials (it being understood and agreed that neither Party shall have the right to distribute the Product as samples except
pursuant to Section 5.7); 
 (viii)     oversee global harmonization of the Product;

 (ix)       be responsible for publication matters as described in
Section 2.3(b)(xvi) upon transition of such responsibility from the JDC to the JCC; and 

(x)        perform such other functions as appropriate to further the purposes
of this Agreement, as directed by the JSC. 

(c)        Meetings.  Following its inception, the JCC shall meet at
least one (1) time per Calendar Quarter, spaced at regular intervals unless the Parties mutually agree in writing to a different frequency. Either Party may also call a special meeting of the JCC (by videoconference or teleconference) by at
least ten (10) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, and such Party shall provide the JCC no later than
ten (10) Business Days prior 

  
 22. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
to the special meeting with materials reasonably adequate to enable an informed decision; provided, however, that where a special meeting is called for on shorter notice with regard to a matter
that does not admit delay, such notice and such materials shall be provided as early as possible in advance of such meeting. No later than ten (10) Business Days (or such shorter period as may be necessary in the event of a special meeting
called for on shorter notice in accordance with the foregoing) prior to any meeting of the JCC, the secretariats shall jointly prepare and circulate an agenda for such meeting; provided, however, that either Party shall be free to propose additional
topics to be included on such agenda, either prior to or, subject to the consent of the other Party, in the course of such meeting. The JCC may meet in person, by videoconference, or by teleconference. In-person JCC meetings will be held at
locations alternately selected and hosted by FibroGen and by AstraZeneca. Meetings of the JCC shall be effective only if at least one (1) representative of each Party is present or participating in such meeting. Each Party shall report to the
JCC on all material issues relating to the Commercialization of Products promptly after such issues arise. The host Party shall be responsible for the costs and expenses of the JCC meeting hosted, provided that each Party will bear the expense of
its respective JCC members’ and other attendees’ participation in JCC meetings, including travel costs. The secretariat of the host Party will be responsible for preparing reasonably detailed written minutes of JCC meetings that reflect
all decisions made at such meetings. The secretariat of the host Party shall send meeting minutes to the other Party’s secretariat, and each secretariat shall seek and obtain review and approval of such minutes from its respective Party’s
members of the JCC within ten (10) Business Days after each JCC meeting. Minutes will be deemed approved unless one or more members of the JCC objects to the accuracy of such minutes within ten (10) Business Days of receipt. 

(d)        Decision-Making.  The JCC shall act by consensus. The
representatives from each Party will have, collectively, one (1) vote on behalf of that Party. If the JCC cannot reach consensus on an issue that comes before the JCC and over which the JCC has oversight, then the Parties shall refer such
matter to the JSC for resolution in accordance with Sections 2.2(e) and 2.6. 

2.5        Coordination with Astellas.  FibroGen shall designate one
of AstraZeneca’s JSC representatives (as selected by AstraZeneca) to serve as a member of the steering committee under the Astellas Collaboration, who (except as described in the next sentence) shall be entitled to participate in the decision-making of such committee pursuant to the Astellas EU Agreement. The designated representative will be permitted to attend meetings of such committee; provided that such representative shall not have the
right to attend portions of (or participate in decision-making with respect to) any such meeting that are not relevant to the Development or Commercialization of Products in the Territory or in China. 

2.6        Resolution of Committee Disputes. 

(a)        Within Operating Committees.    All decisions
within any Committee other than the JSC shall be made by consensus, and if a dispute arises which cannot be resolved within such Committee, then the representatives of either Party may cause such matter to be referred to the JSC for resolution as
provided in Section 2.2(e). 
 (b)        Within The
JSC.  All decisions within the JSC (whether originating there, or referred to it by an operating Committee) shall be made by consensus. If a matter is referred by 

  
 23. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
an operating Committee to the JSC, it shall use good faith efforts, in compliance with Section 2.6(d), to resolve promptly such matter. If the JSC is unable to reach consensus on any issue
for which it is responsible, within ten (10) Business Days after a Party affirmatively states that a decision needs to be made, either Party may elect to submit such issue to the Parties’ Executive Officers in accordance with
Section 2.6(c). 
 (c)        Referral to Executive
Officers.  If a Party makes an election under Section 2.6(b) to refer a matter to the Executive Officers, the JSC shall submit in writing the respective positions of the Parties to their respective Executive Officers. Such
Executive Officers shall use good faith efforts, in compliance with Section 2.6(d), to resolve promptly such matter, which good faith efforts shall include at least one meeting (in-person, by telephone,
video conference or other appropriate means) between such Executive Officers within twenty (20) Business Days after the JSC’s submission of such matter to them. If the Executive Officers are unable to reach consensus on any such matter
within such twenty (20) Business Day period, then either Party may invoke the dispute resolution provisions of Article 14; provided, however, that: 

(1)        FibroGen’s Executive Officer shall have the final say with
respect to: [*]; 
 (ii)        AstraZeneca’s Executive Officer shall
have the final say with respect to: [*]; 
 (d)        Good
Faith.   In conducting themselves on Committees, and in exercising their rights under this Section 2.6, all representatives of both Parties shall consider diligently, reasonably and in good faith all input received from the
other Party, and shall use reasonable efforts to reach consensus on all matters before them. In exercising any decision making authority granted to it under this Article 2, each Party shall act based on its good faith judgment of what is in the best
interests of the Products and the Collaboration. 
 2.7        Alliance
Managers.     Each Party shall, within thirty (30) days following the Effective Date, appoint a single person who shall oversee contact between the Parties for all subject matter related to the Collaboration between
meetings of the JSC, JPT, JDC and JCC, and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (such person, the “Alliance Manager”). Each Party may replace its Alliance Manager
at any time by notice in writing to the other Party. The Alliance Managers shall work together to manage and facilitate the Collaboration governance meetings and the communication between the Parties under this Agreement, including the resolution
(in accordance with the terms of this Agreement) of issues between the Parties that arise in connection with this Agreement. The Alliance Managers shall not have final decision-making authority with respect to any matter under this Agreement. 

2.8        General Committee Authority.   Each Committee shall
have solely the powers expressly assigned to it in this Article 2 and elsewhere in this Agreement. No Committee shall have any power to amend, modify, or waive compliance with this Agreement (or any agreement entered into in connection with this
Agreement). It is expressly understood and agreed that the control of decision-making authority by FibroGen or AstraZeneca, as applicable, pursuant to Section 2.6, so as to resolve a disagreement or deadlock on a Committee for any matter will
not authorize either Party to perform any function not delegated to a Committee, and that neither FibroGen nor AstraZeneca shall have any right to unilaterally modify or amend, or waive its own compliance with, the terms of this Agreement. 

  
 24. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 2.9        Joint Project
Team.  The Parties hereby establish a joint project team (the “Joint Project Team” or “JPT”) to develop and propose plans to governing committees, manage operational activities and serve
as an information resource for the Committees. The members of the JPT representing core functions relevant to the joint development and commercialization of Products (the “Core Joint Project Team” or “Core
JPT”) shall provide oversight to the overall JPT. Until such time as when the JDC and the JCC have been formed, the Core JPT shall have the additional responsibilities set out in Schedule G(a) and G(b), respectively. Neither the JPT nor
the Core JPT will have any decision-making authority, except as set out in Schedule G(a) or G(b) or otherwise explicitly authorized by an appropriate Committee. The Parties agree to establish a JPT Charter on or prior to October 31, 2014, which
contains the composition and responsibilities of the JPT and the Core JPT. Subject to the JPT Charter, the Core JPT will consist of project leaders as appointed by FibroGen and by AstraZeneca, and such additional members as the Parties deem
appropriate from time to time. Each Party will appoint appropriately qualified and authorized representatives for each applicable operational area or function. The JPT members will serve as the point of contact for operational matters between the
Parties. The JPT may form subteams to support the efforts of the JPT as agreed by the Parties. As appropriate, FibroGen may arrange, on its own initiative or at AstraZeneca’s reasonable request from time to time, a joint meeting between the JPT
and the project team under the Astellas Collaboration. 
 2.10      Executive
Meetings.    FibroGen’s Chief Executive Officer and an appropriate Executive Vice President of AstraZeneca (or other appropriate representative of AstraZeneca of equivalent seniority) will meet in advance of the
occurrence of key scheduled Development and Commercialization events or in connection with key decisions, to review and discuss the status and direction of the Collaboration. 

2.11      Discontinuation of Participation on a Committee.    Each
Committee shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the Committee, or (b) FibroGen providing to AstraZeneca written notice of its intention to disband and no longer participate in such
Committee, which FibroGen retains the right to do at any time during the Term, in its sole discretion, provided, however, that doing so shall not relieve FibroGen of any of its obligations under this Agreement or the China Agreement (save from the
obligation to participate at the relevant Committee meetings). Once FibroGen has provided written notice as referred to in subsection (b) above, such Committee shall have no further obligations under this Agreement and AstraZeneca shall have
the right to solely decide, without consultation, any matters previously before such Committee, subject to the other terms of this Agreement. 

ARTICLE 3 

DEVELOPMENT 

3.1        Overview.  The Parties agree to undertake a joint
development program to further Develop the Collaboration Compounds and Products as provided in this Article 3 under the direction of the JDC (or, the JSC prior to the inception of the JDC), and pursuant to the Development Plan (such program, the
“Development Program”). Prior to the JDC’s inception, all 

  
 25. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
references to the JDC in this Article 3 and elsewhere in this Agreement will be deemed references to the JSC (which may delegate certain responsibilities to the Core JPT in accordance with
Schedule G(a)). 
 3.2        Development Plans. 

(a)        General.     All Development of any given
Product pursuant to this Agreement for the U.S. and RoW shall be conducted pursuant to a development plan (the “Development Plan”) that describes (i) the proposed overall program of Development for the applicable Product
and indications in the U.S. and RoW, including Clinical Trials and Nonclinical Studies, toxicology, formulation, packaging development, process and analytical development, production of registration and validation batches, regulatory plans and other
elements of obtaining Regulatory Approval(s) in each applicable country; (ii) the anticipated start dates and data availability dates of such Clinical Trials, Nonclinical Studies and CMC development activities, and timelines for key Regulatory
Authority meetings, filing of applications for Regulatory Approval, and the receipt of Regulatory Approvals and (iii) the respective roles and responsibilities of each Party in connection with such activities. The Development Plan will be
associated with a detailed budget for all such activities conducted by the Parties for the U.S. In the event of any inconsistency between the Development Plan and this Agreement, the terms of this Agreement shall prevail. 

(b)        Initial Development Plan.    The initial
Development Plan, along with the associated Development Budget, describing (among other things) the planned development of the Product for the CKD Indications for the U.S., is attached hereto as Exhibit H (the “Initial Development
Plan”). The Initial Development Plan includes and shall be integrated with those Phase 3 Clinical Trials that are currently being conducted by FibroGen or Astellas under the U.S. and EU plan for conducting Phase 3 Clinical Trials of the
Product for the CKD Indications under the Astellas EU Agreement (the “Transatlantic Clinical Development Plan” or the “TCDP”). FibroGen shall notify AstraZeneca, via the JDC, of all material updates
and material changes to the TCDP. The Initial Development Plan shall further outline such additional Phase 3 Clinical Trials as the Parties have agreed to conduct (i.e. in addition to those being conducted under the TCDP). Within thirty
(30) days after the Effective Date, the JPT will initiate implementation of the Initial Development Plan. 

(c)        Development Strategy.  Within one (1) year after the
Effective Date or at such other time as the Parties may mutually agree, the JDC will prepare for the JSC’s review and approval an overall development strategy for the Product in the Field in the Territory, including the CKD Indications for the
RoW and any other indications (or other life cycle management) the Parties are considering to develop (or conduct) throughout the Territory, which strategy will include anticipated dates (estimated based on the date of completion of certain
development events) for preparing detailed descriptions of applicable events for inclusion in an amended Development Plan (the “Development Strategy”). The Development Strategy will include reasonable timeframes for any
additional indications (i.e., in addition to the CKD Indications) to be developed hereunder, with the understanding that not all such indications will be developed concurrently. 

  
 26. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d)        Amendments to the
Development Plan. 
 (i)        On an annual basis (no later than
October 31st of the preceding Calendar Year), or more often as the Parties deem appropriate, the JDC shall prepare amendments to the then-current Development Plan and Development Budget for
approval of the JSC. Each such amended Development Plan shall specify, with a reasonable level of detail, the items described in Section 3.2(a). Such amended Development Plan shall cover the next Calendar Year (and additional periods as
reasonably determined by the Parties) and shall contain a corresponding budget for U.S. activities. Such updated and amended Development Plan shall reflect any changes, re-prioritization of studies within, reallocation of resources with respect to,
or additions to the then-current Development Plan. In addition, the JDC may prepare amendments for approval of the JSC to the Development Plan and corresponding Development Budget from time to time during the Calendar Year in order to reflect
changes in such plan and budget for such Calendar Year, in each case, in accordance with the foregoing. At the request of either Party, but no more frequently than quarterly, the JDC shall review the Development Budget and propose any necessary
amendments to the JSC for approval. Once approved by the JSC, the amended annual Development Plan and Development Budget shall become effective for the applicable period on the date approved by the JSC (or such other date as the JSC shall specify).
Any JSC-approved amended Development Plan and Development Budget shall supersede the previous Development Plan and Development Budget for the applicable period. 

(ii)       Each Party shall notify the other Party promptly upon becoming aware
that it is likely to exceed, or has exceeded, the budget for a particular activity for U.S. Development of the Product allocated to such Party in the Development Plan. Thereafter, the JDC shall promptly meet and determine whether to amend the
Development Plan or Development Budget accordingly, provided that the JDC shall not unreasonably withhold its agreement to any budget amendment proposed by either Party that results from causes outside of such Party’s reasonable control or that
the Parties agree includes expenses reasonably incurred in the performance of the Development Plan. Any such amendment proposed by the JDC shall not be subject to the JSC’s review and will be deemed automatically approved by the JSC, unless
such amendment would cause the total Development Costs incurred by a Party in any Calendar Year to exceed [*] percent ([*]%) of the budgeted Development Costs for such Party in such Calendar Year, in which event JSC approval will be required;
provided that the JSC shall not unreasonably withhold its agreement to any budget amendment proposed by either Party that results from causes outside of such Party’s reasonable control and that the Parties agree includes expenses reasonably
incurred in the performance of the Development Plan. 
 (e)        Development
Responsibilities.  Unless the Parties agree in writing upon an alternate allocation of responsibility, the Parties shall have the following rights and obligations with respect to operational responsibilities under each Development
Plan: 
 (i)        U.S.   Operational responsibility for all
studies designed to support Regulatory Approvals in the U.S. will be shared between the Parties as allocated in the Development Plan; provided that FibroGen and Astellas (it being agreed that as between the Parties FibroGen will be responsible for
all such activities conducted by Astellas; provided however, that [*] Astellas [*] Astellas [*] FibroGen [*] this Agreement [*] FibroGen [*] under the Astellas Agreements with respect to such activities) will be responsible for conducting the first

  
 27. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Phase 3 Clinical Trials (that are included also in the TCDP) of the Product in the CKD Indications under the Initial Development Plan. For clarity, the term ‘first Phase 3 Clinical
Trials’, as used in this section, shall be the studies identified as [*] in the Initial Development Plan. 

(ii)        RoW. AstraZeneca shall be solely responsible for all aspects of
the Development of Collaboration Compounds and Products that are solely applicable to the RoW (which, for clarity, does not include China). 

(iii)       Development Sharing Period. During the Development Sharing Period,
FibroGen shall conduct all Development in good faith, and using Commercially Reasonable Efforts to achieve the then-current timelines in such Development Plan. 

(f)         Development Decision-Making. Except as otherwise expressly
provided in this Agreement, all matters regarding the Development Plan shall be decided by consensus by the JDC, subject to Section 2.6. 

 3.3        Coordination with Astellas. 

(a)        AstraZeneca understands and agrees that FibroGen’s and
AstraZeneca’s conduct of certain Development and Commercialization activities for North America (meaning the U.S., Mexico and Canada) hereunder are subject to the terms of the Astellas EU Agreement, and that FibroGen’s obligations to
Astellas may require additional procedures, consents or adherence to notification obligations. Accordingly, the Parties shall, as applicable, take into consideration such obligations when formulating the plans for, and coordinate, [*], and FibroGen
shall use Commercially Reasonable Efforts to obtain [*] Development in the Territory under this Agreement. [*]. Notwithstanding anything else in this Agreement to the contrary, however, FibroGen shall not be required to perform (or refrain from
performing) any Development activity that would constitute a violation of its obligations under the Astellas Agreements, as disclosed to AstraZeneca prior to the Effective Date. 

(b)        If, [*], FibroGen shall promptly notify AstraZeneca and such matter
shall be discussed at a specially convened JSC meeting. In the event that AstraZeneca, pursuant to Section 3.9, both (i) is not obligated to use Commercially Reasonable Efforts to Develop such Product in such indication; and
(ii) following notification by FibroGen, determines that it does not wish to participate in such Development in such indication, the following shall apply: 

(i)        FibroGen shall be free to Develop, obtain Regulatory Approval for
and Commercialize such Product in such indication throughout the Territory; 

(ii)       As between the Parties, such Development and Commercialization shall be
undertaken at FibroGen’s sole cost; 
 (iii)      FibroGen shall use Commercially
Reasonable Efforts to ensure that such Development and Commercialization shall not materially impact AstraZeneca’s rights under this Agreement (it being understood that such Development and Commercialization are not considered per se to
materially impact AstraZeneca’s rights under this Agreement); 

  
 28. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (iv)       The Parties shall, as soon
as practicable, discuss in good faith an option arrangement whereby AstraZeneca may obtain rights to such Product in such indication at a future decision point. The Parties shall negotiate in good faith the terms under which AstraZeneca would obtain
such rights, which terms include [*] and [*]; and 
 (v)        The Parties
shall discuss in good faith, appropriate amendments to the provisions of this Agreement to reflect such Development and Commercialization of such Product in such indication by FibroGen, including, without limitation, amendments to the
pharmacovigilance provisions in Section 4.3. If the Parties fail to agree on such terms within a reasonable time period, either Party may refer the matter to the Executive Officers for discussion. 

(c)        The Parties shall ensure that each amended Development Plan allows
for the conduct of such Clinical Trials as are included in the then current TCDP. If the JDC agrees that additional studies (i.e. in addition to those included in the TCDP) are required for the Product in the CKD Indications for the U.S., then the
Parties shall, where required, [*]. FibroGen shall use Commercially Reasonable Efforts to [*], shall use Commercially Reasonable Efforts to [*]. 

(d)        FibroGen shall use Commercially Reasonable Efforts from time to
time during the Term to [*] or other rights that AstraZeneca or the Parties reasonably believe [*] in order to allow AstraZeneca to obtain the benefit of its rights and licenses pursuant to this Agreement. 

 3.4       Development Costs. 

(a)        Allocation.  The Parties shall share equally all costs
and expenses incurred by or on behalf of either Party to conduct Development of the Product for the U.S. under the Development Plan during the Development Sharing Period, according to the terms of Section 8.2, including for supply of
Collaboration Compound or Product in accordance with Article 6, in each case to the extent that such Development Costs are not borne or reimbursed by Astellas under the Astellas EU Agreement, provided that FibroGen will timely inform AstraZeneca of
any such costs borne or reimbursed by Astellas. AstraZeneca shall be responsible for all costs and expenses it incurs in the conduct of activities under the Development Plan for the RoW and shall reimburse FibroGen for all costs and expenses
FibroGen incurs (including Personnel Costs, the Fully Burdened Cost of Collaboration Compound or Product or comparator drug, concomitant drug, placebo or other materials used in any Clinical Trial or Nonclinical Studies, and all other out-of-pocket
costs) for activities conducted by FibroGen (i) for the U.S. after the Development Sharing Period and (ii) for the RoW, in each case (i) and (ii) under the Development Plan within the applicable Development Budget (for the U.S.)
or budget (for RoW) (subject to overages described in Section 3.4(b)) and according to the terms of Section 8.2, together with the reimbursement for supply of Collaboration Compound or Product in accordance with Article 6. For clarity, all
Clinical Trials set out in the Initial Development Plan shall be deemed to be Development of the Product for the U.S. 

(b)        Overage.     Notwithstanding the foregoing
in Section 3.4(a), unless otherwise agreed by the JDC (subject to JSC approval to the extent set forth in Section 3.2(d)(ii)) or by the Parties, either before or after the applicable expense is incurred (which agreement shall not be
unreasonably withheld for any budget overage outside the applicable Party’s reasonable 

  
 29. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
control and reasonably incurred in the performance of the Development Plan), for any Calendar Quarter, each Party will be solely responsible for Development Costs it incurs in excess of [*]
percent ([*]%) of the total amount allocated to such Party’s activities in such Calendar Quarter in the Development Budget, and for any Calendar Year, each Party will be solely responsible for Development Costs it incurs in excess of [*]
percent ([*]%) of the total amount allocated to such Party’s activities in such Calendar Year in the Development Budget, provided that Development Costs incurred in excess of [*]% for the Calendar Quarter or [*]% for the Calendar Year, as
applicable, of the amounts so budgeted shall also be reimbursed if the Parties determine in good faith that such Development Costs were reasonably incurred in the performance activities under the Development Plan and that such budget overage was
caused by circumstances outside of such Party’s reasonable control. 

 3.5       Indications Outside the Field. 

(a)        Inclusion.   If either Party desires to develop a
particular Product for an indication outside the Field, it may propose such indication to the other Party in writing by providing the other Party with a high-level proposed development plan for such Product in such indication. Upon the other
Party’s request within sixty (60) days after receipt of such development plan, the Parties shall meet to discuss such proposed indication and shall work together in good faith to generate and gather the necessary information to support
such potential development and to prepare a detailed development plan. If the Parties agree on such plan, AstraZeneca shall have the right to include the proposed indication in the Field, solely with respect to the applicable Product, by written
notice to FibroGen. If AstraZeneca exercises such right, such indication will be a “Designated Indication”, the Field will automatically be expanded to include the Designated Indication (without payment of any additional
upfront fees, milestones or other consideration except those payments already provided for under this Agreement), the terms of this Agreement (including payment terms and diligence obligation) will apply to such indication and the JDC shall promptly
prepare a development plan for such indication for review and approval by the JSC. 

(b)        Termination.   The Field will automatically be
amended to remove any Designated Indication upon the occurrence of any of the following events: (a) the permanent cessation (excluding, for example, suspension, termination or completion pending further review, consideration or development
planning) of all Clinical Trials by both Parties with respect to such Product for such Designated Indication prior to Regulatory Approval in any country in the Territory in such Designated Indication, (b) the termination of all Regulatory
Approvals for such Designated Indication in the Territory without either Party intending or considering to restore or replace any such Regulatory Approval, or (c) the decision of the JSC to permanently cease all Commercialization of such
Product in such Designated Indication. 

(c)        Restriction.  For clarity, Designated Indications are
only those indications outside the Field that AstraZeneca agrees to include in this Agreement. Except for Designated Indications pursuant to this Agreement, FibroGen shall not Develop or Commercialize (directly or indirectly, by license, supply of
Product or otherwise) any Product for any indication outside the Field in the Territory during the term of this Agreement. 

  
 30. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  3.6      Additional Compounds. 

(a)        Added by FibroGen. At any time during the Term, FibroGen may upon
written notice to AstraZeneca include any HIF Compound in the definition of Collaboration Compound (and Product). Effective upon such written notice, the identified HIF Compound shall be deemed a Collaboration Compound, provided that AstraZeneca
shall not have any obligations with respect to such Collaboration Compound (or Product) under this Agreement unless and until AstraZeneca’s acceptance thereof through written notice to FibroGen. 

(b)        Added by Agreement. 

(i)        If AstraZeneca wishes to include additional HIF Compounds as
Collaboration Compounds (and Products), it may make such a request to FibroGen. Upon receipt of such request, FibroGen shall make good faith and diligent efforts to present to the JSC for review all reasonably relevant data and other information
(excluding chemical structures) Controlled by FibroGen that is related to those HIF Compounds that it reasonably believes offer substantial clinical benefit over then-current Collaboration Compounds from its library of HIF Compounds, including
results from any Phase 2 Clinical Trial conducted in the Field. For clarity, the foregoing does not impose any obligation on FibroGen to identify or generate any additional HIF Compounds. 

(ii)       If AstraZeneca and FibroGen, through the JDC and JSC, agree upon a
development program for any such HIF Compounds, then the Parties shall negotiate in good faith to agree on any additional consideration to be payable by AstraZeneca to FibroGen for inclusion of such additional HIF Compounds as Collaboration
Compounds, and upon agreement, will amend this Agreement accordingly. 

(c)        Subject to Section 3.3 and to FibroGen’s obligations
under the Astellas EU Agreement, FibroGen will use good faith in designating additional HIF Compounds as Collaboration Compounds pursuant to this Section 3.6, and shall not nominate additional HIF Compounds for Development in the [*] without
approval of the JSC. 
  3.7       Veterinary
Applications.  Following the first approval of an NDA for a Product, the Parties may agree to develop the Product for a veterinary application. No additional consideration shall be payable by AstraZeneca to FibroGen with respect to
such development. Upon agreement, the Parties shall enter into a separate agreement governing such applications or amend this Agreement accordingly prior to conducting any activities with respect to veterinary applications. 

 3.8       Research Collaboration.    Upon FibroGen’s
request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the
Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly. 

  
 31. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 3.9        Diligence; Standards of
Conduct. 
 (a)        Each Party shall use Commercially Reasonable
Efforts to Develop and obtain Regulatory Approval for the Products throughout the Territory (i) in the CKD Indications and (ii) in each [*], other indication in the Field and Designated Indication that [*] in the Development Plan. If at
any time there is only one Collaboration Compound (either because no additional Collaboration Compounds have been developed or because development of all other Collaboration Compounds have been terminated), then the foregoing obligation shall be for
one Product only. 
 (b)        Each Party shall use Commercially Reasonable
Efforts to carry out the tasks assigned to it under the Development Plan in a timely and effective manner. Each Party shall conduct its activities under the Development Plan in a good scientific manner and in compliance in all material respects with
all applicable laws and regulations. Without prejudice to the aforesaid, the Party responsible for the conduct of any Clinical Trials hereunder shall perform such Clinical Trials in a good scientific manner, in compliance with all applicable laws
and regulations, GCP, this Agreement and the Development Plan as well as the relevant protocol and investigator’s brochure. Such Party shall further require the principal investigators, study sites and any contractors involved in the
performance of such Clinical Trials to comply with all safety reporting procedures set forth in the Pharmacovigilance Agreement in connection with their performance of such Clinical Trials. 

3.10      Development Data. 

(a)        Ownership and Disclosure.  FibroGen shall solely own all
data, records and reports generated by or on behalf of either Party in the conduct of Development activities under this Agreement (collectively, the “Development Data”), and AstraZeneca hereby assigns, and shall assign, to
FibroGen, all of its right, title and interest in and to the Development Data. Each Party shall provide access to and, where practical, copies of the Development Data it (or its Affiliates or Sublicensees, or Third Parties acting on their behalf)
generates to the other Party promptly upon receipt or development thereof, including nonclinical and clinical data (including raw data), analysis, reports and protocols. With respect to any data, records and reports, including nonclinical and
clinical data (including raw data), analysis, reports and protocols, generated by or on behalf of FibroGen [*]”), the following shall apply. [*]. AstraZeneca shall reimburse FibroGen for any translation costs, costs for photocopying or other
similar administrative expenses incurred by FibroGen in connection with providing access to the [*]. Each Party will reasonably respond to the other Party’s request for access to and questions about the Development Data and Astellas Data. Such
Development Data will be provided in electronic form if requested by the other Party or reasonably convertible to such electronic form. 

(b)        Use.  Each Party shall have the right to use the
Development Data, and [*], for the purpose of Developing and Commercializing Products in the Field in the Territory in accordance with the terms of this Agreement and in China in accordance with the terms of the China Agreement. [*]. AstraZeneca
hereby grants [*]. AstraZeneca will take all actions reasonably requested by FibroGen to enable [*], at FibroGen’s cost and expense. FibroGen hereby grants AstraZeneca, its Affiliates and Sublicensees a right of access, a right of reference and
a right to use and incorporate all Development Data [*] in any regulatory filings for Products in the 

  
 32. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Territory. FibroGen will take all actions reasonably requested by AstraZeneca to enable AstraZeneca and its Affiliates and Sublicensees to practice such rights, at AstraZeneca’s cost and
expense. 
  3.11    Development Records and Reports.    Each Party
shall maintain or cause to be maintained complete and accurate records (in the form of technical notebooks and/or electronic files where appropriate) of all work conducted by it or on its behalf under the Development Plan and all Information
resulting from such work, including in the case of FibroGen, records of whether Development Costs are borne or reimbursed by Astellas under the Astellas EU Agreement. Such records, including any electronic files where such Information may also be
contained, shall fully and properly reflect all work done and results achieved in the performance of the Development Plan in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Such records shall be
retained by such Party for at least five (5) years after the term of this Agreement or such longer period as may be required by applicable laws. Each Party shall have the right to review and copy such records maintained by the other Party at
reasonable times and to obtain access to originals to the extent needed for patent or regulatory purposes or for other legal proceedings. Each Party shall provide the JDC with regular reports, at least annually, detailing its Development activities
under the Development Plan and the results of such activities. 

 3.12    Subcontracts.     Each Party may perform any of its
Development Program obligations under this Agreement through one or more subcontractors or consultants, provided that (a) such Party remains responsible for the work allocated to, and payment to, such subcontractors and consultants as it
selects to the same extent it would if it had done such work itself; (b) the subcontractor undertakes in writing obligations of confidentiality and non-use regarding Product Information and Confidential Information, that are substantially the
same as those undertaken by the Parties pursuant to Article 12 hereof, and (c) the subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work under the Development Program to the
Party retaining such subcontractor. A Party may also subcontract work on terms other than those set forth in this Section 3.12, with the prior approval of the JDC. 

ARTICLE 4 

REGULATORY MATTERS 

 4.1      Regulatory Filings and Approvals. 

(a)        In General.  The Parties intend that the Development Plan
will set forth the regulatory strategy for seeking Regulatory Approvals (including any pricing and reimbursement approvals) throughout the Territory for all Products being Developed. All decisions regarding regulatory issues shall be made in
accordance with the decision-making rules that are set forth in Article 2. 

(b)        Rights and Obligations. 

(i)        Lead Regulatory Party.      The lead
regulatory Party, on a jurisdiction-by-jurisdiction basis, shall be responsible for preparing and filing all Regulatory Materials, including INDs, shall be the holder of all Regulatory Approvals in such jurisdiction and

  
 33. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
will have primary operational responsibility for interactions with Regulatory Authorities, including taking the lead role at all meetings with Regulatory Authorities, subject to the right of the
other Party to attend such meetings, participate in such activities and provide input, which the lead regulatory Party will consider in good faith. Without limitation, this right of participation covers all regulatory activities, including
development of regulatory strategy and review of regulatory submissions, attendance at all meetings with Regulatory Authorities that may potentially impact the Development of or registration package for a particular Product, and review of outcomes
of such meetings. 
 (ii)       U.S.  FibroGen shall be the lead
regulatory Party in the U.S. with respect to each Product and each indication through approval of the first NDA or supplemental NDA for such Product and indication. The Parties shall cooperate in maintaining each IND and preparing and submitting
each NDA and applying for Regulatory Approval in the U.S. Following such approval, FibroGen will assign and transfer each such approved NDA or supplemental NDA to AstraZeneca (but not the ownership of Development Data therein, which shall be
retained by FibroGen pursuant to Section 3.10(a)), and AstraZeneca will become the lead regulatory Party for such Product and indication in the U.S.; provided that (A) FibroGen will remain the lead regulatory Party with respect to the CMC
section of each NDA for so long as FibroGen is conducting manufacturing activities under this Agreement, and (B) FibroGen will continue to have access to all information in each NDA. FibroGen shall duly execute and deliver, or cause to be duly
executed and delivered, such instruments and shall do and cause to be done such acts, including the filing of such assignments, agreements, documents and instruments, as may be reasonably necessary to effectively complete such assignment and
transfer of such approved NDA or supplemental NDA to AstraZeneca. Each Party shall provide reasonable cooperation, information and other support to the other Party with respect to such other Party’s obligations to comply with regulatory
requirements, regardless of whether such other Party is the lead regulatory Party, including following the transfer of an NDA to AstraZeneca following Regulatory Approval. 

(iii)      RoW. AstraZeneca shall be the lead regulatory Party in the RoW for all
Products and indications. 
 (c)        Reporting and Review. 

(i)        The JPT or JDC shall develop and implement procedures for drafting
and review of material Regulatory Materials for Products in the Territory, which shall provide sufficient time (at least one week) for each Party to provide substantive comments prior to the filing of such Regulatory Materials (with material
regulatory filings, or regulatory filings that materially change existing regulatory filings, subject to prior approval by the JPT or, when formed, the JDC or the JSC pursuant to Section 2.2(c)(ix) or Section 2.3(b)(xv), as applicable).

 (ii)       Each Party shall promptly notify the other Party of all Regulatory
Materials that it submits for Products anywhere in the Territory and shall promptly (and in any event within one week) provide the non-responsible Party with a copy (which may be wholly or partly in electronic form) of such Regulatory Materials. The
lead regulatory Party will provide the non-responsible Party with reasonable advance notice of any scheduled meeting with any Regulatory Authority and/or any Regulatory Materials with respect to Products throughout the Territory, and the
non-responsible Party shall have the right to participate in any such meeting, 

  
 34. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
except to the extent prohibited under applicable law and regulations. Representatives of the Party primarily responsible for such Regulatory Materials will be the primary spokespeople at any such
meeting. The Party primarily responsible for such Regulatory Materials also shall promptly furnish the non-responsible Party with copies of all material correspondence to or from, and minutes of material meetings with, any Regulatory Authority
relating to Development of such Product. 
  4.2        Notification of
Threatened Action.  Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action, inspection or communication by or from any Third Party, including a Regulatory
Authority, which may materially affect the Development, Commercialization or regulatory status of a Product, whether in or outside the Territory. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a
mutually acceptable procedure for taking appropriate action. 

 4.3        Adverse Event Reporting and Safety Data
Exchange.  At a time determined by the JSC, but in any event prior to the first to occur of (i) the commencement of any Clinical Trial to be conducted by AstraZeneca or (ii) the transfer of the first NDA in the U.S. to
AstraZeneca, the Parties shall define and finalize the methods and procedures (based on and consistent where possible with those methods and procedures used by Astellas and FibroGen under the Astellas EU Agreement, unless otherwise mutually agreed)
that the Parties shall employ with respect to Products to protect patient safety and promote the appropriate treatment of safety information of Products in a written pharmacovigilance agreement (the “Pharmacovigilance
Agreement”). For clarity, the Pharmacovigilance Agreement shall include all relevant safety data regarding the Product, irrespective of territory or indication. These responsibilities shall include mutually acceptable guidelines and
procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of any Product. Such guidelines and procedures
shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under applicable laws and regulations. Furthermore, such agreed procedure shall be consistent with GCP and relevant ICH guidelines,
except where such guidelines may conflict with existing local regulatory reporting or safety reporting requirements, in which case the local reporting requirements shall prevail. FibroGen shall maintain a global safety database for the Products, the
expenses for which will be included in Development Costs and reimbursed by AstraZeneca, to the extent not borne or reimbursed by Astellas. Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement and
to cause its Affiliates and permitted sublicensees to comply with such obligations. If and to the extent necessary, the Pharmacovigilance Agreement shall be amended by the Parties, or shall be superseded, so that an appropriate commercial-stage
pharmacovigilance agreement is in place in advance of the first NDA approval for a Product. 

 4.4        Product Withdrawals and Recalls.  If any Regulatory
Authority in or outside the Territory (a) threatens, initiates or advises any action to remove any Product from the market or (b) requires or advises FibroGen, AstraZeneca, or any of their respective Affiliates or Sublicensees to
distribute a “Dear Doctor” letter or its equivalent regarding use of such Product, then FibroGen or AstraZeneca, as applicable, shall notify the other Party of such event within three (3) Business Days (or sooner if required by law)
after such Party becomes aware of the action, threat, advice or requirement (as applicable). The JSC will discuss and attempt to agree upon whether to recall or 

  
 35. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
withdraw a Product; provided, however, that if the Parties fail to agree within an appropriate time period, the Party who is the then-holder of the NDA for the Product at issue shall decide
whether to recall or withdraw such Product. AstraZeneca shall be responsible, at its sole expense, for conducting any recalls or taking such other necessary remedial action in the Territory, except that FibroGen will be responsible for such expenses
to the extent (i) resulting from the failure of any Product supplied by FibroGen to conform to the applicable specifications; or (ii) such recall results from an event outside the Territory and outside the territory licensed under the
China Agreement. 
 ARTICLE 5 

COMMERCIALIZATION 

 5.1       Overview.  The Parties agree to collaborate with respect
to the Commercialization of Products in the Field in the U.S. as provided in this Article 5 under the direction of the JCC, and pursuant to the U.S. Commercialization Plan applicable to each Product. AstraZeneca shall have the sole right and
responsibility for Commercializing Products in the Field in the RoW under the direction of the JCC, in accordance with this Agreement and as provided in this Article 5. Prior to the JCC’s inception, all references to the JCC in this Article 5
and elsewhere in this Agreement will be deemed references to the JSC (which may delegate certain responsibilities to the Core JPT in accordance with Schedule G(b)). 

 5.2       U.S. Commercialization Plan.    As further
described in this Section 5.2, the comprehensive strategy for the Commercialization of each Product in the U.S. shall be described in a comprehensive plan that describes the pre-launch, launch and subsequent Commercialization of such Product in
the U.S. (including without limitation the high level strategies regarding messaging, branding, pricing, advertising, planning, marketing, sales force training and allocation, and reimbursement/managed care), key tactics for implementing those
activities and the relative responsibilities of the Parties (each such plan, a “U.S. Commercialization Plan”), and the associated budget for such activities that details the anticipated Commercialization Costs (each such
budget, a “U.S. Commercialization Budget”). 

(a)        Promptly after the Effective Date, the JCC (or if not formed, the
JSC) will determine the initial pre-commercial activities for which AstraZeneca will prepare an initial U.S. Commercialization Plan, which activities will include [*], but need not include all activities described in the first paragraph of this
Section 5.2. Within ninety (90) days thereafter, AstraZeneca will present such plan to the JCC for review and approval. Within two (2) years after the Effective Date but in any event not later than two (2) years prior to the then
currently anticipated NDA submission date, AstraZeneca will present to the JCC a U.S. Commercialization Plan covering all activities described in the first paragraph of this Section 5.2, for review and approval by the JCC, which plan will
include the key prelaunch and launch activities, marketing and sales deployment required for the initial launch of the Product and associated budgets. The JCC shall review, revise and recommend for approval by the JSC such U.S. Commercialization
Plan promptly after receipt thereof. If the JCC is not yet formed by any of the foregoing dates, the JSC will review, revise and approve the applicable U.S. Commercialization Plan. 

(b)        AstraZeneca will prepare a detailed U.S. Commercialization Plan and
U.S. Commercialization Budget in preparation for U.S. launch of the Product for review and approval by the JCC no later than the submission of the first NDA for the Product, or at such other time determined by the JSC. 

  
 36. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c)        All U.S.
Commercialization Plans and U.S. Commercialization Budgets with respect to Products in the U.S. and subsequent revisions thereto will contain such information as the JCC believes necessary for the successful Commercialization of such Product in the
U.S., both pre- and post-launch, and shall generally conform to the level of detail utilized by AstraZeneca in preparation of its own product commercialization plans. On an annual basis (no later than October 31st of the preceding Calendar Year), or more often as the Parties deem appropriate, the JCC shall prepare amendments to the then-current U.S. Commercialization Plan(s) and the corresponding U.S.
Commercialization Budgets. In the event of any inconsistency between a U.S. Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Each Party shall conduct its activities under the U.S. Commercialization Plan in
compliance in all material respects with all applicable laws and regulations. 

 5.3       RoW Commercialization Plans.  AstraZeneca shall prepare
Commercialization plans with respect to Products in the RoW on an annual basis, shall submit such plans to the JCC for review and approval, and shall respond in a timely fashion to any reasonable requests of FibroGen or the JCC with respect to such
plans and Commercialization activities in the RoW. 

 5.4       Commercialization Costs.     AstraZeneca
shall be solely responsible for all Commercialization Costs incurred by it or by or on behalf of FibroGen under the Co-Commercialization Agreement and in the Commercialization of Products in the U.S. and RoW. AstraZeneca will reimburse FibroGen for
such costs incurred by FibroGen, plus a markup of [*] to be applied to FibroGen’s [*] costs only, all pursuant to more detailed provisions to be included in the Co-Commercialization Agreement. 

 5.5       Sales and Distribution; Returns; Customer
Support.  AstraZeneca shall be solely responsible for handling all returns, recalls, order processing, invoicing and collection, booking of sales, distribution, and inventory and receivables for Products in the Territory. FibroGen
shall not accept orders for Products or make sales for its own account or for AstraZeneca’s account, and if FibroGen receives any order for Products in the Territory, it shall refer such orders to AstraZeneca for acceptance or rejection.
AstraZeneca shall be responsible for handling all returns of any Product. If Products are returned to FibroGen, FibroGen shall promptly ship such Products to AstraZeneca. FibroGen, if requested by AstraZeneca, shall advise the customer who made the
return that the Products have been returned to AstraZeneca. AstraZeneca shall be responsible for providing customer support, handling medical queries, and responding to product and medical complaints relating to Products. 

 5.6       Commercialization Reports.   Each Party shall keep
the JCC fully informed regarding the progress and results of Commercialization activities for Products in the U.S. and RoW, including an annual review of results versus plans (as set forth in the U.S. Commercialization Plan(s)). 

 5.7       Samples.  At a time determined by the JSC, the Parties
will discuss in good faith whether, how, and under what circumstances the Parties would allow distribution of samples (i.e., Products provided free of or for a nominal charge) of Product for treatment of anemia in patients

  
 37. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
with chronic kidney disease not undergoing dialysis, or in other applicable indications outside of the CKD Indications. Neither Party will have the right to distribute Product samples without the
prior written consent of the other Party, and, if such consent is granted, each Party will distribute such samples only according to the procedures and in the amounts agreed by the Parties in writing. 

5.8        Commercialization Standards of Conduct. 

(a)        Execution of U.S. Commercialization
Plan.    Each Party shall use Commercially Reasonable Efforts to carry out the tasks assigned to it under the U.S. Commercialization Plan and the Co-Commercialization Agreement in a
timely and effective manner and in compliance with all applicable laws and regulations. 

(b)        AstraZeneca Diligence Obligations. AstraZeneca shall use
Commercially Reasonable Efforts to Commercialize each Product in each indication and country in the Territory for which Regulatory Approval is obtained, except for indications and countries for which FibroGen has independently obtained Regulatory
Approval, without opt-in by AstraZeneca, under Section 3.3(b). 

5.9        Subcontracts.    Each Party may perform any of
its obligations under the U.S. Commercialization Plan through one or more subcontractors or consultants, provided that (a) AstraZeneca will not subcontract any such activities without [*]; (b) such Party remains responsible for the work
allocated to, and payment to, such subcontractors and consultants as it selects to the same extent it would if it had done such work itself; (c) the subcontractor undertakes in writing obligations of confidentiality and non-use regarding
Product Information and Confidential Information, that are substantially the same as those undertaken by the Parties pursuant to Article 12 hereof, and (d) the subcontractor agrees in writing to assign all intellectual property developed in the
course of performing any such work under the U.S. Commercialization Plan to the Party retaining such subcontractor. A Party may also subcontract work on terms other than those set forth in this Section 5.9, with the prior approval of the JCC.
AstraZeneca will have [*] (subject to compliance with clauses (b) – (d) of this Section 5.9), except that AstraZeneca will be required to reasonably [*] Third Party subcontractors for such activity. 

5.10       Co-Commercialization Agreement.  Following submission of the
first NDA for a Product or at such earlier time as AstraZeneca may request, the Parties will negotiate and enter into an agreement (the “Co-Commercialization Agreement”) governing the
Parties’ conduct of activities for Commercializing the Product in the U.S. The Co-Commercialization Agreement will be consistent with the terms of this Article 5, Exhibit I, other terms agreed by the Parties, and other customary terms
for such an agreement. 
 5.11       Regulatory Compliance. 

(a)        Each of FibroGen and AstraZeneca shall reasonably cooperate with
the other Party in its efforts toward ensuring that all government reporting (including price and gift reporting), sales, marketing and promotional practices in respect of each Product meet the standards required by (A) applicable laws and
regulations; (B) applicable guidelines concerning the advertising and promotion of prescription drug products, including without limitation the Office of the Inspector General’s (“OIG”) Compliance Guidance Program
issued in 2003, the 

  
 38. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
American Medical Association (the “AMA”) Guidelines on Gifts to Physicians, the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare
Professionals, as hereafter amended from time to time (the “PhRMA Code”), the PhRMA Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results, and the standards set forth by the Accreditation
Council for Continuing Medical Education relating to educating the medical community in the United States (“ACCME Standards”); (C) the Prescription Drug Marketing Act of 1987, as amended, and the rules, regulations and
guidelines promulgated thereunder; (D) federal, state and local agencies and all payor “fraud and abuse”, and consumer protection and false claims statutes and regulations, including the Medicare and State Health Programs
Anti-Kickback Law (42 U.S.C. §1320a-7b(b)) and the Safe Harbor Regulations which are found at 42 C.F.R. §1001.952 et seq.; and (E) the FCPA. The Parties shall cooperate in good faith to update their obligations under this
Section 5.11(a) from time to time to reflect any changes in any of the foregoing (A) – (E) or to resolve any conflicts in any of the foregoing standards as applied to the Parties’ activities under this Agreement. 

(b)        Each Party shall be responsible for tracking and reporting
transfers of value initiated and controlled by its employees and/or contractors pursuant to the requirements of Section 6002 (Transparency Reports and Reporting of Physician Ownership and Investment Interest) of the Affordable Care Act,
commonly referred to as the “Sunshine Act”, and state marketing reporting laws. The value reported to the Centers for Medicare & Medicaid Services shall be the amount expended by the controlling Party, irrespective of the division
of or reconciliation of expenses between the Parties. 

(c)        AstraZeneca shall provide its sales representatives appropriate
training on proper marketing and sales techniques. Such training will include, among other topics, FDA requirements and other state and federal regulations and guidelines concerning the advertising of prescription drug products, the OIG Compliance
Guidance Program, the AMA Guidelines on Gifts to Physicians, the PhRMA Code, and the ACCME Standards. If requested by FibroGen, AstraZeneca shall provide a written description of the training to FibroGen no less frequently than on an annual basis.

 (d)        Each of FibroGen and AstraZeneca shall reasonably cooperate
with the other Party to provide the other Party access to any and all information, data and reports required by the other in order to comply with the relevant provisions of the Medicare Modernization Act and any other applicable laws and
regulations, including without limitation reporting requirements, in a timely and appropriate manner. AstraZeneca shall ensure that its reporting to the Centers for Medicare and Medicaid Services and other federal and state healthcare programs
related to the Products is true, complete and correct in all respects; provided however, that AstraZeneca shall not be held responsible for submitting erroneous reports if such deficiencies result from information provided by FibroGen which itself
was not true, complete and correct. 
 (e)        AstraZeneca shall, so far
as practicable, provide to FibroGen in advance any submission containing any information provided by FibroGen pursuant to this Section 5.11 that AstraZeneca proposes to submit to any governmental entity. AstraZeneca further agrees to seek
confidential treatment of any such information related to FibroGen that it submits to any governmental entity to the extent permitted under any applicable laws and regulations. 

  
 39. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (f)        FibroGen and
AstraZeneca shall confer with each other on a regular basis to discuss and compare their respective procedures and methodologies relating to each Party’s compliance to any applicable laws or regulations or fulfillment of any other obligation
contained in this Section 5.11. In the event that the parties have different understandings or interpretations of this Section 5.11 or of the applicability of, or standards required by, any applicable laws or regulations, then the Parties
shall confer and seek to reach common agreement on such matters. 

(g)        Each of AstraZeneca and (where applicable) FibroGen agrees that:

 (i)        it will instruct its sales representatives to use, and will
use Commercially Reasonable Efforts to train and monitor its sales representatives to ensure that such sales representatives use, only Promotional Materials and literature approved for use under subsection (h) of Exhibit I for the
promotion of the Products in the U.S.; 
 (ii)        it will instruct its
sales representatives not to misbrand, change, alter or adulterate any Promotional Materials supplied to it in any way prior to or during their distribution or use; and 

(iii)       it will instruct its sales representatives to do, and will use
Commercially Reasonable Efforts to train its sales representatives to do, and will establish appropriate internal systems, policies and procedures for the monitoring of its sales representatives with the goal of ensuring that such personnel do, the
following: 
 (1)        limit claims of efficacy and safety for the
Products to those that are (A) consistent with approved promotional claims in, and not add, delete or modify claims of efficacy and safety in the promotion of such Products in any respect from those claims of efficacy and safety that are
contained in, the then effective U.S. Commercialization Plan, (B) consistent with applicable laws and regulations, and (C) consistent with the Product labeling approved by the FDA; 

(2)        not make any changes in Promotional Materials, and use Promotional
Materials within the U.S. only in a manner that is consistent with (A) the then effective U.S. Commercialization Plan, (B) applicable laws and regulations and (C) the Product labeling approved by the FDA; 

(3)        promote the Products in compliance with applicable legal and
professional standards that are generally accepted by the pharmaceutical industry in the applicable market, including applicable laws and regulations and the applicable guidelines concerning the advertising and promotion of prescription drug
products described in this Section 5.11; and 
 (4)        not to,
directly or indirectly, pay, promise to pay, or authorize the payment of any money, or give, promise to give, or authorize the giving of anything of value to any official or employee of any Governmental Authority, or to any political party, or
official thereof, or to any candidate for political office (including any party, official, or candidate) for the purpose of promoting the sale or improper use of a Product. 

  
 40. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 6 

MANUFACTURE AND SUPPLY 

6.1        Purchase and Supply Commitment. AstraZeneca hereby appoints FibroGen
as its exclusive supplier of Product (drug substance and drug product) for the Territory for use in accordance with the terms of this Agreement. AstraZeneca agrees to purchase, and FibroGen agrees to supply, all of AstraZeneca’s and its
Affiliates’ and their respective Sublicensees’ requirements of Product (as bulk drug product and drug substance) for Development and Commercialization in the Territory under the terms of this Article 6. AstraZeneca shall have the exclusive
right to perform (itself or through its Affiliates, Sublicensees or Distributors) and shall be solely responsible for final product labeling and secondary packaging for sale to end users in the Territory. To the extent that such labeling and
packaging are relevant to FibroGen’s activities to seek and obtain Regulatory Approval for the Product, AstraZeneca will reasonably and timely cooperate with FibroGen, in a manner sufficient to enable FibroGen to receive Regulatory Approval and
to provide materials and Information as requested by FibroGen. The right of FibroGen to manufacture on behalf of AstraZeneca contemplates that at a time to be determined by the JSC, and in any event before the point in time when [*] in any twelve
(12) month period, AstraZeneca will have the right to select, or obligate FibroGen to select, a second supplier (which may be AstraZeneca itself), and FibroGen will have the obligation to complete activities to undertake technology transfer in
order for such secondary source to establish and secure regulatory approval as a second source for drug substance for Product, which shall in any event not limit FibroGen’s right to continue to ensure that a source of Product be maintained in
the U.S. in order to satisfy FibroGen’s obligations under the Astellas Agreements and the DFCI Agreement. For clarity, FibroGen shall have the right to manufacture Product outside the Territory to fulfill its supply obligations under this
Agreement. For clarity, subject to the terms of this Agreement, FibroGen shall have the right to satisfy its obligations under this Article 6 through a Third Party contract manufacturer. In connection with FibroGen’s manufacture of Products for
use under this Agreement, FibroGen shall have the right to manufacture in the Territory for supply of Products under the Astellas Agreements. 

6.2        Development Supply.     In connection with
the supply of any Product for non-commercial use, FibroGen shall supply Product in compliance with applicable law and regulations, including GMP requirements, and in accordance with forecasts set forth in the Development Plan or, if not specified
therein, the forecasts developed by the JDC as necessary for the conduct of Clinical Trials set forth in the Development Plan. FibroGen shall use Commercially Reasonable Efforts to meet any applicable timelines for supplying Product, subject to the
reasonable lead time requirements of Third Party contract manufacturers. AstraZeneca will pay FibroGen’s Fully Burdened Cost for all Product supplied for Development, within forty-five (45) days after receipt of invoice therefor. All
Products supplied for a country after Regulatory Approval in such country will be considered to be for commercial use, unless used specifically for Clinical Trials under the Development Plan. The terms of supply by FibroGen to AstraZeneca for use in
any Clinical Trial conducted under the sponsorship of AstraZeneca or for other non-commercial use by or on behalf of AstraZeneca, are as set forth on Exhibit J. 

6.3        Commercial Supply Agreement.  At a time specified by
AstraZeneca, but in any event in a reasonable period in advance of the anticipated launch date for the Product in the U.S., 

  
 41. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
the Parties will negotiate in good faith and enter into separate supply and quality agreements governing the commercial supply of Product (in bulk and primary packaged forms) from FibroGen to
AstraZeneca (together, the “Supply and Quality Agreement”). The Supply and Quality Agreement will include the terms and conditions set forth on Exhibit K and contain such further customary and commercially reasonable
terms governing similar supply arrangements and other terms as the Parties may agree, including appropriate forecasting and firm purchase order lead times, taking into consideration the reasonable notice requirements of FibroGen as well as any other
terms set forth in this Article 6. The initial Supply and Quality Agreement shall have a term of [*] years for the supply of drug substance, after which AstraZeneca would have the right to extend the term for an additional [*] years or to assume
responsibility for drug substance manufacture upon agreement of terms mutually agreed by the Parties, including [*] in the form of drug substance. Under the Supply and Quality Agreement, the obligation to supply drug product shall have a term of
five (5) years, which will automatically renew for succeeding five (5)-year terms and will include the price applicable pursuant to Section 6.5. In the event of any inconsistency between the Supply and Quality Agreement and Article 6 of
this Agreement with regard to matters relating to supply, quality control and quality assurance, the terms of the Supply and Quality Agreement shall prevail. 

6.4        Contract Manufacture Process.    FibroGen is
currently utilizing a contract manufacturer to fulfill its manufacturing timelines to complete drug product development in time for the expected commercial launch of the Product in the U.S. and under the Astellas Agreements. Notwithstanding the
provisions of Section 6.3, upon AstraZeneca’s written request to FibroGen, not to be submitted earlier than six (6) months after the Effective Date, the Parties will discuss in good faith whether to select a separate contract
manufacturer mutually acceptable to the Parties to be used for formulation and bulk drug product manufacture (using drug substance supplied by FibroGen) for commercial supply under this Agreement. The Parties shall discuss in good faith the
transfer, including timely technology transfer, as soon as practicable following such mutual agreement. Such selection will be conducted in accordance with the following process: As soon as reasonably practicable following AstraZeneca’s
request, the Parties will afford an opportunity for at least two (2) different Third Party contract manufacturers that are mutually acceptable to the Parties, consent not to be unreasonably withheld, to submit bids to conduct such manufacture.
Such bids shall be based on a request for quotation, the contents of which shall be agreed by the Parties in good faith (and shall contain such specifications and forecasts as are reasonably necessary for a contract manufacturer to submit a bid with
respect to such manufacture). AstraZeneca and its Affiliates shall provide a proposal on the same basis as the Third Party contract manufacturers. The Parties shall review and assess in good faith the bids submitted by the Third Party manufacturers
and by AstraZeneca or its Affiliate and shall recommend to the JDC the bid that, on the whole, offers the most favorable terms for such manufacture based on a reasonable assessment of the relevant factors, including price, capital requirements,
quality, capacity, capability to maintain continuity of supplies, considerations related to the supply of Product to Astellas and global supply of Product and overall timeline. FibroGen will enter into a supply and quality contract with the Third
Party contract manufacturer, on terms consistent with the selected bid and otherwise reasonably acceptable to the Parties, or the responsibility to manufacture shall be transferred to AstraZeneca, as determined by the JDC. In the event FibroGen
shall contract with AstraZeneca or its Affiliate in accordance with this Section 6.4, FibroGen shall – as soon as reasonably practicable after the completion of the selection process – provide the necessary technology transfer as well
as all necessary assistance to obtain required regulatory approvals, all 

  
 42. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
to enable AstraZeneca or its Affiliate to conduct the formulation and bulk drug product manufacture (using drug substance supplied by FibroGen) for supply of Product under this Agreement, and to
Astellas under the Astellas Agreements. If AstraZeneca is not selected as the contract manufacturer, then at any time after the [*], at AstraZeneca’s request, the Parties shall [*]. For clarity, to the extent that the alternative formulation
and drug product manufacture is transferred to such Third Party, FibroGen shall have the right to use such source of supply to satisfy FibroGen’s obligations under the Astellas Agreements. 

6.5        Transfer Price. 

(a)        FibroGen will supply to AstraZeneca (or its designated Affiliate or
Sublicensee) Product for commercial use as drug product at a transfer price equal to [*] during the Calendar Year in which such Product is delivered. Notwithstanding the foregoing, in the event that the Parties agree that AstraZeneca shall supply
drug product and FibroGen shall only supply drug substance, the transfer price for such drug substance shall be [*] during the Calendar Year in which such Product is delivered. 

(i)        If FibroGen supplies Product as drug product, then not less than
thirty (30) days prior to the beginning of each Calendar Year during which FibroGen will be supplying product (each a “Delivery Year”), the Parties will calculate a preliminary transfer price per unit (the
“Preliminary Price Per Unit”), which shall be equal to [*] multiplied by the fraction (A)/(B), where (A) shall be the estimated [*] for such Delivery Year and (B) shall be the estimated [*] in the Territory during
such Delivery Year (all estimations to be made by the Parties in good faith). FibroGen will invoice AstraZeneca upon delivery of each shipment of product at the Preliminary Price Per Unit and AstraZeneca will pay for such product at such price
within forty-five (45) days after its receipt of such invoice. Within forty-five (45) days following the end of each Delivery Year, the Parties will calculate the definitive transfer price per unit
(“Definitive Price Per Unit”) for such year, which shall be equal to [*] multiplied by the fraction (A)/(B), where (A) shall be the actual [*] made during the Delivery Year and (B) shall be the actual [*] in the
Territory during such Delivery Year (excluding [*]). If the transfer price for the total volume of product actually delivered by FibroGen during the Delivery Year at the Definitive Price Per Unit (the “Total Definitive
Price”) exceeds the transfer price for such volume based on the Preliminary Price Per Unit (the “Total Preliminary Price”), then AstraZeneca shall pay the difference to FibroGen within forty-five (45) days
after its receipt of an invoice from FibroGen for such amount. If the Total Preliminary Price exceeds the Total Definitive Price, FibroGen shall issue a credit note to AstraZeneca for the difference. AstraZeneca shall be entitled to set off the
amount due under the credit note against any subsequent payments owed by AstraZeneca to FibroGen under this Agreement (or, in the absence of any such subsequent payments, such credit note shall be settled by FibroGen within forty-five (45) days
after its receipt thereof). 
 (ii)        If FibroGen supplies Product as
drug substance, then the Parties shall calculate the price for Product according to a process similar to that described in clause (i) above, except that the multiplier shall be [*] during the Delivery Year. 

(b)        Potential Cost Reductions.  At either Party’s
request during the Term, the Parties shall discuss and explore potential means of collaborating to reduce the overall costs of manufacture and supply of Products as drug substance or bulk drug product under this Agreement,

  
 43. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
with the understanding that the Parties shall share the financial benefits of any such cost reductions achieved in a reasonable manner taking into account to what extent each Party has
contributed to such cost reductions. 
 (c)        Adjustment for Generic
Entry.    If at any time FibroGen’s net margin percentage on any Product supplied to AstraZeneca falls below [*] after a Generic Product is sold in any country in the Territory, FibroGen shall have the right to
renegotiate the manufacturing and supply payment terms under the Supply and Quality Agreement. Upon FibroGen’s request, the Parties shall renegotiate reasonable terms in good faith, taking into account also the overall profitability of such
Product to AstraZeneca. 
 ARTICLE 7 

LICENSES AND EXCLUSIVITY 

7.1        License to AstraZeneca. 

(a)        License Grant.  Subject to the terms and conditions of
this Agreement, FibroGen hereby grants AstraZeneca (i) a co-exclusive (with FibroGen), royalty-bearing, sublicensable (solely as permitted in accordance with Section 7.3) license under the FibroGen Technology to Develop (solely in
accordance with the Development Plan) Products in the Field in the Territory and (ii) an exclusive, royalty-bearing, sublicensable (solely as permitted in accordance with Section 7.3) license under
the FibroGen Technology to Commercialize, to make and have made (solely for use in the Territory under this Agreement), and to use, sell, offer for sale, and import Products in the Field in the Territory (subject, however to a retained right for
FibroGen to perform Development and Commercialization (including manufacturing) activities pursuant to this Agreement or the China Agreement or under the Astellas Agreements). 

(b)        DFCI Agreement. 

(i)        The terms and conditions of Sections [*] of the DFCI Agreement are
binding on AstraZeneca in its capacity as a sublicensee of FibroGen under the DFCI Agreement. 

(ii)        AstraZeneca acknowledges and agrees that its rights to the
FibroGen Technology that is licensed to FibroGen under the DFCI Agreement are at all times subject to the applicable terms of the DFCI Agreement. [*]. 

(iii)       FibroGen shall use best efforts to maintain the DFCI Agreement in
effect. [*]. 
 (iv)       The license granted in Section 7.1(a) is subject
to certain reserved rights as set forth in Section [*] of the DFCI Agreement. 

7.2        License to FibroGen.    Subject to the terms and
conditions of this Agreement, AstraZeneca hereby grants FibroGen a non-exclusive, worldwide, sublicensable, royalty-free, fully-paid license, under the AstraZeneca Technology during the Term, to conduct any and all activities assigned to FibroGen
under the Development Plans and U.S. Commercialization Plans, and to Develop and Commercialize Products outside the Territory. 

  
 44. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.3        Sublicensing. 

(a)        Scope of Permissible Sublicensing.   The license
granted by FibroGen to AstraZeneca in Section 7.1 may be sublicensed by AstraZeneca: (i) to an Affiliate of AstraZeneca without any requirement of consent, provided that such sublicense to an Affiliate of AstraZeneca shall immediately
terminate if and when such party ceases to be an Affiliate of AstraZeneca, or (ii) where such sublicense is made to enable a Third Party to provide contract research or development services or contract manufacturing services for AstraZeneca,
its Affiliates or Sublicensees, without such Third Party being granted the right to distribute, market or sell a Product, to such Third Party without any requirement of consent, but upon written notice to FibroGen and subject to Sections 3.12 and
5.9, and no sooner than twelve (12) days after such notice, or (iii) otherwise (i.e. other than pursuant to (i) or (ii) above) only with the prior written consent of FibroGen, not to be unreasonably withheld, and no sooner than
twelve (12) days after such consent is obtained. It will not be unreasonable for FibroGen to withhold its consent to a sublicense pursuant to subsection (iii) above to (1) any entity that [*] or (2) any company engaged in the
sales of tobacco or tobacco-related products. AstraZeneca shall be liable to FibroGen for the acts or omissions of its Sublicensees, and any breach of an applicable provision of this Agreement by a Sublicensee shall be deemed to be a breach by
AstraZeneca. 
 (b)        Sublicense Agreements.  AstraZeneca
shall, in each agreement under which it grants a sublicense under a license set forth in Section 7.1 (each, a “Sublicense Agreement”), require the Sublicensee to (A) comply with the obligations in Section 7.8
(as applied to such Sublicensee and its Affiliates) and (B) provide the following to FibroGen if this Agreement terminates and to AstraZeneca if only such Sublicense Agreement terminates: (i) the assignment and transfer of ownership and
possession of all Regulatory Materials and Regulatory Approvals held or possessed by such Sublicensee (which assignment could also be directly to AstraZeneca prior to any such termination), and (ii) the assignment of, or a freely sublicensable
exclusive license to, all intellectual property Controlled by such Sublicensee that covers or embodies a Product or Collaboration Compound or its respective use, manufacture, sale, or importation and was created by or on behalf of such Sublicensee
during the exercise of its rights or fulfillment of its obligations pursuant to such Sublicense Agreement. Each Sublicense Agreement shall be subject to the applicable terms and conditions of this Agreement, the DFCI Agreement and any Third Party
licenses sublicensed to the Sublicensee. AstraZeneca shall include a copy of the DFCI Agreement in all Sublicense Agreements. AstraZeneca shall forward a copy of each Sublicense Agreement (which may be redacted but shall contain all provisions
relevant to this Agreement unredacted) to FibroGen within twenty (20) days after execution thereof, and FibroGen shall have the right to provide such copy to DFCI; provided that with respect to any Sublicense Agreement with an Affiliate of
AstraZeneca, AstraZeneca shall only be required to provide such copy upon FibroGen’s request. Annually, AstraZeneca shall forward to FibroGen a copy of the reports received by AstraZeneca from its Sublicensees during the preceding twelve
(12) month period under each Sublicense Agreement as shall be pertinent to (i) the Sublicensee’s operations under each Sublicense Agreement and (ii) a royalty accounting under the Sublicense Agreement, in each case solely to the
extent relevant to FibroGen’s rights under this Agreement or (to the extent different, as notified by FibroGen to AstraZeneca) DFCI’s rights under the DFCI Agreement. FibroGen shall have the right to provide each such report to DFCI.
FibroGen shall require DFCI to comply with confidentiality and non-use obligations in respect of information disclosed to DFCI in accordance with this Section 7.3(b), which obligations shall be substantially the same as those undertaken by the
Parties pursuant to Article 12. 

  
 45. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

(c)        Distributorships.  AstraZeneca shall have the right, in
its sole discretion, to appoint its Affiliates, and AstraZeneca, its Affiliates and its Sublicensees shall have the right, in their sole discretion, to appoint any other person or entity, in the Territory, to distribute, market and sell the
Products, with or without packaging rights. In circumstances where such appointed person or entity purchases its requirements of Products from AstraZeneca, its Affiliates or its Sublicensees, but does not otherwise make any royalty or other payment
to AstraZeneca, its Affiliates or its Sublicensees with respect to intellectual property rights, and where such person is not an Affiliate of AstraZeneca, then that person or entity shall be a “Distributor” for purposes of
this Agreement. The term “packaging rights” in this Section 7.3(c) shall mean the right for the Distributor to package Products supplied in unpackaged bulk form into individual ready-for-sale packs. 

(d)        Co-Promotion.  Subject to Section 5.9, AstraZeneca
and its Affiliates shall have the right, in their sole discretion, to co-promote the Products with any other person or entity, or to appoint one or more Third Parties to promote the Products without AstraZeneca in all or any part of the Territory,
provided however that the foregoing shall not adversely impact FibroGen’s right to co-promote the Product as described under this Agreement. 

7.4        FibroGen’s Activities. 

(a)        Covenant by FibroGen.  Except pursuant to this Agreement
or the China Agreement, FibroGen and its Affiliates shall not, and shall not license or authorize any Third Party to, directly or indirectly, 

(i)        at any time during the Term Develop or Commercialize any Product in
the Territory within or outside of the Field; 
 (ii)       at any time during
the period starting on the Effective Date and continuing until the earlier to occur of (A) the [*] this Agreement and (B) the [*] this Agreement (“Covenant Period 1”) Develop any HIF Compound in any ESA Indication
in the Territory or any indication for which AstraZeneca is Developing or Commercializing a Collaboration Compound or Product under this Agreement; and 

(iii)     at any time during the period starting on the Effective Date and continuing until
the earlier to occur of (A) the [*] of this Agreement and (B) the [*] in the Territory (“Covenant Period 2”) Commercialize any HIF Compound in any ESA Indication in the Territory or any indication for which
AstraZeneca is Developing or Commercializing a Collaboration Compound or Product under this Agreement. 

(b)        Astellas Agreements.  [*]. 

(c)        Termination of Astellas Agreements.  Effective upon the
termination of either of the Astellas Agreements with respect to a particular country or countries (the “Astellas Terminated Territory”), FibroGen hereby grants AstraZeneca a right of first negotiation to obtain a license to
develop and commercialize Products in the Astellas Terminated Territory, as detailed 

  
 46. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
in this Section 7.4(c). Accordingly, prior to entering into any agreement with a Third Party for such purpose, FibroGen shall provide to AstraZeneca a written notice of FibroGen’s
interest in entering into an agreement with respect to the development and/or commercialization of Products in the Astellas Terminated Territory. [*]. If the Parties do not reach an agreement with respect to the grant of such rights with respect to
Products in the Astellas Terminated Territory [*] FibroGen shall have no further obligation with respect to the Astellas Terminated Territory under this Section 7.4(c). Notwithstanding the foregoing sentence, if FibroGen enters into an
agreement with a Third Party (a “Subsequent Licensee”) with respect to the Products and the Astellas Terminated Territory (a “Subsequent Agreement”), FibroGen shall ensure that such Subsequent
Agreement does not conflict with the terms of this Agreement and shall use Commercially Reasonable Efforts to ensure that AstraZeneca [*] under such Subsequent Agreement [*], and in any event shall ensure that AstraZeneca’s rights with respect
to the Subsequent Licensee [*]. 
 (d)        Remedy.  FibroGen
hereby acknowledges and agrees that in the event of any actual or threatened breach of this Section 7.4, AstraZeneca will suffer an irreparable injury, such that no remedy at law shall afford it adequate protection against, or appropriate
compensation for, such injury. Accordingly, FibroGen hereby agrees that AstraZeneca shall be entitled to specific performance of FibroGen’s obligations under this Section 7.4, as well as such further timely injunctive relief as may be
granted by a court of competent jurisdiction. 
 7.5       Cross-Territorial
Restriction. 
 (a)        AstraZeneca hereby covenants and agrees that
it shall not, and will ensure that its Affiliates and Sublicensees will not, either directly or indirectly, actively promote, market, distribute, import, sell or have sold Product into countries outside the Territory. As to such countries outside
the Territory: (i) AstraZeneca shall not, and will ensure that its Affiliates and Sublicensees will not, engage in any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the
Product located in such countries; and (ii) AstraZeneca shall not, and will ensure that its Affiliates and Sublicensees will not, solicit orders for Products from any prospective purchaser located in such countries. If AstraZeneca receives any
order for Products from a prospective purchaser located in a country outside the Territory from which re-imports into the Territory are unlikely, AstraZeneca shall immediately refer that order to FibroGen. AstraZeneca shall not accept any such
orders. AstraZeneca may not deliver or tender (or cause to be delivered or tendered) any Product into a country outside of the Territory from which re-imports into the Territory are unlikely. AstraZeneca shall not, and will ensure that its
Affiliates and Sublicensees will not, restrict or impede in any manner FibroGen’s exercise of its retained rights outside the Territory, provided that any such exercise of rights by FibroGen shall comply with the terms of this Agreement. 

(b)        FibroGen hereby covenants and agrees that it shall not and will
ensure that its Affiliates and any Subsequent Licensee shall not, either directly or indirectly, actively promote, market, distribute, import, sell or have sold Product into countries within the Territory. As to such countries within the Territory:
(i) FibroGen shall not, and will ensure that its Affiliates and Subsequent Licensees will not, engage in any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product
located in such countries; and (ii) FibroGen shall not, and will ensure that its Affiliates and Subsequent Licensees will not, solicit orders for Products from any prospective purchaser located in such countries. If

  
 47. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
FibroGen receives any order for Products from a prospective purchaser located in a country within the Territory from which re-imports out from the Territory are unlikely, FibroGen shall
immediately refer that order to AstraZeneca. FibroGen shall not accept any such orders. FibroGen may not deliver or tender (or cause to be delivered or tendered) any Product into a country within the Territory from which re-imports out of the
Territory are unlikely. FibroGen shall not, and will ensure that its Affiliates and Subsequent Licensees will not, restrict or impede in any manner AstraZeneca’s rights within the Territory, provided that any such exercise of rights by
AstraZeneca shall comply with the terms of this Agreement. In addition to the foregoing, FibroGen shall use Commercially Reasonable Efforts to invoke and enforce the provisions of the Astellas Agreements with respect to restrictions on supply and
commercialization in the Territory. 
 7.6        Negative
Covenant.    Each Party covenants that it will not knowingly use or practice any of the other Party’s intellectual property rights licensed to it under this Article 7 except for the purposes expressly permitted in the
applicable license grant. 
 7.7        No Implied
Licenses.   Except as explicitly set forth in this Agreement, neither Party grants to the other Party any license, express or implied, under its intellectual property rights. This Agreement confers no license or rights by
implication, estoppel, or otherwise under any patent applications or patents owned in whole or in part by DFCI other than the particular patents and patent applications licensed under the DFCI Agreement. 

7.8        Exclusivity. 

(a)        Restrictive Covenant by
AstraZeneca.      Except pursuant to this Agreement or the China Agreement, AstraZeneca and its Affiliates shall not, and shall not license or authorize any Third Party to, directly or indirectly, 

(i)        at any time during Covenant Period 1, or such longer period as may
follow from Section 13.6(i), research or Develop any HIF Compound in the Field; or 

(ii)       at any time during Covenant Period 2 and three (3) years
thereafter, Commercialize any HIF Compound in the Field and in the Territory. 

(b)        Acquisition.  Notwithstanding the foregoing in
Section 7.8(a), neither AstraZeneca’s nor any of its Affiliates’ direct or indirect acquisition of or merger with, in whole or in part, a person or entity (or group of companies) or the business of a person or entity (or group of
companies) having any activity contravening the covenants set forth in Section 7.8(a) shall constitute a breach of such covenants by AstraZeneca if AstraZeneca or its Affiliate, as the case may be, notifies FibroGen within forty-five
(45) days following the closing of such acquisition or merger of its intent to divest itself of such assets and complies with the following: 

(i)        AstraZeneca shall ensure that no Development Data, Information
related to Commercialization in connection with this Agreement, FibroGen Technology or Confidential Information of FibroGen is used in or for the purpose of the activities contravening such covenants. 

(ii)       AstraZeneca shall (or, as the case may be, cause its relevant Affiliate
to) [*] the sale or transfer to a Third Party of the relevant part of the business contravening 

  
 48. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
such covenants, and in any case, shall enter into (or, as the case may be, cause its relevant Affiliate to enter into) a binding definitive agreement with a Third Party for such sale or transfer
no later than [*] after the closing of the acquisition or merger transaction under which the relevant business was acquired. 

(iii)        Neither AstraZeneca nor its Affiliates shall, during such [*]
period, Commercialize a product being the subject of research or Development activities forming part of the relevant business which is to be divested, unless such product was already Commercialized prior to the closing of the acquisition or merger
transaction. 
 (iv)        AstraZeneca shall, notwithstanding anything to
the contrary in this Section 7.8(b), at all times continue to be obligated to use Commercially Reasonable Efforts to Develop or Commercialize a Product in accordance with its obligations under and subject to Sections 3.9 and 5.8. 

(c)        Remedy.  AstraZeneca hereby acknowledges and agrees that
in the event of any actual or threatened breach of this Section 7.8, FibroGen will suffer an irreparable injury, such that no remedy at law shall afford it adequate protection against, or appropriate compensation for, such injury. Accordingly,
AstraZeneca hereby agrees that FibroGen shall be entitled to specific performance of AstraZeneca’s obligations under this Section 7.8, as well as such further timely injunctive relief as may be granted by a court of competent jurisdiction.

 (d)        [*].    In the event AstraZeneca or its
Affiliates conducts any activities prohibited under this Section 7.8, any [*] shall be subject to the following [*]. AstraZeneca [*]. Such [*] shall be in addition to all other remedies available to FibroGen. 

7.9        Additional Provisions Regarding Restrictive Covenants and
Exclusivity. 
 (a)        The Parties agree that the restrictions
contained in Sections 7.4, 7.5, 7.8 and 13.6(i) are reasonable and necessary for the protection of the Parties’ and their Affiliates’ respective confidential information and business, that such restrictions are reasonable in all the
circumstances and that the Parties would not have entered into this Agreement without the protections afforded to them under Sections 7.4, 7.5, 7.8 and 13.6(i). 

(b)        The words “Develop” and “Commercialize” and all
variations thereof included in Sections 7.4 and 7.8 with reference to HIF Compounds shall include the activities described in the definitions of such words in Article 1, but with such activities being with respect to HIF Compounds rather than with
respect to a Product as set forth in the relevant definition. 

  
 49. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 8 

FINANCIALS 

8.1        License Fees.  AstraZeneca shall pay to
FibroGen each of the following non-refundable, non-creditable license fees on or before the applicable date set forth below; provided that with respect to payment 1, FibroGen shall provide an invoice on or before the Effective Date, and with respect
to payments 2, 3 and 4, FibroGen shall provide an invoice at least forty-five (45) days before each applicable due date: 
  

					
	
Number  
  
	  	 Due Date

 
	  	
Payment
  

	
1  

 
	  	 15th Business Day after the
Effective Date
  
	  	 $70 million

 

	
2  

 
	  	 June 30, 2014

 
	  	 $110 million

 

	
3  

 
	  	 June 30, 2015

 
	  	 [*]

 

	
4  

 
	  	 June 30, 2016

 
	  	 [*]

 

  
 If this Agreement is terminated prior to
the due date of payment 2 or 3, then each such payment shall remain due and payable despite such termination. If this Agreement is terminated prior to the due date of payment 4, then payment 4 will remain due and payable despite such termination;
[*]. 
 8.2        Development and Commercialization Cost
Reimbursement. 
 (a)        Prior to First NDA Approval during
Development Sharing Period. The following procedure in this subsection (a) will apply prior to the first NDA approval for a Product and during the Development Sharing Period. 

(i)        On or before the Effective Date, FibroGen will submit an invoice to
AstraZeneca for an amount of [*] in respect of certain Development Costs incurred by FibroGen under the Development Plan prior to the Effective Date. AstraZeneca shall pay such invoice within fifteen (15) Business Days of receipt of invoice.

 (ii)        Within twenty (20) days if reasonably possible for
AstraZeneca using reasonable endeavors to meet such timeline and in no event later than twenty five (25) days after the end of each Calendar Quarter during the Development Sharing Period, and within fifteen (15) days if reasonably possible
for FibroGen using reasonable endeavors to meet such timeline and in no event later than twenty (20) days after the end of each Calendar Quarter, the Party shall provide the other Party with a statement setting forth (A) the actual
Development Costs incurred by such Party in such Calendar Quarter, (B) the Development Costs budgeted for activities conducted by such Party in such Calendar Quarter under the Development Plan, (C) the amount (if any) by which the actual
costs differed from the budgeted costs, subject to the provisions on budget overages in Section 3.4(b), (the “Excess Spend”), (D) the amount carried over from the previous Calendar Quarters for which the Development
Costs incurred by AstraZeneca were greater than the Development Costs incurred by FibroGen. As soon as practicable, and not later than within thirty two (32) days of the end of the Calendar Quarter, the Parties shall discuss and resolve any
issues with respect to such statements and shall use best efforts to agree the amount owed from one Party to the other for Development Costs in such Calendar Quarter, so that each Party bears fifty percent (50%) of the Development Costs
incurred (subject to Section 3.4(b)), provided, however that each Party shall generate any questions and respond to any inquiries regarding the invoices as promptly as reasonably possible following receipt, including within forty-eight
(48) hours for response to ordinary inquiries. Following the reconciliation process for the applicable Calendar Quarter, and not later than thirty two (32) days of the end of the Calendar 

  
 50. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Quarter, each of FibroGen and AstraZeneca shall provide an invoice to the other Party reflecting fifty percent (50%) of their respective Development Costs incurred. Within forty five
(45) days after its receipt of such invoice from FibroGen, if the amount invoiced by FibroGen to AstraZeneca is greater than the amount invoiced by AstraZeneca to FibroGen, then AstraZeneca shall pay FibroGen an amount equal the difference
between the invoices, subject to the offset of outstanding Development Costs as detailed below in this Section 8.2(a)(ii). If during the Development Sharing Period and following the quarterly process set out above, FibroGen owes a payment to
AstraZeneca, then no payment will be made by FibroGen, to AstraZeneca. Instead such amount, in aggregate with any other such amounts, will be carried forward by AstraZeneca and set off against any subsequent Development Cost payments owed by
AstraZeneca to FibroGen under this Section 8.2. For clarity, Development Costs advanced or paid under this Section 8.2(a)(ii) do not include amounts incurred prior to August 1, 2013. 

(b)        Prior to First NDA Approval after the Development Sharing Period.
The following procedure in this subsection (b) will apply prior to the first NDA approval for a Product and after the Development Sharing Period. 

(i)        No earlier than forty-five (45) days prior to the beginning of
each Calendar Quarter after the Development Sharing Period, FibroGen shall submit to AstraZeneca an invoice for the Development Costs budgeted to be incurred by FibroGen to conduct its activities under the Development Plan in such Calendar Quarter,
as adjusted for the Cost Difference as set forth in 8.2(b)(ii) below. AstraZeneca shall pay each such invoice within forty-five (45) days after the invoice date, subject to the offset of Development Cost provisions in Section 8.2(a). 

(ii)       No later than twenty (20)) days after the end of each Calendar
Quarter after the Development Sharing Period, FibroGen shall send to AstraZeneca a statement setting forth (i) the actual Development Costs incurred by FibroGen in such Calendar Quarter, (ii) the Development Costs budgeted for activities
conducted by FibroGen in such Calendar Quarter in the Development Plan, (iii) the amount (if any) by which the actual costs differed from the budgeted costs and (iv) the difference between the amount advanced by AstraZeneca under this
Section 8.2(b) and the Development Costs actually incurred, to the extent below [*] percent ([*]%) of the budgeted amount (the “Cost Difference”). FibroGen shall adjust the invoice to be submitted to AstraZeneca under 8.2(b)(i) for
the subsequent Calendar Quarter to account for the Cost Difference. Not later than within thirty two (32) days of the end of the Calendar Quarter, the Parties shall discuss and resolve any issues with respect to such statement and shall use
best effort to agree the amount payable thereunder. If any items not material to FibroGen’s financial statements remain outstanding at the end of the reconciliation and resolution process, the parties shall continue to work toward resolution by
the end of following calendar quarter. Notwithstanding anything else set forth herein, if all amounts invoiced by FibroGen and settled under Section 8.2(a) exceed fifty per cent (50%) of the difference between the Development Costs
incurred by FibroGen and the Development Costs incurred by AstraZeneca during the Development Sharing Period (subject to the provisions on budget overages in Section 3.4(b)), then any such excess may be credited by AstraZeneca against any
subsequent Development Costs payments owed by AstraZeneca to FibroGen under this Section 8.2(b) and Section 8.2(c), or, in the event that the Development Costs incurred by FibroGen are no longer being incurred under this Agreement and are
insufficient to make up such excess, such excess may be credited against any other payments owed by AstraZeneca to FibroGen under this Agreement, until fully used. 

  
 51. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c)        Adjustment in Payment
Schedule.  At any time after January 1, 2015 and prior to the time at which ninety percent (90%) of the targeted enrollment in any CKD Indication Clinical Trials (conducted by FibroGen and for which FibroGen will be incurring
Development Costs) has been achieved (the “Increased Advance Period”), upon request of FibroGen, the Parties shall discuss in good faith the upcoming spending plans for the Development Budget in which FibroGen reasonably anticipates
that significant cost variances, such as those associated with patient enrollment rates or other reasonably unforeseen causes, may occur with respect to such CKD Indication Clinical Trials during the next Development Budget year and thereafter. The
Parties shall agree upon the timing of the implementation of a further advance in any Calendar Quarter in an upcoming period during the Increased Advance Period: If FibroGen reasonably determines that anticipated spending in respect of such CKD
Indication Clinical Trials such as enrollment rate is proceeding in a manner that the Development Costs for which advances have been received in a Calendar Quarter under Section 8.2(a) or (b) will likely be exceeded, then FibroGen shall
notify the JSC of the basis for such anticipated overage and if such overage is anticipated to exceed by [*] percent ([*]%) or more such budgeted amount, then FibroGen may invoice AstraZeneca prior to the end of the Calendar Quarter an amount it
reasonably believes is necessary to cover such overage. AstraZeneca shall pay such amount within forty-five (45) days of invoice and any such amounts advanced under such invoice under this Section 8.2(c) shall be deducted from the
subsequent payment under Section 8.2(a), (b) or (d). 

(d)        Following First NDA Approval.     The
following procedure in this subsection (d) will apply after the first NDA approval for a Product, unless otherwise agreed by the JDC. Within thirty (30) days after the end of each Calendar Quarter in which FibroGen conducts activities
under the Development Plan, FibroGen shall send to AstraZeneca an invoice for all Development Costs incurred by FibroGen in such Calendar Quarter, up to an amount equal to [*] percent ([*]%) of the budgeted amount for the applicable activities.
AstraZeneca shall pay each such invoice within forty-five (45) days after receipt thereof. 

(e)        Annual Reconciliation.    Within thirty
(30) days after the end of each Calendar Year in which either Party conducts activities under the Development Plan, such Party shall send to the other Party a statement setting forth the Development Costs actually incurred by such Party and the
budgeted amounts for all activities conducted by such Party under the Development Plan during such Calendar Year; provided that if no part of such Calendar Year was during the Development Sharing Period, or if only FibroGen is conducting Development
activities, only FibroGen shall be required to provide such statement. FibroGen’s statement will also include the Development Costs incurred by FibroGen and actually reimbursed by Astellas for such Calendar Year. If during the Development
Sharing Period, such actual amount exceeds the budgeted amount (or amount otherwise approved by the JSC) by more than [*] percent ([*]%) of the budgeted amount, then fifty percent (50%) of the excess (i.e., above [*] percent ([*]%)) will be
credited against or added to (depending on which Party incurred the excess) the subsequent payment from AstraZeneca to FibroGen under this Section 8.2. After the Development Sharing Period, if such actual amount incurred by FibroGen exceeds the
budgeted amount (or amount otherwise approved by the JSC) by more than [*] percent ([*]%) of the budgeted amount, the excess (i.e., above [*] percent ([*]%)) will be credited against the subsequent payment from AstraZeneca to FibroGen under this
Section 8.2. 

  
 52. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (f)        RoW
Activities.    Within thirty (30) days after the end of each Calendar Quarter in which FibroGen conducts activities under the Development Plan for the RoW, FibroGen shall send to AstraZeneca an invoice for all costs
incurred by FibroGen in such Calendar Quarter for such activities, including Personnel Costs, the Fully Burdened Cost of Collaboration Compound or Product or comparator drug, concomitant drug, placebo or other materials used in any Clinical Trial or
Nonclinical Studies, and all other out-of-pocket costs. AstraZeneca shall pay each such invoice within forty-five (45) days after receipt thereof. 

(g)        Commercialization Cost.    Within thirty
(30) days after the end of each Calendar Quarter in which FibroGen conducts activities under the U.S. Commercialization Plan, FibroGen shall send to AstraZeneca an invoice for all Commercialization Costs incurred by FibroGen in such Calendar
Quarter. AstraZeneca shall pay each such invoice within forty-five (45) days after receipt thereof. 

8.3       Development Milestone Payments. 

(a)        Payments. AstraZeneca shall make milestone payments to FibroGen
based on achievement by AstraZeneca, its Affiliate or a Sublicensee (or, if applicable, by FibroGen) of the development and regulatory milestone events set forth in this Section 8.3(a) with respect to any indication other than an indication
independently developed by FibroGen pursuant to Section 3.3(b) for which AstraZeneca does not opt in. 
  

					
	  

 Number   
  
	  	 Milestone Event

 
	 	
      Payment      

 

	
1   
	  	  
 This milestone event will be
deemed achieved on the [*].
  
  
	 	$[*] million 
	  

2   

 
	  	 [*]
  
	 	$[*] million 
	  

3   

 
	  	 [*]
  
	 	$[*] million 
	  

4   

 
	  	 [*]
  
	 	$[*] million 
	  

5   

 
	  	 [*]
  
	 	$[*] million 
	  

6   

 
	  	 [*]
  
	 	$[*] million 
	  

7   

 
	  	 [*]
  
	 	$[*] million 

  
 53. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b)       Clarifications. 

(i)        With respect to the first milestone event in Section 8.3(a),
if AstraZeneca [*] within such thirty (30) day period, then (A) this milestone event will be [*] and (B) this milestone event will be [*]. 

(ii)       Each milestone payment in Section 8.3(a) shall be paid only once,
without regard to whether two or more Products ultimately achieve any such milestone event. For the purposes of milestone events no. 5, 6 and 7 in Section 8.3(a), the Parties agree that the [*] shall be regarded as one and the same indication
and thus not constitute [*]. 
 (iii)      The foregoing milestone events do not
include events achieved by the Product for indications independently developed by FibroGen pursuant to Section 3.3(b) for which AstraZeneca does not opt in. 

(c)        Notice; Payment. The applicable Party shall notify the other Party
upon achievement of each milestone in Section 8.3(a). AstraZeneca shall pay to FibroGen the amounts set forth in Section 8.3(a) within forty-five (45) days after receipt by AstraZeneca of an invoice from FibroGen for the relevant
amount, following the achievement of the applicable milestone event by AstraZeneca, its Affiliate or a Sublicensee (or, if applicable, by FibroGen). Each such payment shall be made by wire transfer of immediately available funds into an account
designated by FibroGen. Each such payment is nonrefundable and non-creditable against any other payments due hereunder. 

8.4        [*] Milestone. 

(a)        Milestone. AstraZeneca shall pay a milestone to FibroGen in
the amount of the discounted value of [*], discounted using ten percent (10%) annual compounding, applied from the Trigger Date to the Discount Date (each as defined below) (such value, the [*] Milestone”) following the first
[*] (meaning that – notwithstanding anything else set forth herein – AstraZeneca shall never be obligated to pay the Deferred Approval Milestone prior to the [*]) as of the payment date determined in accordance with Section 8.4(b);
provided that and notwithstanding anything else set forth below in this Section 8.4, if any of [*]”) on or before [*]”) then the [*] Milestone will not be payable. The [*] Milestone is nonrefundable and non-creditable against any
payments due hereunder. 
 (b)        Payment Date. If payable pursuant to
Section 8.4(a), the [*] Milestone will be due as follows: 

(i)        If all [*], the “Discount Date” will be the
date of first [*], and the [*] Milestone will be payable within forty-five (45) days thereafter, provided that there is then no [*]. 

  
 54. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (ii)        If [*], the
“Discount Date” will be January 1 of the Calendar Year following the Calendar Year in which [*], and the [*] Milestone will be payable on the Discount Date, provided that there is then no [*]. 

(iii)       If [*], but if there is no [*], then the [*] Milestone (the full
undiscounted amount of [*] will be payable on the Trigger Date. 

(iv)        If any [*], the Discount Date will be the later to occur of
(a) the date of [*] and (b) the first [*], and the [*] Milestone will be payable within forty-five (45) days after the Discount Date. 

(v)         At any time prior to the Trigger Date, AstraZeneca may elect
to pay the [*] Milestone, and the Discount Date will be the date of payment. 

(c)        Trigger Date. The “Trigger Date” means [*],
the date on which such [*]. For example, if no [*], the Trigger Date is [*]. If a [*], then the Trigger Date is [*]. 

8.5        Sales Milestone Payments. 

(a)        U.S. Events. AstraZeneca shall make each of the sales milestone
payments indicated below to FibroGen when aggregate Annual Net Sales of all Products across all indications in the U.S. (other than sales by FibroGen in indications independently developed by FibroGen pursuant to Section 3.3(b) for which
AstraZeneca does not opt in) first reach the Dollar values indicated below. 
  

			
	 Aggregate Annual Net Sales in the U.S.

 
	  	
            Payment          
  
  

	 $[*]

 
	  	
$[*] million
  

	 $[*]

 
	  	
$[*] million
  

	 $[*]

 
	  	
$[*] million
  

 Each milestone in this Section 8.5(a) shall be paid only once. 

(b)        Additional U.S. Milestones. AstraZeneca shall make each of the
sales milestone payments indicated below to FibroGen when aggregate Annual Net Sales of Products in LDOs in the U.S. (other than sales by FibroGen in indications independently developed by FibroGen pursuant to Section 3.3(b) for which
AstraZeneca does not opt in) first reach the Dollar values indicated below in any Calendar Year from 2018-2022 (inclusive). 
  

			
	 Aggregate Annual Net Sales to LDOs in the U.S.

 
	  	
            Payment          
  
  

	 $[*]

 
	  	
$[*] million
  

	 $[*]

 
	  	
$[*] million
  

	 $[*]

 
	  	
$[*] million
  

  
 55. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c)        RoW
Events.  AstraZeneca shall make each of the sales milestone payments indicated below to FibroGen when aggregate Annual Net Sales of all Products across all indications in the RoW (other than sales by FibroGen in indications
independently developed by FibroGen pursuant to Section 3.3(b) for which AstraZeneca does not opt in) first reach the Dollar values indicated below. 
  

			
	 Aggregate Annual Net Sales in RoW

 
	  	
          Payment          

 

	 $[*]

 
	  	
$[*] million
  

	 $[*]

 
	  	
$[*] million
  

 Each milestone in this Section 8.5(c) shall be paid only once. 

(d)        Notice; Payment. AstraZeneca shall notify FibroGen of achievement
of each of the milestone events in this Section 8.5 within forty-five (45) days after the end of the Calendar Quarter in which achieved. AstraZeneca will pay to FibroGen the amounts set forth in Sections 8.5(a), 8.5(b) and 8.5(c) within
forty-five (45) days after AstraZeneca’s receipt of an invoice from FibroGen following the end of the Calendar Quarter during which the applicable milestone event has been achieved. If more than one such milestone is achieved in any
Calendar Quarter, then all applicable payments will be due. Each such payment shall be made by wire transfer of immediately available funds into an account designated by FibroGen. Each such payment is nonrefundable and non-creditable against any
other payments due hereunder. 
 8.6        Royalties 

(a)        Royalty Rates.  AstraZeneca shall pay to FibroGen
non-refundable, non-creditable royalties on the amount of aggregate Annual Net Sales of each Product in the Territory as calculated by multiplying the applicable royalty rates set forth below by the corresponding amount of incremental aggregate
Annual Net Sales in the Territory of such Product in such Calendar Year. For clarity, royalties are not due on sales of Products by FibroGen solely in indications independently developed by FibroGen pursuant to Section 3.3(b) for which
AstraZeneca does not opt in. 
  

			
	 Aggregate Annual Net Sales
(Per Product)

 
	  	
          Royalty Rate          

  

	 Portion less than $[*]

 
	  	
[*]%
  

	 Portion greater than or equal to $[*]

 
  
	  	
[*]%
  

  
 56. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 By way of example, if the aggregate Annual Net Sales of a Product in the Territory in a
particular Calendar Year is two billion five hundred million Dollars ($2,500,000,000), the amount of royalties payable hereunder shall be as follows: 

$ [*] 

$ [*] 

[*] 

(b)        Sales Subject to Royalties.  Sales between AstraZeneca,
its Affiliates and Sublicensees shall not be subject to royalties hereunder unless the purchaser is an end user. Royalties shall be calculated on AstraZeneca’s, its Affiliates’ and Sublicensees’ sales of the Products to a Third Party,
including Distributors (but excluding for the avoidance of doubt Sublicensees). Royalties shall be payable only once for any individual S.K.U. of a Product. For the purpose of determining Net Sales, the Product shall be deemed to be sold when
invoiced and a “sale” shall not include, and no royalties shall be payable on, transfers by AstraZeneca, its Affiliates or Sublicensees of reasonable quantities of clinical trial materials, or other transfers or dispositions of reasonable
quantities of Products for charitable, promotional, nonclinical, clinical, manufacturing, testing or qualification, regulatory or governmental purposes in compliance with this Agreement (it being understood and agreed that neither Party shall have
the right to distribute the Product as samples except pursuant to Section 5.7). 

(c)        Generic Competition.  If, in any country in the
Territory, the Net Sales of any Product in any rolling four Calendar Quarter period following the first sale of a Generic Product to such Product in such country is less than [*] of the Net Sales for such Product in such country in the immediately
preceding four Calendar Quarter period, then the royalty rate for such Product in such country shall be reduced to [*] that would otherwise have been applicable under Section 8.6(a) for Net Sales of such Product in such country. For clarity, if
the Generic Product is barred or withdrawn from sale in such country and the Net Sales in such country in any rolling four Calendar Quarter period is greater than [*] of the value for the rolling four quarter period prior to the first sale of a
Generic Product, then the foregoing reduction shall no longer apply effective as of the Calendar Quarter in which the Generic Product is barred or withdrawn from sale. The calculation of the royalty reduction under this Section 8.6(c) shall be
conducted separately for each Product in each country. By way of example, if during the first Calendar Quarter of a particular Calendar Year in which the foregoing reduction applies, the Net Sales in such Calendar Quarter in a country in which the
foregoing reduction applies are one billion five hundred million Dollars ($1,500,000,000), and the Net Sales in such Calendar Quarter in a country in which the foregoing royalty reduction does not apply are one billion Dollars ($1,000,000,000), the
following shall apply with respect to the royalty payment owed for such Calendar Quarter: The royalty payment without regard to the reduced rate would be [*]. 

(d)        Compulsory Licenses.  If a court or a governmental agency
of competent jurisdiction requires AstraZeneca or its Affiliate or Sublicensee to grant a compulsory license to a Third Party and if as a result of the compulsory license the Net Sales of such Product in any rolling four Calendar Quarter period
following the first grant of such compulsory license in such country is less than [*] of the Net Sales for such Product in such country in the immediately preceding four 

  
 57. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Calendar Quarter period, then the royalty rate for such Product in such country shall be reduced to [*] of the royalty rates (in each tier) that would otherwise have been applicable under
Section 8.6(a) for Net Sales of such Product in such country. For clarity, to the extent that the compulsory licenses in the relevant country are duly terminated or expire in such country and the Net Sales in such country in any rolling four
Calendar Quarter period is greater than [*] of the value for the rolling four quarter period prior to the first grant of the compulsory license in such country, then the foregoing reduction shall no longer apply effective as of the Calendar Quarter
in which the compulsory license is terminated or expires. The calculation of the royalty reduction under this Section 8.6(e) shall be conducted separately for each Product in each country. 

(e)        Order of Royalty Reduction and Royalty Floor.  Any
reductions set forth in Sections 8.6(c), 8.6(d) and 8.8(c) shall be applied in the order in which the event triggering such reduction occurs, provided that in no event shall, due to the cumulative reductions set out in Sections 8.6(c) and 8.6(d),
the royalty that would otherwise have been payable to FibroGen under this Section 8.6 in a particular Calendar Quarter be reduced below [*]) of the royalty set forth in Section 8.6(a). 

(f)        Royalty Term.   AstraZeneca’s obligation to pay
royalties due under this Section 8.6 with respect to a particular Product in each country in the Territory will commence upon the First Commercial Sale of such Product in such country and will be payable for so long as such Product is sold in
such country by AstraZeneca or its Affiliate or Sublicensee. 

(g)        Royalty Payments and Reports.   All amounts payable
to FibroGen pursuant to this Section 8.6 shall be paid in Dollars within forty-five (45) days after the end of each Calendar Quarter with respect to Net Sales in such Calendar Quarter. Each payment of royalties due to FibroGen shall be
accompanied by a statement, on a country-by-country basis, of the amount of gross sales of Products in the Territory during the applicable Calendar Quarter, a calculation of Net Sales in the Territory showing the aggregate deductions from gross
sales provided for in the definition of Net Sales during such Calendar Quarter, and a calculation of the amount of royalty payment due on such sales for such Calendar Quarter. For the avoidance of doubt, FibroGen acknowledges and agrees that each
statement provided by AstraZeneca under this Section 8.6(g) shall constitute Confidential Information of AstraZeneca and FibroGen shall comply with its confidentiality and non-use obligations in respect
of such statements as set forth in Article 12. 

(h)        Clarification.  AstraZeneca acknowledges that it will
continue to enjoy substantial benefit from its license under, and the transfer to AstraZeneca of certain elements of, the FibroGen Technology pursuant to this Agreement, as well as from AstraZeneca’s own development of inventions derived from
the practice of such license and AstraZeneca’s use of such FibroGen Technology, even after the expiration of all FibroGen Patents claiming the Product in a particular country in which Products are sold. In addition, AstraZeneca acknowledges
that the application of a uniform royalty structure during the sale of Products is more convenient to the Parties, facilitates payments, and reduces accounting burdens on the Parties, as compared with a payment structure dependent on the expiration
of FibroGen Patents. 
 8.7        FibroGen
IPO.    AstraZeneca shall make a one-time, non-refundable, non-creditable payment of [*] to FibroGen upon a FibroGen IPO; provided that (a) if such IPO has 

  
 58. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
not occurred prior to December 1, 2015, AstraZeneca will make such payment on December 15, 2015, and (b) if the Parties agree upon terms (and FibroGen undertakes, upon
AstraZeneca’s request, to negotiate such terms in good faith), including a lock-up and standstill agreement (subject to maximum ownership of [*]%), then in lieu of such payment, AstraZeneca will make a [*] equity investment in FibroGen at the
initial public offering price simultaneous with the closing of a FibroGen IPO. 

8.8        Third Party Intellectual Property. 

(a)        DFCI Agreement.  FibroGen shall be solely responsible for
all payments to DFCI under the DFCI Agreement. 
 (b)        Right to Obtain
License.  If either Party desires to obtain a license under any Third Party’s intellectual property in connection with the Development and Commercialization of Products, such Party will notify the other Party. FibroGen will have
the first right (but not the obligation) to obtain such license. If FibroGen elects not to obtain such license, or is unsuccessful in doing so, then AstraZeneca will have the right (but not the obligation) to negotiate and obtain such license at its
sole discretion and expense (but subject to Section 8.8(c)). The negotiating Party will obtain such license, with the right to sublicense, in order to permit AstraZeneca to exercise its rights and to perform its obligations under this
Agreement. Subject to the foregoing, the terms and conditions involved in obtaining such license shall be determined at such negotiating Party’s sole discretion. 

(c)        AstraZeneca Obtains License.  In the event AstraZeneca
obtains a license under any Third Party patents that claim the composition of matter, formulation (to the extent AstraZeneca is performing any formulation activities, which activities it may perform only with FibroGen’s prior written consent),
method of treatment or other use of a Collaboration Compound or Product, AstraZeneca shall provide to FibroGen a copy thereof and shall have the right to offset, against royalties payable to FibroGen under Section 8.6 for the applicable
Product, [*] actually paid by AstraZeneca to such Third Party under such license for the sale of the applicable Product in the applicable country and Calendar Quarter; provided that the royalties payable to FibroGen for any Product in any Calendar
Quarter under Section 8.6 may not be reduced by more than [*] of those otherwise due to FibroGen under Section 8.6(a) in any Calendar Quarter for such Product as a result of such offset and other reductions under Section 8.6. Except
as provided above in this subsection (c), AstraZeneca will be solely responsible for all amounts owed by AstraZeneca or its Affiliates to Third Parties under a license to intellectual property on account of AstraZeneca’s or its Affiliates’
manufacture, use, sale, offer for sale, or import of Products. 

(d)        FibroGen Obtains License.   Except as provided in
subsection (a) above, the FibroGen Technology licensed to AstraZeneca in this Agreement will include patents, patent applications and Information licensed to FibroGen by a Third Party if (i) AstraZeneca assumes [*] of all payment
obligations under such license agreement to the extent arising out of the use, Development or manufacture of any Product or Commercialization of any Product by or on behalf of AstraZeneca in the Territory, as well as all other obligations of such
license agreement that are applicable to AstraZeneca, and (ii) AstraZeneca acknowledges in writing that its sublicense under such license agreement is subject to the terms and conditions of such license agreement. If any such payments are not
allocated among countries, the Parties shall reasonably allocate such payments to within and outside the Territory in good faith. 

  
 59. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 8.9        Taxes. 

(a)        Taxes on Income.  Each Party shall be solely responsible
for the payment of all taxes imposed on its share of income arising directly or indirectly from the collaborative efforts of the Parties under this Agreement. 

(b)        Withholding Tax.  The Party making payments under this
Agreement (the “Payor”) to the other Party (the “Payee”) shall deduct or withhold from the payments any Taxes that it is required by applicable law to deduct or withhold. The Payee shall provide the
Payor any tax forms or appropriate governmental authorization that may be reasonably necessary in order for Payor to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. The Payee shall use
reasonable efforts to provide any such tax forms to the Payor at least thirty (30) days prior to the due date for any payment for which the Payee desires that Payor apply a reduced withholding rate and in any event at least fifteen
(15) days prior to the time the applicable payment is due. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable laws and regulations, of withholding taxes, Indirect Taxes, or similar
obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or Indirect Taxes. 

(c)        Payment of Tax.  To the extent the Payor is required by
applicable law or regulations to deduct and withhold taxes on any payment to the Payee, the Payor shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to the Payee an official tax
certificate or other evidence of such withholding sufficient to enable the Payee to claim such payment of taxes. 

(d)        Indirect Tax.   All payments to be made by one Party
to another Party, pursuant to the terms of this Agreement, are stated exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of such payments, the Party making shall payment shall pay such Indirect Taxes at the applicable rate
following the receipt where applicable of an Indirect Taxes invoice in the appropriate form issued. Each Party shall issue valid invoices for all amounts payable under this Agreement consistent with all applicable laws and irrespective of whether
such amounts may be netted for settlement purposes. The Parties shall cooperate in accordance with applicable law to minimize Indirect Taxes. 

(e)        Imports.  For the avoidance of doubt, the Parties
acknowledge and agree that none of the upfront payments, milestone payments or royalties payable under this Agreement are related to the license (or right) to import or any import of Products. The Parties shall cooperate to ensure that the Party
responsible for shipping values Product in accordance with applicable laws and maximizes the full benefits of available duty free or savings programs and minimizes where permissible any such duties and any related import taxes that are not
reclaimable from the relevant authorities. The receiving Party shall be responsible for any import clearance, including payment of any import duties and similar charges, in connection with any Products transferred to such Party under this Agreement.

  
 60. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 8.10      Blocked
Currency.   In each country where the local currency is blocked and cannot be removed from the country, royalties accrued on Net Sales in that country shall be paid to FibroGen in the equivalent amount in Dollars. 

8.11      Foreign Exchange.   Conversion of sales or expenses recorded in
local currencies to Dollars will be performed in a manner consistent with each Party’s normal practices used to prepare its audited financial statements for external reporting purposes, provided that such practices use a widely accepted source
of published exchange rates. 
 8.12      Late Payments.   If a Party
does not receive payment of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until the date of payment at a rate equal to the U.S. Prime Rate for the date
payment was due as reported by the Wall Street Journal. 
 8.13      Financial
Records; Audits. 
 (a)        Records.    Each
Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the amount to be reimbursed, pursuant to Section 8.2, with respect to Development Costs or Commercialization Costs or
other amounts to be reimbursed or shared hereunder incurred or generated (as applicable) by such Party, achievement of sales milestones, royalty payments and other compensation payable under this Agreement. Each Party shall keep or cause its
Affiliates to keep such records for a period of the later of (a) six (6) years after the end of the period to which such books, records and accounts pertain and (b) the expiration of the applicable tax statute of limitations (or any
extensions thereof), or for such longer period as may be required by applicable law. Each Party shall maintain such records at its principal place of business or the principal place of business of the appropriate division of such Party to which this
Agreement relates. 
 (b)        Procedure.    Upon
reasonable prior notice, such records shall be open during regular business hours for a period of three (3) years from the creation of individual records, in each case, for examination at the auditing Party’s expense, and not more often
than once each Calendar Year, by an independent certified public accountant selected by the auditing Party and reasonably acceptable to the audited Party (or in the case of audits of AstraZeneca, by DFCI under the terms of Section 4.2.2 of the
DFCI Agreement) for the sole purpose of verifying for the auditing Party the accuracy of the financial reports or sales milestone notices furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by
or to the audited Party to the other pursuant to this Agreement. Any such auditor shall not disclose the audited Party’s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of
the financial reports furnished by the audited Party or the amount of payments due by the audited Party under this Agreement. Any amounts shown to be owed but unpaid, or overpaid and in need of reimbursement, shall be paid or refunded (as the case
may be) within thirty (30) days after the accountant’s report, plus interest (as set forth in Section 8.12) from the original due date (unless challenged in good faith by the audited Party in which case any dispute with respect
thereto shall be resolved in accordance with Article 14). The auditing Party shall bear the full cost of such audit unless such audit reveals an overcharge or underpayment by the audited Party that resulted from a discrepancy in a report that the
audited Party provided to the other Party during the applicable audit period, which underpayment or overcharge was more than five percent (5%) of the amount set forth in such report, in which case the audited Party shall bear the full cost of
such audit. 

  
 61. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c)        Audit
Dispute.   In the event of a dispute with respect to any audit under Section 8.13(b), FibroGen and AstraZeneca shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable
resolution of any such dispute within thirty (30) days, the dispute shall be submitted for resolution to an independent certified public accounting firm jointly selected by each Party’s certified public accountants or to such other entity
or individual as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of such resolution as well as the initial audit shall be borne between the Parties in such manner as
the Auditor shall determine. Not later than ten (10) days after such decision and in accordance with such decision, the audited Party shall pay the additional amounts, with interest from the date originally due as provided in Section 8.12
or the auditing Party shall reimburse the excess payments, as applicable. 

8.14      Manner and Place of Payment.  All payments owed under this Agreement
shall be made by wire transfer in immediately available funds to a bank and account designated in writing by FibroGen or AstraZeneca (as applicable), unless otherwise specified in writing by such Party. All payments hereunder shall be invoiced by
the Payee to the Payor. Each invoice to AstraZeneca shall fulfill the requirements set forth on Exhibit L. 

8.15      Estimated Sales and Accruals.   To the extent Net Sales are
based on quarterly estimates or accruals for anticipated sales of Products in the Territory, AstraZeneca shall notify FibroGen of any such estimates or accruals or adjustments or changes based on a revision in estimates and accruals within thirty
(30) days of each Calendar Quarter in order to allow FibroGen to timely meet any then applicable public reporting requirements of FibroGen with respect to sales and royalties to FibroGen for Products. 

ARTICLE 9 

INTELLECTUAL PROPERTY 

9.1        Intellectual Property Committee.  The Parties shall,
promptly after the Effective Date, establish an intellectual property committee (the “IP Committee”) comprised of at least one senior patent attorney from each Party, together with other representatives of the Parties as the
Parties may determine to be appropriate from time to time, to review and discuss, in each case with respect to FibroGen Patents and Joint Patents, the patent prosecution strategy (including whether and where to file patent applications), Orange Book
Listings, applications for patent term extension and notices of infringement, as well as the selection, registration, maintenance and defense of Marks and interest in Third Party intellectual property. The IP Committee will serve solely an advisory
purpose and shall not have authority to approve or disapprove any actions with respect to patent filing, prosecution and maintenance under this Agreement. 

9.2        Ownership of Inventions.  Ownership of Information and
inventions, whether or not patentable, made during the Term in the course of conducting activities under this Agreement, including all intellectual property rights therein (collectively, “Inventions”) shall be as follows:
(a) FibroGen shall own all Inventions [*], whether made solely by employees, agents or independent 

  
 62. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
contractors of either Party or its respective Affiliates, or jointly by employees, agents or independent contractors of both Parties or their respective Affiliates (collectively,
“Collaboration Inventions”), (b) AstraZeneca shall own all Inventions that are made solely by employees, agents or independent contractors of AstraZeneca or its Affiliates that are not Collaboration Inventions,
(c) FibroGen shall own all Inventions that are made solely by employees, agents or independent contractors of FibroGen or its Affiliates that are not Collaboration Inventions, and (d) the Parties shall jointly own all Inventions that are
made jointly by employees, agents, or independent contractors of each Party or its Affiliates that are not Collaboration Inventions (“Joint Inventions”). Except to the extent either Party is restricted by the licenses granted
to the other Party under this Agreement, each Party shall be entitled to practice, grant licenses to, assign and exploit the Joint Inventions and Patents claiming Joint Inventions (“Joint Patents”) without the duty of
accounting or seeking consent from the other Party. AstraZeneca hereby assigns to FibroGen all of its and its Affiliates’ right, title and interest in and to the Collaboration Inventions, and agrees to take such further actions reasonably
requested by FibroGen to evidence such assignment, except where such Collaboration Inventions have been made by an independent contractor retained by AstraZeneca without such contractor having agreed to assign such Collaboration Inventions to
AstraZeneca, as approved by the JDC. 
 9.3        Disclosure of
Inventions.    Each Party shall promptly disclose to the other all Inventions promptly after becoming aware of them, including all invention disclosures or other similar documents submitted to such Party by its, or its
Affiliates’, employees, agents or independent contractors describing such Inventions. Such Party shall also respond promptly to reasonable requests from the other Party for more Information relating to such Inventions. 

9.4        Prosecution of Patents. 

(a)        FibroGen Patents.  Except as otherwise provided in this
Section 9.4(a), as between the Parties, FibroGen shall have the sole right and authority to manage all FibroGen Patent prosecution activities under this Agreement, at its sole expense. This includes the right and authority to prepare, file,
prosecute and maintain all FibroGen Patents in any jurisdiction in the world, including defending such FibroGen Patents in any patent office proceedings, pre- or post-grant or issuance, including reissue, reexamination, limitation or invalidation
proceedings, or any opposition- or interference-type proceeding or challenge. FibroGen shall provide AstraZeneca reasonable opportunity to review and comment on filing and prosecution efforts regarding the FibroGen Patents in the Territory. FibroGen
shall, if requested by AstraZeneca, provide AstraZeneca with copies of material communications from any patent authority in the Territory regarding any FibroGen Patents, and shall if requested provide drafts of any material filings or material
responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses so that AstraZeneca may have the opportunity to review and comment thereon. FibroGen shall further take into account and
may include, at FibroGen’s sole discretion, any reasonable comments provided by AstraZeneca prior to submission of any such filings or responses. 

(b)        Requested Filings.  If AstraZeneca desires FibroGen to
file, in a particular jurisdiction in the Territory, a FibroGen Patent that claims priority to (or is based on the subject matter of) another FibroGen Patent, or that claims a Collaboration Invention, AstraZeneca shall provide written notice to
FibroGen requesting that FibroGen file such patent application in such 

  
 63. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
jurisdiction. If AstraZeneca provides such written notice to FibroGen, FibroGen shall file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction;
provided that FibroGen shall not be obligated to conduct any such activities (including filing a patent application) that FibroGen reasonably believes may have an adverse effect on the FibroGen Patents anywhere in the Territory. 

(c)        Joint Patents.   With respect to any potentially
patentable Joint Invention, AstraZeneca shall have the first right, but not the obligation, to prepare patent applications based on such Joint Invention, to file and prosecute (including defense of any oppositions, interferences, reissue proceedings
and reexaminations) such patent applications, and to maintain any Joint Patents issuing therefrom, in any jurisdictions throughout the Territory. FibroGen shall have the corresponding first right, but not the obligation, in any jurisdictions outside
of the Territory other than China, in respect of which the China Agreement shall govern. If AstraZeneca determines in its sole discretion to abandon, cease prosecution or otherwise not file or maintain any Joint Patent anywhere in the Territory,
then AstraZeneca shall provide FibroGen written notice of such determination at least thirty (30) days before any deadline for taking action to avoid abandonment (or other loss of rights) and shall provide FibroGen with the opportunity to
prepare, file, prosecute and maintain such Joint Patent. The Party that is responsible for preparing, filing, prosecuting, and maintaining a particular Joint Patent (the “Prosecuting Party”) shall provide the other Party
reasonable opportunity to review and comment on such prosecution efforts regarding such Joint Patent, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting Party shall provide the other Party
with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent being prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such patent
authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary or desirable to enable the other Party to comply with the duty of
candor/duty of disclosure requirements of any patent authority. Either Party may determine that it is no longer interested in supporting the continued prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which
case: (i) the disclaiming Party shall, if requested in writing by the other Party, assign its ownership interest in such Joint Patent in such country or jurisdiction to the other Party for no additional consideration; and (ii) if such
assignment is effected, any such Joint Patent would thereafter be deemed a FibroGen Patent in the case of assignment to FibroGen, or a AstraZeneca Patent in the case of assignment to AstraZeneca; provided, however, that the disclaiming party would
have an immunity from suit under such FibroGen Patent or AstraZeneca Patent, as the case may be, in the applicable country or jurisdiction. In addition, any Joint Patent that becomes a FibroGen Patent pursuant to the preceding sentence shall be
excluded from the license granted to AstraZeneca in Section 7.1. Each Party shall bear its own internal costs in respect of the prosecution of Joint Patents. Out-of-pocket costs incurred in respect of the prosecution and maintenance of Joint
Patents in the Territory shall be borne equally by AstraZeneca and FibroGen. In the event a Party elects to disclaim its interest in a Joint Patent, the costs incurred with respect to such Patent after the date of such disclaimer shall thereafter be
borne exclusively by the other Party, without reimbursement or credit. 

(d)        Cooperation in Prosecution.  Each Party shall, through
the IP Committee, provide the other Party all reasonable assistance and cooperation in the Patent prosecution efforts provided above in this Section 9.4, including providing any necessary powers of attorney and executing any other required
documents or instruments for such prosecution. 

  
 64. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.5        Infringement of FibroGen
Patents by Third Parties. 
 (a)        Notification. 

(i)        Within five (5) Business Days from (A) a Party’s or
its Affiliate’s receipt of any notice of any certification filed under the U.S. “Drug Price Competition and Patent Term Restoration Act” of 1984 as amended or supplemented or any successor law or (B) a Party’s or its
Affiliate’s receipt of any notice of any certification filed under Section 505(j) of the FD&C Act or an application under Section 505(b)(2) of the FD&C Act naming a Product as a reference listed drug and including a
certification under Section 505(j)(2)(A)(vii)(IV) or 505(b)(2)(A)(iv), respectively or (C) any equivalent proceeding in any country in RoW (each of (A), (B) and (C), a “Product Infringement”) such Party shall
notify the other Party thereof in writing. 
 (ii)       If there is any
infringement, threatened infringement, imminent infringement or alleged infringement of any FibroGen Patent on account of a Third Party’s manufacture, use, offer for sale, or sale of a Collaboration Compound or Product in the Territory not
within Section 9.5(a)(i) (“Other Infringement”) then each Party shall promptly notify the other Party in writing of any such Other Infringement of which it becomes aware, and shall provide evidence in such Party’s
possession demonstrating such Other Infringement. 
 (b)        Enforcement
Rights. 
 (i)        RoW Litigation.  AstraZeneca
shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity allegedly engaged in any Product Infringement or Other Infringement of the FibroGen Patents in the RoW (and to defend any
related counterclaim), at AstraZeneca’s expense. AstraZeneca shall have a period of one hundred eighty (180) days after its receipt or delivery of notice and evidence pursuant to Section 9.5(a)(i), to elect to so enforce such FibroGen
Patent in the RoW (or to settle in accordance with Section 9.5(c) or otherwise secure the abatement of such Product Infringement or Other Infringement). In the event AstraZeneca does not so elect (or settle or otherwise secure the abatement of
such Product Infringement or Other Infringement), it shall so notify FibroGen in writing as soon as practicable following the decision and in any event within such one hundred eighty (180)-day period, and FibroGen shall have the right to commence a
suit or take action to enforce the applicable FibroGen Patents with respect to such Product Infringement or Other Infringement in the RoW (and to defend any related counterclaim) at FibroGen’s expense. The IP Committee shall take the necessary
actions to ensure that AstraZeneca has proper standing to bring suit under this Section 9.5(b)(i). 

(ii)       U.S. Litigation. AstraZeneca shall have the first right, but not
the obligation, to bring an appropriate suit or other action against any person or entity allegedly engaged in any Product Infringement or Other Infringement of the FibroGen Patents in the U.S. (and to defend any related counterclaim), at
AstraZeneca’s expense. AstraZeneca shall have a period of thirty (30) days, with respect to a Product Infringement, and one hundred eighty (180) days with respect to an Other Infringement, after its receipt or delivery of notice and
evidence 

  
 65. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
pursuant to Section 9.5(a)(i), to elect to so enforce such FibroGen Patent in the U.S. (or to settle in accordance with Section 9.5(c) or otherwise secure the abatement of such Product
Infringement or Other Infringement). The Parties shall meet periodically to discuss in good faith and determine an enforcement strategy, and AstraZeneca shall act consistently with any such agreed strategy. In the event AstraZeneca does not so elect
(or settle or otherwise secure the abatement of such Product Infringement or Other Infringement), it shall so notify FibroGen in writing as soon as practicable following the decision and in any event within such thirty (30)- or one hundred eighty
(180)-day period, as applicable, and FibroGen shall have the right to commence a suit or take action to enforce the applicable FibroGen Patents with respect to such Product Infringement or Other Infringement in the U.S. (and to defend any related
counterclaim), at FibroGen’s expense. The IP Committee shall take the necessary actions to ensure that AstraZeneca has proper standing to bring suit under this Section 9.5(b)(ii). 

(iii)        Cooperation.  In any action, suit or proceeding
instituted under this Section 9.5(b), the Parties shall cooperate with and assist each other in all reasonable respects. Upon the reasonable request of the Party instituting such action, suit or proceeding, the other Party shall join such
action, suit or proceeding and shall be represented using counsel of its own choice, at the requesting Party’s expense. If a Party with the right to initiate legal proceedings under this Section 9.5(b) lacks standing to do so and the other
Party has standing to initiate such legal proceedings, then the Party with standing shall initiate such legal proceedings at the request and expense of the other Party (including reasonable internal personnel costs at the Hourly Rate). 

(c)        Settlement.   Without the prior written consent of
the other Party, neither Party shall settle any claim, suit or action that it brought under Section 9.5(b) involving FibroGen Patents in any manner that would negatively impact such intellectual property or that would limit or restrict the
ability of either Party to sell Products anywhere in or outside the Territory. 

(d)        Recoveries.  If either Party recovers monetary damages
from a Third Party in a suit or action in respect of a Product Infringement or Other Infringement, such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation and any remaining amount shall
be deemed Net Sales and retained by (or paid to) AstraZeneca, subject to royalty payments on such deemed Net Sales pursuant to Section 8.6. 

(e)        Designated Products.   Notwithstanding anything to
the contrary in this Agreement: 
 (i)          FibroGen shall
have the sole right to enforce the FibroGen Patents against any of the Designated Products (“Designated Product Infringement”), and AstraZeneca shall be solely responsible for all expenses reasonably incurred in connection
therewith and subject further to (ii) below. FibroGen will invoice AstraZeneca for its share of such expenses on a Calendar Quarter basis (including its internal personnel costs at the Hourly Rate), and AstraZeneca will pay each such invoice
within forty-five (45) days after receipt thereof. 

(ii)         Notwithstanding (i) above, (A) in no event shall
[*]; provided that in Calendar Years 2018, 2019 and 2020, AstraZeneca shall not be obligated to [*], except that if AstraZeneca reimburses [*] (the “Deficit”), the [*] (see example below); (B) in enforcing the FibroGen
Patents against any of the Designated Products, the Parties shall unanimously select 

  
 66. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
outside counsel to represent FibroGen in such enforcement proceedings (failing such unanimous agreement AstraZeneca shall be [*] (C) FibroGen shall, at all times, keep AstraZeneca reasonably
informed regarding such enforcement proceedings and shall take into account any good faith comments made by AstraZeneca relating to such enforcement proceedings; and (D) FibroGen shall provide AstraZeneca with reasonably sufficient information
regarding such enforcement proceedings to demonstrate that any such proceedings have a good faith basis and are brought and maintained in good faith. By way of example of clause (A), [*]. 

(f)        Non-Product-Related Infringements.  As between the
Parties, FibroGen shall have the sole right to enforce the FibroGen Patents in the Territory against any infringement, imminent infringement, threatened infringement or alleged infringement that is not a Product Infringement, a Designated Product
Infringement or an Other Infringement, at its expense, and to retain all associated recoveries; provided that in no event will FibroGen place an Orange Book-listed FibroGen Patent (or a FibroGen Patent listed on a Form 3542 submitted in accordance
with Section 9.12 upon or after approval of the NDA as a timely filed patent) into litigation without AstraZeneca’s prior written approval, which approval will not be unreasonably withheld. 

(g)        Joint Patents.    Each Party shall promptly
notify the other Party upon becoming aware of any infringement, imminent infringement, threatened infringement or alleged infringement of any Joint Patent (“Joint Patent Infringement”). The Parties will promptly thereafter
meet to discuss in good faith how and whether to proceed to enforce the applicable Joint Patent against such Joint Patent Infringement. If the Parties fail to agree within sixty (60) days, then either Party shall have the right to take any
action permitted under applicable law. 
 (h)        Patents Licensed from Third
Parties.    Each Party’s rights under this Section 9.5 with respect to any FibroGen Patent licensed from a Third Party shall be subject to the rights of such Third Party to enforce such FibroGen Patent and/or defend
against any claims that such FibroGen Patent is invalid or unenforceable. 

9.6        Defense of FibroGen Patents.    To the extent
any Party receives notice by counterclaim, or otherwise, alleging the invalidity or unenforceability of any FibroGen Patent in the Territory, it shall bring such fact to the attention of the other Party, including all relevant information related to
such claim. The Parties, through the JSC, shall discuss such claim. Where such allegation is made within the context of a patent office proceeding, the provisions of Section 9.4 shall apply. Where such allegation is made in a counterclaim to or
in connection with a suit or other action brought under Section 9.5, the provisions of Section 9.5 shall apply. In all other cases, (a) where such action relates to a FibroGen Patent in the U.S., FibroGen shall have the first right to
defend such action, at FibroGen’s expense, and AstraZeneca will cooperate with FibroGen, at FibroGen’s expense, in such defense, and (b) where such action relates to a FibroGen Patent within the RoW, AstraZeneca shall have the first
right but not the obligation to defend such action, at AstraZeneca’s expense, and FibroGen will cooperate with AstraZeneca, at AstraZeneca’s expense, in such defense. In the event a Party does not so elect to exercise its first right to
defend an action under this Section 9.6, it shall so notify the other Party in writing, and such other Party shall have the right to so defend such action at its expense. Each Party shall provide to the Party defending any such rights under
this Section 9.6 all reasonable assistance in such enforcement, at such defending Party’s request and expense. The defending Party shall keep the other Party regularly informed of the status and progress of such efforts, and shall
reasonably consider the other Party’s comments on any such efforts. 

  
 67. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.7        Third Party
Patents.  FibroGen shall have the sole right and authority to initiate and/or pursue at its sole expense any patent office proceeding, pre- or post-grant or issuance, including reissue, reexamination, limitation, or invalidation
proceedings, or any opposition- or interference-type proceeding or challenge against any Third Party Patent that relates or that may potentially relate to the manufacture, use, or sale of a HIF Compound, a Product, or a Designated Product. 

9.8        Defense of Infringement Actions.  During the Term, each
Party shall bring to the attention of the other Party all information regarding potential infringement or any claim of infringement of Third Party intellectual property rights in connection with the development, manufacture, production, use,
importation, offer for sale, or sale of Products in the Territory. Subject to Article 11, each Party shall be solely responsible at its sole expense for defending any action, suit, or other proceeding brought against it alleging infringement of
Third Party intellectual property rights in connection with its activities under this Agreement. This Section 9.8 shall not be interpreted as placing on either Party a duty of inquiry regarding Third Party intellectual property rights. 

9.9        Patent Marking.      AstraZeneca
shall, and shall require its Affiliates and Sublicensees to, mark Products sold by it hereunder (in a reasonable manner consistent with industry custom and practice) with appropriate patent numbers or indicia to the extent permitted by applicable
law and regulations, in those countries in which such markings or such notices impact recoveries of damages or equitable remedies available with respect to infringements of patents. The Parties agree that listing the appropriate Patent(s) in the
Orange Book shall be deemed a marking in a reasonable manner consistent with industry custom and practice under this Section 9.9, and FibroGen agrees to use good faith efforts to obtain, as soon as reasonably practicable after the Effective
Date, a written confirmation from DFCI that DFCI so agrees. 
 9.10      Personnel
Obligations.  Prior to beginning work under this Agreement relating to any research, Development or Commercialization of a Collaboration Compound or a Product, to HIF or in the Field, each employee, agent or independent contractor of
AstraZeneca or FibroGen or of either Party’s respective Affiliates shall be bound by non-disclosure and invention assignment obligations which are consistent with the obligations of AstraZeneca or FibroGen, as appropriate, in this Article 9,
including without limitation: (a) promptly reporting any invention, discovery, process or other intellectual property right; (b) assigning to AstraZeneca or FibroGen, as appropriate, all of his or her right, title and interest in and to
any invention, discovery, process or other intellectual property right, such that AstraZeneca or FibroGen, as appropriate, can then comply with its obligations under this Agreement with respect to such invention, discovery, process or other
intellectual property right; (c) cooperating in the preparation, filing, prosecution, maintenance and enforcement of any patent and patent application; (d) performing all acts and signing, executing, acknowledging and delivering any and
all documents required for effecting the obligations and purposes of this Agreement; and (e) abiding by the obligations of confidentiality and non-use set forth in Article 12. It is understood and agreed that such non-disclosure and invention
assignment agreement need not reference or be specific to this Agreement. 

  
 68. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.11      Trademarks.  The Parties
shall use Commercially Reasonable Efforts to develop a worldwide trademark, and if not possible, trademark for the Territory consistent with the trademarks for Products selected under the Astellas Collaboration. AstraZeneca, following discussion
with FibroGen, shall be responsible for the selection, registration, ownership, maintenance and defense of all trademarks for use in connection with the sale or marketing of Products in the Field in the Territory (the
“Marks”), as well as all expenses associated therewith. All uses of the Marks shall be reviewed by the JCC and shall comply with all applicable laws and regulations (including those laws and regulations particularly applying
to the proper use and designation of trademarks in the applicable countries). Neither Party shall, without the other Party’s prior written consent, use any trademarks or house marks of the other Party (including the other Party’s corporate
name), or marks confusingly similar thereto, in connection with such Party’s marketing or promotion of Products under this Agreement, except as may be expressly authorized in connection with activities under Article 5 and except to the extent
required to comply with applicable laws and regulations. During the Term, AstraZeneca grants to FibroGen the non-exclusive right, free of charge, to use the AstraZeneca name and logo in the U.S. solely for the purpose of Commercializing the Products
in accordance with the terms of this Agreement, the U.S. Commercialization Plan and the Co-Commercialization Agreement, and FibroGen grants to AstraZeneca the non-exclusive right, free of charge, to use the FibroGen name and logo in the U.S. solely
for the purpose of Commercializing the Products in accordance with the terms of this Agreement, provided that such rights shall be exercised, and all Products bearing such names and/or logos shall be manufactured, in accordance with the quality
standards for such logos and trademarks established by the JSC. AstraZeneca shall remain the owner of the AstraZeneca name and logo and the trademarks and the goodwill pertaining thereto. FibroGen shall remain the owner of the FibroGen name and logo
and the trademarks and the goodwill pertaining thereto. 

9.12      Listing.    Prior to the submission of the first NDA of a
Product in the U.S., the Parties shall discuss in good faith in the IP Committee the Orange Book listings. FibroGen shall be responsible for the submission of documents associated with Orange Book listings in accordance with the plan set forth by
the IP Committee. Upon FibroGen’s receipt of a notice of allowance (or equivalent) of an applicable FibroGen Patent, FibroGen shall promptly provide AstraZeneca notification of such allowance and the Parties shall discuss in good faith in the
IP Committee whether to list such FibroGen Patent in the Orange Book maintained by the FDA or similar or equivalent patent listing source, if any, in other countries in the Territory. FibroGen shall cooperate with AstraZeneca’s reasonable
requests in connection therewith, including meeting any submission deadlines. 

9.13      Patent Term Extension.    AstraZeneca shall be responsible
for and control, but shall confer with FibroGen in, the selection of the appropriate FibroGen Patents as listed in the patent information section of the NDA or MAA for Products for filing to obtain a Patent Term Extension pursuant to all applicable
laws, including without limitation any other extensions that are now or become available in the future wherever applicable to such patents that are applicable to the Products; provided, however, that AstraZeneca shall not have the right to make any
such filing with respect to any FibroGen Patent that is not set forth on Exhibit M without the prior written consent of FibroGen. 

  
 69. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 10 

REPRESENTATIONS AND WARRANTIES 

10.1      Mutual Representations and Warranties.      Each
Party hereby represents, warrants, and covenants (as applicable) to the other Party as follows, as of the Effective Date: 

(a)        Corporate Existence and Power.    It is a
company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets
and to carry on its business as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder. 

(b)        Authority and Binding Agreement.    (i) It
has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against
it in accordance with its terms. 
 (c)        No
Conflict.   It is not a party to and will not enter into any agreement that would prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under this Agreement. 

(d)        No Debarment.   In the course of the Development of
Products, such Party has not used prior to the Effective Date and shall not use, during the Term, any employee, agent or independent contractor who has been debarred by any Regulatory Authority, or, to the best of such Party’s knowledge, is the
subject of debarment proceedings by a Regulatory Authority. 
 10.2      Representations
and Warranties by FibroGen.  FibroGen hereby represents and warrants to AstraZeneca, as of the Effective Date, as follows: 

(a)        Title; Encumbrances.  Except for the Patents licensed to
FibroGen under the DFCI Agreement and the Information licensed to FibroGen under the Astellas Agreements, FibroGen is the sole and exclusive owner of the entire right, title and interest in (a) the Listed Patents and (b) the FibroGen
Know-How existing as of the Effective Date. FibroGen has all rights necessary to grant the licenses under the FibroGen Technology that it grants to AstraZeneca under this Agreement. Neither the Listed Patents nor the FibroGen Know-How is subject to
any mortgage, pledge, lien, security interest, conditional and installment sale agreements, encumbrance or charges or claims of any kind. 

(b)        No Other Patents than those Listed.  The Listed Patents
represent all Patents that, as of the Effective Date, are Controlled by FibroGen and which, to FibroGen’s knowledge, cover or claim any invention necessary or useful for the Development or Commercialization of Collaboration Compounds or
Products in the Field in the Territory as contemplated as of the Effective Date. 

  
 70. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c)        Prosecution of Patents
etc.  To FibroGen’s knowledge, the Listed Patents are being diligently prosecuted before the respective patent authorities in accordance with applicable law. All applicable fees due to patent authorities with respect to the filing
and prosecution of the Listed Patents existing as of the Effective Date have been paid on or before the due date for payment (as such due date may be extended in accordance with applicable laws or patent authority rules and regulations). FibroGen
has not received any written notice alleging that the Listed Patents existing as of the Effective Date, if issued, would be invalid or unenforceable or that the Patent applications included in such Listed Patents will not proceed to grant. To
FibroGen’s knowledge, in respect of any pending U.S. patent applications included in the Listed Patents, FibroGen has submitted all material prior art of which it is aware in accordance with the requirements of the United States Patent and
Trademark Office. To its knowledge, FibroGen has properly identified each and every inventor of the claims of the Listed Patents existing as of the Effective Date. 

(d)        No Infringement or Misappropriation.  FibroGen has not
received any written notice from any Third Party asserting or alleging that any research or development of Collaboration Compounds or Products by FibroGen or by Astellas prior to the Effective Date infringed or misappropriated the intellectual
property rights of such Third Party and FibroGen has no reason to suspect that any such infringement or misappropriation has occurred. To FibroGen’s knowledge, the conception, development and reduction to practice of the Listed Patents and
FibroGen Know-How existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or other proprietary rights of any person or entity. 

(e)        Non-infringement of Third Party Rights.  To
FibroGen’s knowledge, the research, development, manufacture, use and sale after the Effective Date of FG-4592 in the CKD Indications can be carried out in the manner reasonably contemplated as of the Effective Date without infringing any
published patent applications or patents owned or controlled by a Third Party. 

(f)        No Proceedings.     There are no pending
actions, suits or proceedings against FibroGen or any of its Affiliates involving the FibroGen Technology, Collaboration Compounds or Products. 

(g)        Third Party Activities.  To FibroGen’s knowledge,
except as disclosed in a writing of even date herewith by FibroGen to AstraZeneca, there are no activities by Third Parties that would constitute infringement or misappropriation of the FibroGen Technology (in the case of pending claims, evaluating
them as if issued). 
 (h)        DFCI
Agreement.     The DFCI Agreement is in full force and effect. FibroGen has no cause to believe that the DFCI Agreement is likely to be terminated prior to its expiry. To FibroGen’s knowledge, neither DFCI nor
FibroGen is in breach of any of its obligations under the DFCI Agreement. [*]. 

(i)         Astellas Agreements.  Nothing in the Astellas
Agreements prevents FibroGen from granting the rights to AstraZeneca granted under this Agreement or prevents either FibroGen or AstraZeneca from exercising their rights or performing their obligations under this Agreement. 

  
 71. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (j)        Documentation Made
Available to AstraZeneca.   FibroGen has made available to AstraZeneca all material Regulatory Material, FibroGen Know-How and other Information in its possession or Control regarding or related to any Collaboration Compound and
Product. All Regulatory Material, FibroGen Know-How and other Information in FibroGen’s possession and Control provided to AstraZeneca regarding or related to any Collaboration Compound or Product are, to FibroGen’s knowledge, true,
complete and correct in all material respects. As of the Effective Date, FibroGen has prepared, maintained and retained in all material respects all material Regulatory Material that FibroGen is required to maintain or report pursuant to and in
accordance with GLP, GCP, regulations and other applicable law. 

(k)        Patent Litigation.    Neither FibroGen nor its
Affiliates will initiate or maintain any patent enforcement proceeding or litigation with respect to any Designated Product unless it has a good faith basis for doing so. 

10.3     Anti-Bribery and Anti-Corruption Compliance. 

(a)        Each Party agrees, on behalf of itself, its officers, directors and
employees and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (together with such Party, the “Representatives”) that for the
performance of its obligations hereunder: 
 (i)          The
Representatives shall not directly or indirectly pay, offer or promise to pay, authorize the payment of any money or give, offer or promise to give, or authorize the giving of anything else of value, to: (a) any Government Official in order to
influence official action; (b) any individual or entity (whether or not a Government Official) (1) to influence such individual or entity to act in breach of a duty of good faith, impartiality or trust (“acting improperly”),
(2) to reward such individual or entity for acting improperly or (3) where such individual or entity would be acting improperly by receiving the money or other thing of value; (c) any individual or entity (whether or not a Government
Official) while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or
against either Party in connection with the matters that are the subject of this Agreement; or (d) any individual or entity (whether or not a Government Official) to reward that individual or entity for acting improperly or to induce that
individual or entity to act improperly. 
 (ii)        The Representatives
shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws. 

(b)        The Representatives shall comply with the Anti-Corruption Laws plus
the AstraZeneca Anti-Corruption Rules and Policies and shall not take any action that will, or would reasonably be expected to, cause either Party or its Affiliates to be in violation of any such laws or policies. 

(c)        Each Party, on behalf of itself and its other Representatives,
represents and warrants to the other Party that to the best of such Party’s and its Affiliates’ knowledge, no Representative that will participate or support its performance of its obligations hereunder has,

  
 72. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
directly or indirectly, (i) paid, offered or promised to pay or authorized the payment of any money, (ii) given, offered or promised to give or authorized the giving of anything else of
value or (iii) solicited, received or agreed to accept any payment of money or anything else of value, in each case ((i), (ii) and (iii)), in violation of the Anti-Corruption Laws during the three (3) years preceding the date of this
Agreement. 
 (d)        Each Party shall promptly provide the other Party
with written notice of the following events: (i) upon becoming aware of any breach or violation by such Party or its Representative of any representation, warranty or undertaking set forth in Sections 10.3(a)-(c); or (ii) upon receiving a
formal notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of the Representatives
connected with this Agreement that any of them is the target of a formal investigation by a governmental authority for a Material Anti-Corruption Law Violation. 

(e)        Without prejudice to any auditing or inspection rights set forth
elsewhere in this Agreement, each Party shall for the term of this Agreement and six (6) years thereafter, for the purpose of allowing the other Party to audit and monitor the performance of its compliance with this Agreement and particularly
this Section 10.3 permit the other Party, its Affiliates, any auditors of any of them and any governmental authority to have reasonable access to any premises of such Party or other Representatives used in connection with this Agreement,
together with a right to reasonably access personnel and records that relate to this Agreement (“Compliance Audit”). The results of any such audit shall constitute Confidential Information of the audited Party, in respect of
which the other Party shall comply with the provisions contained in Article 12 (subject to the terms and exceptions set forth therein or in this Section 10.3). 

(i)           To the extent that any Compliance Audit by a
Party requires access and review of any commercially or strategically sensitive information of the other Party or any of its other Representatives relating to the business of such Party or any other Representatives (including information about
prices and pricing policies, cost structures and business strategies), such activity shall be carried out by a Third Party professional advisor appointed by the other Party and such professional advisors shall only report back to the other Party
such information as is directly relevant to informing the other Party on such Party’s compliance with the particular provisions of the Agreement being Compliance Audited. 

(ii)         Each Party shall, and shall cause its Representatives to,
provide all cooperation and assistance during normal working hours as reasonably requested by the other Party for the purposes of a Compliance Audit. Such other Party shall ensure that any Third Party auditor enters into a confidentiality agreement
consistent with applicable requirements of Article 12 hereof in all material respects. Such other Party shall instruct any Third Party auditor or other Person given access in respect of a Compliance Audit to cause the minimum amount of disruption to
the business of the audited Party and its Affiliates and to comply with relevant building and security regulations. 

(iii)        The costs and fees of any Compliance Audit shall be paid by the
auditing Party, except that if an inspection or Compliance Audit reveals any breach or violation by the audited Party (including through its other Representatives) of any representation, warranty or 

  
 73. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
undertaking set forth in Sections 10.3(a)-(c), the costs of such inspection or Compliance Audit shall be paid by the audited Party. The audited Party shall bear its own costs of rendering
assistance to the Compliance Audit. 
 (f)        On the occurrence of any
of the following events: (A) A Party becomes aware of, whether or not through a Compliance Audit, that the other Party (or any other Representative) is in breach or violation of any representation, warranty or undertaking in Sections
10.3(a)-(c) or of the Anti-Corruption Laws; or (B) notification is received under Section 10.3(d) relating to any suspected or actual Material
Anti-Corruption Law Violation by a Party or its Representative, in either case ((A) or (B)), the other Party shall have the right, in addition to any other rights or remedies under this Agreement or to which
such other Party may be entitled in law or equity, to (x) take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by such other Party or any of its Affiliates of the Anti-Corruption Laws,
including by requiring that the Party agrees to such additional measures, representations, warranties, undertakings and other provisions as such other Party believes in good faith are reasonably necessary (“Provisions”) and
(y) terminate any or all of the activities conducted by the Party pursuant to this Agreement or this Agreement in its entirety, immediately in the event that: 

(i)         A Party refuses to agree to all of the Provisions required by
the other Party pursuant to this clause; provided that such other Party has (a) provided the Party an explanation in reasonable detail as to why such other Party considers such provisions necessary, (b) given the Party a reasonable
opportunity to review and comment on the proposed Provisions and to provide its view as to the necessity or usefulness of these to address the event concerned and (c) considered such comments in good faith, or 

(ii)        A Party reasonably concludes that there is no Provision available
that would enable such Party or its Affiliates to avoid a potential violation or continuing violation of applicable Anti-Corruption Laws. 

(g)        Any termination of this Agreement pursuant to Section 10.3(f)
shall be treated as a termination for breach and the consequences of termination set forth in Sections 13.6 and 13.7, as applicable, shall apply and additionally: (i) subject to the accrued rights of the Parties prior to termination, the
terminating Party shall have no liability to the other Party for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination; and (ii) any amounts that would
otherwise be payable with respect to such terminated activities or pursuant to this Agreement in its entirety, as applicable, including any then outstanding and unpaid claims for payment shall be null and void to the extent permissible under
applicable laws. 
 (h)        Each Party shall be responsible for any
breach of any representation, warranty or undertaking in this Section 10.3 or of the Anti-Corruption Laws by any of its Representatives. 

(i)         Each Party may disclose the terms of this Agreement or any
action taken under this Section 10.3 to prevent a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of the other Party and the payment terms, to any Governmental Authority if such Party
determines, upon advice of counsel, that such disclosure is necessary. 

  
 74. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (j)        Each Party represents
and warrants that (i) it has reviewed its internal programs in relation to the Anti-Corruption Laws and the ability of the Representatives to adhere to the AstraZeneca Anti-Corruption Rules and Policies
in performance of its obligations hereunder in advance of the signing of this Agreement, (ii) it and the other Representatives can and will continue to comply with such Anti-Corruption Laws and the AstraZeneca Anti-Corruption Rules and Policies
in performance of its obligations hereunder. Should either Party identify in writing to the other Party any measures that should be reasonably taken to improve the Representatives’ compliance with such Anti-Corruption Laws and the AstraZeneca Anti-Corruption Rules and Policies for the performance of its obligations hereunder (the “Improvement Plan”), the other Party shall implement such Improvement Plan within an agreed reasonable
timeframe (which shall in any event not be in excess of three (3) calendar months) from the date the Improvement Plan is delivered to the receiving Party or otherwise the requesting Party shall be entitled to (x) terminate this Agreement,
upon written notice to the other Party with immediate effect, (y) be relieved of any obligations hereunder and (z) seek compensation from the other Party. 

10.4      Disclaimer.     Each Party understands that the
Collaboration Compounds and Products are the subject of ongoing clinical research and development and that the other Party cannot assure the safety or usefulness of the Collaboration Compounds or Products. In addition, FibroGen makes no warranties
except as set forth in this Article 10 concerning the FibroGen Technology, and AstraZeneca makes no warranties except as set forth in this Article 10 concerning the AstraZeneca Technology. 

10.5      No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN
SECTION 5.11 AND THIS ARTICLE 10, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY
OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
 ARTICLE 11 

INDEMNIFICATION 

11.1      Indemnification by FibroGen.    FibroGen shall defend,
indemnify, and hold AstraZeneca, its Affiliates, and their respective officers, directors, employees, and agents (the “AstraZeneca Indemnitees”) harmless from and against any and all damages or other amounts payable to a
Third Party claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such AstraZeneca Indemnitees (collectively, “AstraZeneca Damages”), all to the extent resulting from claims, suits,
proceedings or causes of action brought by such Third Party (“AstraZeneca Claims”) against such AstraZeneca Indemnitee that arise from or are based on: (a) a breach of any of FibroGen’s representations, warranties,
and obligations under this Agreement; 

  
 75. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
(b) the willful misconduct or grossly negligent acts or omissions of FibroGen, its Affiliates, or the officers, directors, employees, or agents of FibroGen or its Affiliates in the performance of
activities under this Agreement; (c) the research or Development of Collaboration Compounds or Products by FibroGen before the Effective Date; or (d) the Development, testing, manufacture, storage, handling, use, sale, offer for sale,
distribution and importation of Products by FibroGen or its Affiliates or licensees (excluding, for clarity, AstraZeneca). The foregoing indemnity obligation shall not apply if the AstraZeneca Indemnitees materially fail to comply with the
indemnification procedures set forth in Section 11.3, or to the extent that such AstraZeneca Claim is based on or alleges: (i) a breach of any of AstraZeneca’s representations, warranties, and obligations under this Agreement; or
(ii) the willful misconduct or grossly negligent acts or omissions of AstraZeneca or its Affiliates, or the officers, directors, employees, or agents of AstraZeneca or its Affiliates in the performance of activities under this Agreement. 

11.2      Indemnification by AstraZeneca. AstraZeneca shall defend, indemnify, and
hold FibroGen, its Affiliates, and each of their respective officers, directors, employees, and agents, (the “FibroGen Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party
claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such FibroGen Indemnitees (collectively, “FibroGen Damages”), all to the extent resulting from any claims, suits, proceedings or
causes of action brought by such Third Party (collectively, “FibroGen Claims”) against such FibroGen Indemnitee that arise from or are based on: (a) the Development, testing, manufacture, storage, handling, use, sale,
offer for sale, distribution and importation of Products by AstraZeneca or its Affiliates, Sublicensees, or distributors; (b) a breach of any of AstraZeneca’s representations, warranties, and obligations under the Agreement; or
(c) the willful misconduct or grossly negligent acts or omissions of AstraZeneca or its Affiliates, or the officers, directors, employees, or agents of AstraZeneca or its Affiliates in the performance of activities under this Agreement. The
foregoing indemnity obligation shall not apply if the FibroGen Indemnitees materially fail to comply with the indemnification procedures set forth in Section 11.3, or to the extent that any FibroGen Claim is based on or alleges: (i) a
breach of any of FibroGen’s representations, warranties, and obligations under this Agreement; or (ii) the willful misconduct or grossly negligent acts or omissions of FibroGen, its Affiliates, or their officers, directors, employees, or
agents in the performance of activities under this Agreement. 
 11.3      Indemnification
Procedures.  The Party claiming indemnity under this Article 11 (the “Indemnified Party”) shall give written notice to the Party from whom indemnity is being sought (the “Indemnifying
Party”) promptly after learning of the claim, suit, proceeding or cause of action for which indemnity is being sought (“Claim”). The Indemnified Party shall provide the Indemnifying Party with reasonable
assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole
expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified
Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle any such Claim without the
prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend 

  
 76. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified
Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this Article 11. 

11.4      Insurance.  Each Party shall self-insure or procure and maintain
insurance, including product liability insurance, with respect to its activities hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically
tested in human subjects or commercially distributed or sold until the expiration or termination of this Agreement or four (4) years after termination of any such clinical testing or commercial distribution, whichever is later. It is understood
that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 11. Each Party shall provide the other with written evidence of such insurance upon
request. Each Party shall provide the other with written notice at least thirty (30) days prior to the cancellation, non-renewal or material change in such insurance or
self-insurance which materially adversely affects the rights of the other Party hereunder. 

11.5      DFCI Agreement.  [*] 

ARTICLE 12 

CONFIDENTIALITY 

12.1      Product Information.  FibroGen recognizes that by reason of, among
other things, AstraZeneca’s status as licensee pursuant to the grants under Section 7.1, AstraZeneca has an interest in FibroGen’s retention in confidence of information relating to the Collaboration Compounds or Products, and the
Development and Commercialization thereof. Accordingly, during the Term, FibroGen shall, and shall cause its Affiliates and their respective officers, directors, employees and agents to, keep confidential, and not publish or otherwise disclose,
other than under written confidentiality and non-use terms, and not use directly or indirectly for any purpose other than to perform FibroGen’s obligations under this Agreement and the China Agreement, to conduct research, Development and
Commercialization of Products outside the Territory pursuant to the Astellas Agreements or any Subsequent Agreement entered into pursuant to Section 7.4(c), in connection with FibroGen’s research, development and commercialization of other
products, and as otherwise authorized under this Agreement (including pursuant to Section 3.10), any (a) Regulatory Material (including any Regulatory Approvals) with respect to any Collaboration Compound or Product and
(b) Information that is either Controlled by FibroGen or provided to FibroGen pursuant to this Agreement relating to the Development or Commercialization of Collaboration Compounds or Products, including development, sales or marketing plans
therefor (collectively, (a) and (b), “Product Information”), except, in each case, to the extent (i) the Product Information was generally available to the public or otherwise part of the public domain, prior to the
Effective Date, or thereafter became generally available to the public or otherwise part of the public domain through no fault of FibroGen, its Affiliates or any of their respective officers, directors, employees or agents or (ii) the
disclosure or use of such Product Information would be expressly permitted under Section 12.3 or is otherwise expressly authorized under this Agreement. For clarification, the disclosure or transfer by FibroGen to AstraZeneca or

  
 77. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
by AstraZeneca to FibroGen of any Product Information shall not cause such information to cease to be subject to the provisions of this Section 12.1. In the event this Agreement is
terminated in its entirety or in a given country for any reason, this Section 12.1 shall as from the effective date of such termination have no continuing force or effect (provided that if such termination is with respect to one or several
specific country(ies) only, then this Section 12.1 will have no continuing force or effect as to such specific country(ies)) and all Product Information shall be deemed to be Confidential Information of FibroGen for purposes of the surviving
provisions of this Agreement. For clarity, the foregoing shall not affect the Parties’ respective ownership of Product Information. 

12.2     Confidentiality General.   Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing by the Parties, each Party agrees that, during the Term and for ten (10) years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other
than as provided for in this Agreement or the China Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential Information furnished to it by the other Party pursuant to this
Agreement except for that portion of such information or materials that the receiving Party can demonstrate by competent written proof: 

(a)       was already known to the receiving Party or its Affiliate, other than under an
obligation of confidentiality, at the time of disclosure by the other Party; 
 (b)
      was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

(c)       became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d)       is subsequently disclosed to the receiving Party or its Affiliate by a Third
Party without obligations of confidentiality with respect thereto; or 
 (e)       is
independently discovered or developed by the receiving Party or its Affiliate without the aid, application, or use of the disclosing Party’s Confidential Information. 

For the avoidance of doubt, Confidential Information that is also Product Information is governed both by the terms of Section 12.1 and
by the terms of this Section 12.2. 
 12.3     Authorized Disclosure.   FibroGen may
disclose Product Information and each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following situations: 

(a)       filing or prosecuting FibroGen Patents in accordance with Article 9; 

(b)      regulatory filings and other filings with Governmental Authorities (including
Regulatory Authorities), including filings with the SEC or FDA, with respect to a Product; 
 (c)
      prosecuting or defending litigation; 

  
 78. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d)       complying with applicable laws
and regulations, including regulations promulgated by securities exchanges; 
 (e)
      disclosure to its Affiliates, employees, agents, and independent contractors, and any licensees or Sublicensees, in each case only on a need-to-know basis and solely in connection with the performance of this
Agreement or the China Agreement (and in the case of FibroGen, the Astellas Collaboration or any Subsequent Agreement entered into pursuant to Section 7.4(c)), provided, however, that each disclosee must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Article 12 prior to any such disclosure and provided, further, that the disclosing Party shall cause such disclosee to comply with confidentiality and non-use
obligations at least as restrictive as those set forth in this Article 12; 
 (f)
      disclosure of the material terms of this Agreement to any bona fide potential or actual investor, investment banker, acquirer, merger partner, or other potential or actual financial partner, and in the case of
FibroGen, to any licensee or sublicensee of Products (including Astellas and its sublicensees); provided that in connection with such disclosure, the disclosing Party shall inform each disclosee of the confidential nature of such Confidential
Information and cause each disclosee to treat such Confidential Information as confidential; and 
 (g)
      disclosure of any Inventions or status reports (including data from any Clinical Trials) to any bona fide potential or actual investor, investment banker, acquirer, merger partner, or other potential or actual
financial partner, and in the case of FibroGen, to any licensee of Products (including Astellas and its sublicensees); provided that each disclosee must be bound by obligations of confidentiality and non-use at least as restrictive as those set
forth in this Article 12 prior to any such disclosure. 
 Notwithstanding the foregoing, in the event FibroGen is required
to make a disclosure of Product Information or either Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Sections 12.3(a), 12.3(b), 12.3(c) or 12.3(d), it will, except where impracticable, use
Commercially Reasonable Efforts to secure confidential treatment of such information. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. 

12.4     Publicity; Terms of Agreement. 

(a)       The Parties agree that the material terms of this Agreement are the
Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in Section 12.3 and this Section 12.4. The Parties have agreed to make a joint public announcement of the execution of this
Agreement substantially in the form of the press release attached as Exhibit N on or promptly after the Effective Date. 

(b)       After release of such press release, if either Party desires to make a public
announcement concerning the material terms of this Agreement or any activities under this Agreement, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval
(except as otherwise provided herein), such approval not to be unreasonably withheld, except that in the case of a press release or 

  
 79. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
governmental filing required by law, the disclosing Party shall provide the other Party with such advance notice as it reasonably can and shall not be required to obtain approval therefor. A
Party commenting on such a proposed press release shall provide its comments, if any, within five (5) Business Days after receiving the press release for review. FibroGen shall have the right to make a press release announcing the achievement
of each milestone under this Agreement as it is achieved, and the achievements of Regulatory Approvals as they occur, subject only to the review procedure set forth in the preceding sentence. In relation to AstraZeneca’s review of such an
announcement, AstraZeneca may make specific, reasonable comments on such proposed press release within the prescribed time for commentary, but shall not withhold its consent to disclosure of the information that the relevant milestone or Regulatory
Approval has been achieved and triggered a payment hereunder. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement that have already been publicly disclosed by such
Party, or by the other Party, in accordance with this Section 12.4. 
 (c)
      The Parties acknowledge that either or both Parties may be obligated to file a copy of this Agreement with the SEC or other Government Authorities. Each Party shall be entitled to make such a required filing,
provided that it requests confidential treatment of at least the commercial terms and sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each
Party will provide the other Party with a copy of the Agreement marked to show provisions for which such Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent
consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. 

12.5     Publications. 

(a)       Subject to the International Committee of Medical Journal Editors
(“ICMJE”) Uniform Requirements for Manuscripts Submitted to Biomedical Journals and applicable legal requirements, the JDC (with approval of the JSC) will determine the overall strategy for publishing and presenting results of studies
pertaining to the Products and the JDC shall approve all publications in the Territory prior to publication. 
 (b)
     Neither Party shall publicly present or publish results of studies carried out under this Agreement (each such presentation or publication a “Publication”) without the opportunity for prior
review by the other Party, except to the extent otherwise required by applicable laws or regulations, in which case Section 12.4(c) shall apply with respect to disclosures required by applicable securities laws and Section 12.3(b) shall
apply with respect to disclosures required for regulatory filings. The submitting Party shall provide the other Party the opportunity to review any proposed Publication at least thirty (30) days prior to the earlier of its presentation or
intended submission for publication. The submitting Party agrees, upon request by the other Party, not to submit or present any Publication until the other Party has had thirty (30) days to comment on any material in such Publication. The
submitting Party shall consider the comments of the other Party in good faith, and no Publication shall be submitted for publication without the approval of the JDC or JCC. The submitting Party shall provide the other Party a copy of the Publication
at the time of the submission or presentation. Notwithstanding the foregoing, AstraZeneca shall not have the right to publish or present FibroGen’s Confidential Information without FibroGen’s prior written consent, and FibroGen shall not
have the right to publish or 

  
 80. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
present AstraZeneca’s Confidential Information without AstraZeneca’s prior written consent. Each Party agrees to acknowledge the contributions of the other Party, and the employees of
the other Party, in all publications as scientifically appropriate. 
 ARTICLE 13 

TERM AND TERMINATION 

13.1     Term.   This Agreement shall become effective on the Effective Date and, unless
earlier terminated pursuant to this Article 13, shall remain in effect until the date that AstraZeneca is no longer Developing or selling Products in the Territory (the “Term”). 

13.2     Termination by AstraZeneca at Will.   AstraZeneca shall have the right to
terminate this Agreement at any time upon one hundred eighty (180) days prior written notice to FibroGen, either (a) in its entirety or (b) with respect to one or more of the following (each a “region”): (i) the U.S.,
(ii) Asia, (iii) Africa or (iv) one or more of Mexico, Brazil, Canada, India or Australia and New Zealand (each considered a separate region). During such one hundred eighty (180) day period, AstraZeneca shall continue to perform
all of its obligations under this Agreement and shall continue to be responsible for all costs incurred under the Agreement to be borne by AstraZeneca according to the Agreement during such one hundred eighty (180) day period. 

13.3     Termination by AstraZeneca for Technical Product Failure.  AstraZeneca may terminate
this Agreement in its entirety at any time after the Effective Date effective upon written notice to FibroGen in the event of Technical Product Failure, such notice to describe the basis for such Technical Product Failure in reasonable detail;
provided, however, that AstraZeneca shall not be entitled to terminate this Agreement pursuant to this Section 13.3 if such Technical Product Failure pertains only to one or several specific Collaboration Compound(s) or Product(s) but
does not affect (a) FG-4592 (if FG-4592 is then still being Developed or Commercialized under this Agreement) or (b) any other Collaboration Compound or Product then in a Phase 2 Clinical Trial or later stage of Development or
Commercialization under this Agreement. Disputes related to whether or not a Technical Product Failure has occurred will be resolved in accordance with Section 14.8. 

13.4     Termination by Either Party for Breach. 

(a)       Breach.   Subject to Section 13.4(b), FibroGen shall have the
right to terminate this Agreement upon written notice to AstraZeneca if AstraZeneca materially breaches its obligations under this Agreement and, after receiving written notice from FibroGen identifying such material breach by AstraZeneca in
reasonable detail, fails to cure such material breach within ninety (90) days from the date of such notice (or within thirty (30) days from the date of such notice in the event such material breach is solely based upon AstraZeneca’s
failure to pay any material amounts due to FibroGen hereunder). Subject to Section 13.4(b), AstraZeneca shall have the right to terminate this Agreement upon written notice to FibroGen if FibroGen materially breaches its obligations under this
Agreement and, after receiving written notice from AstraZeneca identifying such material breach by FibroGen in reasonable detail, fails to cure such material breach within ninety (90) days from the date of such notice (or within thirty
(30) days from the date of such notice in the event such material breach is solely based upon FibroGen’s failure to pay any material amounts due to AstraZeneca hereunder). 

  
 81. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b)       Disputed Breach.  If the
alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party in accordance with Section 13.4(a), and such alleged breaching Party provides the other Party notice of
such dispute within such ninety (90) day (or thirty (30) day, as the case may be) period, then the non-breaching Party shall not have the right to terminate this Agreement under Section 13.4(a) unless and until the arbitral tribunal,
in accordance with Article 14, has determined that the alleged breaching Party has materially breached the Agreement and such Party fails to cure such breach within ninety (90) days following such arbitral tribunal’s decision (except to
the extent such breach is solely based on the failure to make a payment when due, which breach must be cured within thirty (30) days following such arbitral tribunal’s decision); provided that with respect to a failure to pay amounts due,
arbitration shall be conducted in accordance with Article 14, except that it shall be conducted by only one arbitrator and shall be resolved within ninety (90) days. It is understood and agreed that during the pendency of such dispute, all of
the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. 

(c)       DFCI Agreement.  FibroGen shall have the right to terminate
AstraZeneca’s license under the FibroGen Technology licensed from DFCI immediately upon written notice upon a termination of the DFCI Agreement under Section 8.2 of the DFCI Agreement, provided, however, that FibroGen shall use Commercially
Reasonable Efforts to ensure that AstraZeneca is afforded an opportunity to obtain a license directly with DFCI as set out in Section 8.4.5 of the DFCI Agreement. 

13.5     Termination for Patent Challenge.  FibroGen may terminate this Agreement in its
entirety immediately upon written notice to AstraZeneca if AstraZeneca or its Affiliates or Sublicensees (directly or indirectly, individually or in association with any other person or entity) challenges the validity, enforceability or scope of any
FibroGen Patent in the Territory and such challenge is not permanently withdrawn within ninety (90) days. 
 13.6
    Effects of Termination.  Upon any termination of this Agreement other than pursuant to Section 13.3 for Technical Product Failure, the following shall apply (in addition to any other rights and obligations under
Section 13.8 or otherwise under this Agreement with respect to such termination) and, in the case of termination with respect to a particular region only, shall apply only to the terminated region (it being understood that any reference below
to the “terminated region” will apply to the Territory as a whole if this Agreement is terminated in its entirety): 

(a)       Rights and Licenses to the FibroGen Technology. As from the effective date of
the termination, all licenses and rights to the FibroGen Technology granted to AstraZeneca under Article 7 shall terminate with respect to the terminated region, except to the extent and for so long as is necessary to permit AstraZeneca to comply
with its obligations under this Section 13.6, to dispose of any remaining inventory of Products pursuant to Section 13.6(g) and to perform any activity that cannot be terminated as of such date under applicable law, including GCP, it being
agreed that all such activities and responsibilities shall be discontinued and ceased (unless otherwise agreed) by transitioning such activities and responsibilities to FibroGen as soon as practicable and subject to applicable law, including GCP.

 (b)       AstraZeneca Technology.     AstraZeneca hereby grants
to FibroGen, effective only upon the effective date of such termination, a non-exclusive, fully-paid, perpetual, 

  
 82. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
irrevocable, royalty-free license, with the right to grant multiple tiers of sublicenses, under the AstraZeneca Technology, to research, develop, make, have made, use, import, export, offer for
sale, and sell Products in the Field in the terminated region; provided that FibroGen shall indemnify, defend and hold harmless AstraZeneca and each of the AstraZeneca Indemnitees as set forth in Section 11.1 from and against any AstraZeneca
Damages arising out of or resulting from AstraZeneca Claims that arise or result from FibroGen’s, its Affiliates’ or licensees’ activities performed under the foregoing license. 

(c)       Marks.  AstraZeneca shall assign to FibroGen all right, title and
interest in and to the Marks for the terminated regions (excluding any such Marks that include, in whole or part, any corporate name or logo of AstraZeneca or its Affiliate or Sublicensee or that relate to any other products of AstraZeneca or its
Affiliates). 
 (d)       Regulatory Materials. AstraZeneca shall transfer and
assign to FibroGen all Regulatory Materials and Regulatory Approvals for Products in the terminated regions, if any, that are Controlled by AstraZeneca or its Affiliates or Sublicensees. 

(e)       Transition Assistance.  AstraZeneca shall, at no cost to FibroGen,
provide reasonable consultation and assistance for a period of no more than one hundred eighty (180) days following the effective date of termination for the purpose of transferring or transitioning to FibroGen, all AstraZeneca Know-How solely
related to a Product not already in FibroGen’s possession, and, at FibroGen’s request, all then-existing commercial arrangements relating specifically to the terminated region and the Products to the extent reasonably necessary or useful
for FibroGen to commence or continue developing, manufacturing, or commercializing Products in the terminated region, and further to the extent AstraZeneca is contractually able to do so. The foregoing consultation and assistance shall include,
without limitation, assigning, upon request of FibroGen, any agreements with Third Party suppliers or vendors that specifically cover the supply or sale of Products in the Territory, to the extent such agreements are assignable by AstraZeneca. If
any such contract between AstraZeneca and a Third Party is not assignable to FibroGen (whether by such contract’s terms or because such contract does not relate specifically to Products) but is otherwise reasonably necessary or useful for
FibroGen to commence or continue developing, manufacturing, or commercializing Products, then AstraZeneca shall reasonably cooperate with FibroGen to negotiate for the continuation of such license and/or supply from such entity. In any event, if
AstraZeneca is manufacturing bulk or finished Product under an agreement entered into pursuant to Section 6.4, then AstraZeneca shall supply such bulk or finished Product, as applicable, to FibroGen and Astellas, for a reasonable transitional
period (not to exceed twelve (12) months from the effective date of the termination, subject to reasonable extension by FibroGen if AstraZeneca is unable to timely effect the technology transfer required to have a Third Party manufacturer
designated by FibroGen undertake the manufacturing responsibilities) under the terms of such agreement until FibroGen either enters into a separate agreement with such Third Party supplier or vendor or establishes an alternate, validated source of
supply for the Products. In consideration of such supplies, FibroGen shall pay to AstraZeneca a price equal to AstraZeneca’s actual cost to manufacture or acquire such supplies, provided that where termination is by AstraZeneca pursuant to
Section 13.4(a), FibroGen shall pay to AstraZeneca a price equal to AstraZeneca’s actual cost to manufacture or acquire such supplies plus a mark-up [*] of such actual cost. 

  
 83. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (f)       Ongoing Clinical Trials.
 As soon as practicable and subject to applicable law, including GCP, AstraZeneca shall transfer to FibroGen the management and continued performance of all Clinical Trials for Products for the terminated regions ongoing as of the effective
date of such termination, that are being conducted by AstraZeneca at such time. 

(g)       Remaining Inventories.  If this Agreement is terminated in its
entirety, FibroGen shall have the right to purchase from AstraZeneca any or all of the inventory of Products held by AstraZeneca as of the effective date of the termination (that are not committed to be supplied to any Third Party in the ordinary
course of business as of the date of termination) at a price equal to AstraZeneca’s actual cost to acquire such inventory. FibroGen shall notify AstraZeneca within sixty (60) days after the effective date of the termination whether
FibroGen elects to exercise such right. In the event FibroGen does not elect to exercise such right AstraZeneca shall be entitled to dispose of such inventory as it sees fit in compliance with applicable law, subject to all applicable payments to
FibroGen under Article 8. 
 (h)       Funding of Development Costs.
    If AstraZeneca terminates this Agreement under Section 13.2 (but not in the event of any other termination), then AstraZeneca shall remain responsible for all (or, if during the Development Sharing Period, fifty percent
(50%) of) Development Costs and all Commercialization Costs incurred by FibroGen under the respective Development Plans and Commercialization Plans [*], under the process in Section 8.2. If AstraZeneca terminates this Agreement under
Section 13.2 (but not in the event of any other termination), AstraZeneca shall [*]. 

(i)       Post-Termination Restriction.  If this Agreement is
terminated by AstraZeneca at will under Section 13.2 or by FibroGen under Section 13.4 for AstraZeneca’s material breach or by FibroGen under Section 13.5 for patent challenge, AstraZeneca shall continue to comply with the
restrictive covenant set out in Section 7.8(a) for three (3) years after the effective date of the termination. 

(j)       No Other Rights.   For the avoidance of doubt, the rights
granted to FibroGen under this Section 13.6 are restricted to Collaboration Compounds and Products and AstraZeneca does not grant any rights whatsoever to any other compounds or products or to any Patents or other intellectual property rights
other than as set forth in this Section 13.6. Moreover, AstraZeneca shall not be obligated to provide FibroGen with any other intellectual property rights or other rights or services than that which are explicitly provided for under this
Section 13.6. 
 (k)      Certain Additional Provisions for Termination for
FibroGen’s Breach.  If this Agreement is terminated under Section 13.4 for FibroGen’s material breach, FibroGen shall – in addition to any other remedies available to AstraZeneca under this Agreement or applicable law as
a consequence of such breach – compensate AstraZeneca for any costs or expenses incurred by AstraZeneca or its Affiliates in connection with performing any of the activities contemplated by the applicable provisions in this Section 13.6.

 13.7      Effect of Termination for Technical Product Failure.  Upon
termination of this Agreement pursuant to Section 13.3 for a Technical Product Failure, all licenses and rights to the FibroGen Technology granted to AstraZeneca under Article 7 shall terminate and, to the extent appropriate given the nature of
the Technical Product Failure and subject to applicable law, including GCP, the other termination consequences set out in Sections 13.6(a) through 13.6(g) as well as Section 13.6(j) shall apply. 

  
 84. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 13.8     Other Remedies. Termination or expiration of
this Agreement for any reason shall not release either Party from any liability or obligation that already has accrued prior to the effective date of such expiration or termination, nor affect the survival of any provision hereof to the extent it is
expressly stated to survive such termination. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether
for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. 

13.9     Bankruptcy. 

(a)       A Party shall have the right to terminate this Agreement in its entirety
before the end of the Term upon the bankruptcy or insolvency of, or the filing of an action to commence insolvency proceedings against the other Party, or the making or seeking to make or arrange an assignment for the benefit of creditors of the
other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy, or the appointment of a receiver or trustee of such Party’s property, in each case that is not discharged within sixty (60) days of the applicable
filing, action or initiation of proceedings. 
 (b)       All rights and licenses
granted under or pursuant to this Agreement by FibroGen and AstraZeneca are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined
under Section 101 of the U.S. Bankruptcy Code. The Parties agree that each Party, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The
Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party (such Party, the “Bankrupt Party”) under the U.S. Bankruptcy Code, the other Party shall be entitled to a complete
duplicate of (or complete access to, as appropriate) any intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not already in such other Party’s possession, shall be promptly delivered
to it (i) upon any such commencement of a bankruptcy proceeding upon such other Party’s written request therefor, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (ii) if not
delivered under clause (i), following the rejection of this Agreement by the Bankrupt Party upon written request therefor by the other Party. 

13.10   Survival.  Termination or expiration of this Agreement shall not affect rights or obligations of
the Parties under this Agreement that have accrued prior to the date of termination or expiration of this Agreement. Notwithstanding anything to the contrary, the following provisions shall survive and apply after expiration or termination of this
Agreement: Sections 3.10(b), 3.11, 4.4 (last sentence only), 7.8(a)-(c) (only as and to the extent set forth in Section 13.6(i)), 7.8(d), 7.9, 8.1, 8.9-8.15, 9.2, 10.5, 12.1 (provided that all Product Information will be FibroGen’s
Confidential Information upon termination (but not expiration) of this Agreement), 12.2, 12.3, 12.4, 13.6, 13.7, 13.8 and 13.10 and Articles 11, 14 and 15. In addition, the other applicable provisions of Article 8 shall survive to the extent
required to make final reimbursements, reconciliations or other payments with respect to Net Sales and costs and expenses incurred or 

  
 85. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
accrued prior to the date of termination or expiration. For any surviving provisions requiring action or decision by a Committee or an Executive Officer, each Party will appoint representatives
to act as its Committee members or Executive Officer, as applicable. All provisions not surviving in accordance with the foregoing shall terminate upon expiration or termination of this Agreement and be of no further force and effect. 

ARTICLE 14 

DISPUTE RESOLUTION AND GOVERNING LAW 

14.1     Disputes. It is the objective of the Parties to establish procedures to facilitate the
resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation
to or in connection with this Agreement (including disputes arising from the JSC that are not resolved pursuant to Section 2.6), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating
to the interpretation or application of this Agreement (each, a “Dispute”), then upon the request of either Party by written notice, the dispute will be referred to the Executive Officers of each Party, who shall meet and
discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting. If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may
then invoke the provisions of Section 14.2. 
 14.2     Arbitration.  Any dispute,
controversy, difference or claim which may arise between the Parties, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation,
enforceability, breach, performance, application or termination of this Agreement) that is not resolved pursuant to Section 14.1, except for a dispute, claim or controversy under Section 14.7 or 14.8, shall be settled by binding
arbitration administered by the American Arbitration Association (the “AAA”) in accordance with its Commercial Arbitration Rules (or the AAA International Arbitration Rules, if recommended under the AAA guidelines), as such
rules may be modified by this Section 14.2 or otherwise by subsequent written agreement of the Parties. The arbitration shall be governed by the U.S. Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the “Federal Arbitration
Act”), to the exclusion of any inconsistent state laws. The arbitration will be conducted in New York, New York. The number of arbitrators shall be three (3), of whom the Parties shall select one (1) each. The two arbitrators so
selected will select the third and final arbitrator. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the AAA shall select the third arbitrator. The language to be used in the arbitral proceedings
will be English. The Parties shall have the right to be represented by counsel. The arbitration proceeding shall be confidential. Except as required by applicable law, no Party shall make (or instruct the arbitrator to make) any public announcement
with respect to the proceedings or decision of the arbitrator without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator,
except as required in connection with the enforcement of such award or as otherwise required by applicable law. Any judgment or award rendered by the arbitrators shall be final and binding on the Parties. The Parties agree that such judgment or
award may be enforced in any court of competent jurisdiction. 

  
 86. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 14.3     Governing Law. Resolution of all Disputes and
any remedies relating thereto shall be governed by and construed under the substantive laws of the State of California, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this
Agreement to the substantive law of another jurisdiction. 
 14.4     Decision.
    The arbitrators shall issue a reasoned opinion following a full comprehensive hearing, no later than twelve (12) months following the selection of the arbitrators. 

14.5     Award. Any award shall be promptly paid in Dollars free of any tax, deduction or offset;
and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement. If as to any issue the arbitrators should determine under the applicable law that the
position taken by a Party is frivolous or otherwise irresponsible or that any wrongdoing it finds is in callous disregard of law and equity or the rights of the other Party, the arbitrators shall also be entitled to award an appropriate allocation
of the adversary’s reasonable attorney fees, costs and expenses to be paid by the offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent with such award has been presented following the
award on the merits. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 14. The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of
the award until paid in full, at a rate fixed by the arbitrators. With respect to money damages, nothing contained herein shall be construed to permit the arbitrators or any court or any other forum to award punitive or exemplary damages. By
entering into this agreement to arbitrate, the Parties expressly waive any claim for punitive or exemplary damages. The only damages recoverable under this Agreement are compensatory damages. 

14.6     Injunctive Relief.  Provided a Party has made a sufficient showing under the rules
and standards set forth in the U.S. Federal Rules of Civil Procedure and applicable case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after either Party submits in writing for
arbitration claims requiring immediate relief. Nothing in this Article 14 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order,
preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. 

14.7     Patent and Trademark Disputes.  Any dispute, controversy or claim relating to the
scope, validity, enforceability or infringement of any patents or trademarks covering the manufacture, use, importation, offer for sale or sale of the Product shall be submitted to a court of competent jurisdiction in the country in which such
patent or trademark rights were granted or arose. 
 14.8     Expedited Arbitration for Disputes
Related to Technical Product Failure.  Disputes with respect to a Technical Product Failure that are not resolved at the JSC or by the Executive Officers within twenty (20) Business Days after referral thereto, in the case of a
Technical Product Failure as defined in Section 1.120(a), or resolved by the Parties, in the case of a Technical Product Failure as defined in Section 1.120(b), shall be finally determined as set forth in this Section 14.8. Within
five (5) Business Days after the end of such twenty (20)-Business Day 

  
 87. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
period, each Party shall propose a list of three (3) individuals, each of whom has at least ten (10) years of significant relevant technical experience in the pharmaceutical industry,
and none of whom is or has been affiliated with either Party or with either Party’s Affiliates, licensees, sublicensees or business partners, or otherwise has any interest in the resolution of the issue to be submitted by the Parties for
resolution (the foregoing requirements, the “Requirements”). Within five (5) Business Days after the Parties exchange such lists, the Parties shall either agree upon one of such proposed individuals to resolve the
disputed matter, or if the Parties do not so select one such individual within such period of time, each Party shall select one (1) such individual from the list proposed by the other Party, and the two (2) selected individuals shall
select a third individual who otherwise meets the Requirements to resolve the disputed matter (the selected individual, the “Industry Expert”). Each Party shall submit written materials to the other Party and to the Industry
Expert relating to the matters in issue within five (5) Business Days after the Industry Expert is selected. Each Party shall then have five (5) Business Days to submit a written rebuttal to the other Party’s submission to the other
Party and to the Industry Expert. The Industry Expert shall have the discretion to interview the Parties’ officers and employees to obtain further information relating to the matters in issue and to hear oral argument. Each Party shall
cooperate with the Industry Expert. The Industry Expert’s determination shall be binding as to whether a Technical Product Failure has occurred, and such determination shall be given retroactive effect. Until such determination is delivered to
the Parties, the Parties shall continue to perform their obligations under this Agreement in good faith and make any applicable payments accordingly. If the Industry Expert decides in AstraZeneca’s favor, then the Parties shall bear all
expenses incurred pursuant to this Section 14.8 equally, and if the Industry Expert decides in FibroGen’s favor, then AstraZeneca shall bear all expenses incurred pursuant to this Section 14.8, including reasonable reimbursement of
FibroGen’s expenses for internal personnel and external advisors. 
 ARTICLE 15 

MISCELLANEOUS 

15.1     Entire Agreement; Amendment.  This Agreement, including the Exhibits hereto, sets
forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the
Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof, including, without limitation, the Existing Confidentiality Agreement. The foregoing shall not be interpreted as a waiver of any
remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations pursuant to the Existing Confidentiality Agreement. In the event of any inconsistency between any plan hereunder
(including the Development Plan and/or U.S. Commercialization Plan) and this Agreement or between the terms of this Agreement and the China Agreement (but solely with respect to the U.S. and RoW), the terms of this Agreement shall prevail. There are
no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to
this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

  
 88. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 15.2     Force Majeure.   Both Parties shall
be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented or delayed by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such
excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall mean conditions beyond the
control of the Parties, including without limitation, an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected
from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances). The non-performing Party shall within thirty (30) days after a force majeure provide the other Party a good faith estimate
of the anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is reasonably necessary and the non-performing Party shall use
Commercially Reasonable Efforts to remedy its inability to perform. Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. 

15.3     Notices.  Any notice required or permitted to be given under this Agreement shall be
in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and
shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable international expedited delivery service, or (b) five (5) Business Days after mailing, if mailed by first class certified
or registered mail, postage prepaid, return receipt requested. 
  

					
	If to FibroGen:	 		 	FibroGen, Inc.
		 		 	 409 Illinois St.
 San Francisco, CA
94158

		 		 	USA
		 		 	Attention: Chief Executive Officer
			
	With a copy to:	 		 	FibroGen, Inc.
		 		 	 409 Illinois St.
 San Francisco, CA
94158

		 		 	USA
		 		 	Attn:  Michael Lowenstein, Vice President, Legal

  
 89. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	If to AstraZeneca:	 		 	AstraZeneca AB
		 		 	Pepparedsleden 1, 431 83 Mölndal
		 		 	Gothenburg
		 		 	Sweden
		 		 	Attention: Chief Financial Officer
			
	With a copy to:	 		 	AstraZeneca UK Limited
		 		 	Alderley Park
		 		 	Macclesfield
		 		 	Cheshire SK10 4TF
		 		 	Attention: Liam McIlveen, Deputy General Counsel

 15.4     No Strict Construction; Headings.  Each of the
Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein,
including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly, in the event an ambiguity or a question of intent or interpretation arises, this Agreement will be construed as
if drafted jointly by the Parties and no presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement. The headings of each Article and Section in this Agreement have
been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

15.5     Assignment.  Neither Party may assign or transfer this Agreement (either in whole or
part) or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party’s consent to Affiliates or to a successor to substantially all of
the business of such Party, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted successor or assignee of rights and/or obligations hereunder shall, in a writing to the other Party, expressly assume performance of
such rights and/or obligations (and in any event, any Party assigning this Agreement to an Affiliate shall remain bound by the terms and conditions hereof). In the event that a Party is acquired by a Third Party (such Third Party, hereinafter
referred to as an “Acquiror”), then the intellectual property of such Acquiror held or developed by such Acquiror (whether prior to or after such acquisition) shall be excluded from the FibroGen Technology (in the case when
the acquired Party is FibroGen) and AstraZeneca Technology (in the case when the acquired Party is AstraZeneca), and such Acquiror (and Affiliates of such Acquiror which are not controlled by the acquired Party itself) shall be excluded from
“Affiliate” solely for purposes of the applicable components of the foregoing intellectual property definitions, in all such cases if and only if: (a) the acquired Party remains a wholly-owned subsidiary of the Acquiror; (b) all
intellectual property of the acquired Party and all research and development assets and operations of the acquired Party with respect to the Product remain with the acquired Party and are not transferred to the Acquiror or another Affiliate of the
Acquiror; (c) the scientific and development activities with respect to Product of the acquired Party and the Acquiror (if any) are maintained separate and distinct, and (d) there is no exchange of confidential Information relating to this
Collaboration between the acquired Party and the Acquiror. For clarity, in the event that a Party is acquired by an Acquiror and any of the criteria described in subsections (a) through (d) is not satisfied, then the intellectual

  
 90. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
property of such Acquiror shall be included within FibroGen Technology (in the case when the acquired Party is FibroGen) and AstraZeneca Technology (in the case when the acquired Party is
AstraZeneca). Any permitted assignment of the rights and obligations of a Party under this Agreement shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this
Section 15.5 shall be null, void and of no legal effect. 
 15.6     Performance by
Affiliates.  Subject to the limitations of Section 7.3, each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such
Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under
this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate. 

15.7     Further Actions.  Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

15.8     Compliance with Applicable Law.  Each Party shall comply with all applicable laws and
regulations in the course of performing its obligations or exercising its rights pursuant to this Agreement. 
 15.9
    Limitation of Liability.    NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR
ANY TORT CLAIMS ARISING HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 15.9 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY
PARTY UNDER SECTION 11.1, 11.2 OR 11.3, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12. 

15.10   Severability.  To the fullest extent permitted by applicable law, each Party hereby waives any
provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitrator or by any court of competent
jurisdiction from which no appeal can be or is taken (within the time period prescribed for appeal), the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall
make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one that achieves, as nearly as possible, the objectives contemplated by the Parties when entering this Agreement. 

15.11   No Waiver.  Any delay in enforcing a Party’s rights under this Agreement or any waiver as
to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular
matter for a particular period of time. 

  
 91. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 15.12   Independent Contractors.  It is expressly agreed
that FibroGen, on the one hand, and AstraZeneca, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither FibroGen, on the one hand,
nor AstraZeneca, on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action that will be binding on the other, without the prior written consent of the other Party to do so.
All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. 

15.13   English Language.  This Agreement shall be written and executed in and all other communications
under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 
 15.14   Counterparts.  This Agreement may be
executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

 
 [Signature Page Follows] 

  
 92. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the
Parties have executed this Agreement in duplicate originals by their duly authorized officers as of the Execution Date. 
  

									
	FIBROGEN, INC.	 		 	ASTRAZENECA AB
					
	By:	 	 Thomas B. Neff
	 		 	By:	 	 /s/ Elisabeth Björk

									
					
	Name:	 	 /s/ Thomas B. Neff
	 		 	Name:	 	 Elisabeth Björk

									
					
	Title:	 	 CEO
	 		 	Title:	 	 VP, GMed Head, CVMD

  

SIGNATURE PAGE TO AMENDED AND RESTATED 

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

93. 
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBITS 

Exhibit A – Territory – Excluded Countries 

Exhibit B – DFCI Agreement 

Exhibit C – Chemical Structure of FG-4592 

Exhibit D – Field Indications 

Exhibit E – Listed Patents 

Exhibit F – AstraZeneca’s Anti-Corruption Rules and Policies 

Exhibit G – Initial Members of the JSC 

Exhibit G(a) – JDC Responsibilities Delegated by the JSC to the Core JPT 

Exhibit G(b) – JCC Responsibilities Delegated by the JSC to the Core JPT 

Exhibit H – Initial Development Plan 

Exhibit I – U.S. Co-Commercialization Terms 

Exhibit J – Development Supply Terms 

Exhibit K – Commercial Supply Terms 

Exhibit L – Invoicing Requirements 

Exhibit M – Patents that May be Extended 

Exhibit N – Joint Press Release 

  
 94. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit A 

Excluded Countries 

 

	—	 	Albania 

	—	 	Andorra 

	—	 	Armenia 

	—	 	Austria 

	—	 	Azerbaijan 

	—	 	Belarus 

	—	 	Belgium 

	—	 	Bosnia & Herzegovina 

	—	 	Bulgaria 

	—	 	Croatia 

	—	 	Cyprus 

	—	 	Czech Republic 

	—	 	Denmark 

	—	 	Estonia 

	—	 	Finland 

	—	 	France 

	—	 	Georgia 

	—	 	Germany 

	—	 	Greece 

	—	 	Hungary 

	—	 	Iceland 

	—	 	Ireland 

	—	 	Italy 

	—	 	Japan 

	—	 	Kazakhstan 

	—	 	Kyrgyzstan 

	—	 	Latvia 

	—	 	Liechtenstein 

	—	 	Lithuania 

	—	 	Luxembourg 

	—	 	Macedonia 

	—	 	Malta 

	—	 	Moldova 

	—	 	Monaco 

	—	 	Netherlands 

	—	 	Norway 

	—	 	Poland 

	—	 	Portugal 

	—	 	Romania 

	—	 	Russia 

	—	 	San Marino 

	—	 	Serbia and Montenegro (Yugoslavia) 

	—	 	Slovakia 

	—	 	Slovenia 

	—	 	Spain 

	—	 	Sweden 

	—	 	Switzerland 

	—	 	Tajikistan 

	—	 	Turkey 

	—	 	Turkmenistan 

	—	 	Ukraine 

	—	 	United Kingdom 

	—	 	Uzbekistan 

	—	 	Vatican City 

	—	 	Bahrain 

	—	 	Egypt 

	—	 	Iran 

	—	 	Iraq 

	—	 	Israel 

	—	 	Jordan 

	—	 	Kuwait 

	—	 	Lebanon 

	—	 	Oman 

	—	 	Qatar 

	—	 	Saudi Arabia 

	—	 	Syria 

	—	 	United Arab Emirates 

	—	 	Yemen 

	—	 	South Africa 

 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit B 

DFCI Agreement 
 This
Exhibit B is filed as Exhibit 10.24 to the Registration Statement on Form S-1 (Commission 
 File No. 333-199069). 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit C 

Chemical Structure of FG-4592 

[*] 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit D 

Field Indications 
 [*] 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit E 

Listed Patents 
  

													
	 DOCKET  

NO.
  
	 	TERRITORY  	 	STATUS	 	APPLICATION  
NO.	 	
FILING
 DATE
	 	
PATENT
 NO.
	 	
GRANT
 DATE

[*] 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit F 

AstraZeneca’s Anti-Corruption Rules and Policies 

ASTRAZENECA GLOBAL POLICY 
 ETHICAL
INTERACTIONS 
 ANTI-BRIBERY & ANTI-CORRUPTION 

EXTERNAL INTERACTIONS 
 This Global Policy describes what is
required to meet our commitment to operate ethically and with integrity in our business and personal interactions and activities. 
 This Policy applies to all
Employees. 
 The Company is committed to acting responsibly and in compliance with the requirements of the UK Bribery Act, Foreign Corrupt Practices Act and other
relevant laws, regulations and adopted industry codes 
 CONTENTS 
 1.
SCOPE, APPLICATION & INTERPRETATION. 
 2. ANTI-BRIBERY & ANTI-CORRUPTION 

3. ITEMS OF VALUE & HOSPITALITY 
 4. PRICING, DISCOUNTS & REBATES

 5. CONTRIBUTIONS (DONATIONS, SPONSORSHIPS & PARTNERSHIPS) 
 6. POLITICAL
SUPPORT & POLITICAL ACTIVITIES 
 7. PAYMENTS TO PUBLIC OFFICIALS & PUBLIC SECTOR ORGANISATIONS 

8. AVOIDING CONFLICTS OF INTEREST 
 9. MEETINGS 

10. ENGAGING THIRD PARTIES & ENSURING COMPLIANCE 
 11. PROMOTIONAL &
NON-PROMOTIONAL ACTIVITIES & MATERIALS 
 12. PRE-AUTHORISATION ACTIVITIES & MATERIALS 

13. NON-INTERVENTIONAL STUDIES 6 
 14. INVESTIGATOR SPONSORED STUDIES 

GLOSSARY REFERENCES 
 1. SCOPE, APPLICATION & INTERPRETATION 

1.1 This Policy applies to all Employees and represents the minimum requirements that the Company has set for Interactions. 

An alphabetised Glossary containing definitions for all capitalised terms used in this Policy is included at the end of this Policy. 

For certain Interactions, You must refer to more than one Section of this Policy. The relevant Sections are cross-referenced as appropriate. 

Other Global Policies may also apply to Interactions. For example, the Global Data Privacy Policy applies to Interactions where there is a need to protect the
confidentiality of Patient information. 
 Global Standards may also apply to Interactions. The Global Standards give additional information about what is required to
ensure compliance for particular Interactions. The requirements of this Policy and of the supporting Global Standards must be considered as a whole to evaluate and support compliant Interactions. Global Standards are cross-referenced in each
relevant section of this Policy. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.2 This Policy expands on the Company’s Code of Conduct, and aligns with (and in some cases
exceeds) the requirements of applicable law and adopted industry codes. 
 You must follow the spirit of this Policy and not just its letter. The absence of a
specific requirement relating to a particular Interaction does not mean that the Interaction is necessarily permitted; You must avoid any Interaction that breaches the Company’s Code of Conduct or supporting Global Policies, Global
Standards or Relevant Procedures. 
 1.3 Employees must not attempt to avoid the requirements of this Policy by requesting, allowing or enabling Third Parties
(including relatives, friends or other associates) to be involved in the Interactions prohibited by this Policy on the Employee’s (or the Company’s) behalf. 

In some cases, local law, adopted industry codes particular to a jurisdiction, or rules particular to a Business Unit (e.g., Senior Executive Team (“SET”)
function), may apply to Interactions, and may be more restrictive than this Policy. Where that is the case, You must follow the more restrictive rules set out in Relevant Procedures. For example, local marketing organisations must establish Relevant
Procedures with respect to Interactions with Public Officials, where local law is more restrictive than this Policy. 
 To the extent appropriate, Business Units must
establish Relevant Procedures to assure compliance with the requirements of this Policy and supporting Global Standards, including requirements for sufficient monitoring and/or audit. Employees must use reasonable judgement to create business
records sufficient to demonstrate compliance with the requirements of this Policy, supporting Global Standards and these Relevant Procedures (e.g., business records of required approvals and required rationales for approvals). 

For purposes of this Policy, required approvals must be obtained in advance of any Interaction. 

Where the scope or interpretation of a particular provision of this Policy, supporting Global Standards or Relevant Procedures is unclear, You should seek guidance from
Your line manager or Your relevant Legal and/or Compliance partner. 
 2. ANTI-BRIBERY & ANTI-CORRUPTION 

2.1 AstraZeneca has zero tolerance for Bribery or corruption (i.e., improper influence). 

The Company will support Employees and Third Parties who refuse requests to Give or Receive Bribes on the Company’s behalf. Employees and Third Parties will not be
subject to retaliation or other adverse consequences for such refusal, even if the Company loses business as a result. 
 See Section 7 for prohibitions and
other requirements regarding Facilitation Payments, including payments Given under duress. 
 2.2 You may Give or Receive something of value in compliance with the
requirements and limits of this Policy, supporting Global Standards and Relevant Procedures. 
 For purposes of this Policy, supporting Global Standards and
Relevant Procedures, “something of value” means any financial or non-financial benefit of any kind, including, but not limited to: 
 a) the Giving and
Receiving of Items of Value and Hospitality (See Section 3 and the Global Standard on Items of Value and Hospitality); 
 b) prices, discounts and rebates
for Company Products Given to Third Parties (See Section 4); 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 c) Contributions Given to Third Parties (See Section 5 and the Global Standard on Contributions); 

d) Political Support Given to Public Officials or Political Organisations and participation in Political Activities (See Section 6); 

e) payments Given to Public Officials and Public Sector Organisations (See Section 7); 

f) appointments, paid and volunteer work outside of the Company or other interests associated with actual, apparent or potential Conflicts of Interest (See
Section 8); 
 g) the venue, conduct or other arrangements made for Meetings, as well as the selection and/or support of External Stakeholders to attend Meetings
or independent congresses, including professional education credits and capability-building sessions (See Section 9 and the Global Standard on Meetings); 

h) the engagement of Third Parties to provide Services, including compensation and expense reimbursement (See Section 10 and the Global Standard on Engaging
Third Parties); and 
 i) support for External Stakeholders for Non-Interventional Studies and Investigator Sponsored Studies (See Sections 13 and 14). 

2.3 You must not Give or Receive something of value that is intended or could be seen as improper influence. 

If you are in doubt about any Interaction, you must consult with your line manager or your relevant Legal and/or Compliance partner for appropriate guidance. 

2.4 All monetary payments by the Company to Third Parties that are permitted by this Policy must be made via an approved Company financial payment system by bank
transfer, cheque or company credit card, must not take the form of cash or cash equivalent (e.g., debit cards, gift cards, gift certificates), and must be accurately and appropriately recorded in the Company’s books and records. 

All such payments may also be made via a specifically authorised Third Party (unless otherwise noted in this Policy or supporting Global Standards), when genuine
business needs require, and Relevant Procedures (with adequate controls) support such an arrangement. In such cases, the Third Party must be contractually obligated to accurately document, track and report to the Company the amounts paid on its
behalf, as required by the Relevant Procedures. 
 This Section 2.4 prohibits cash and cash equivalent payments by Employees (or Third Parties acting on the
Company’s behalf), except as specifically permitted by Relevant Procedures established or approved by the Global Finance function. Also, see paragraph 1.18 of the Global Standard on Items of Value and Hospitality for requirements
regarding exceptional Cultural Courtesy Gifts in the form of cash or cash equivalent. 
 2.5 You must not Give a Bribe. 

Give means to directly or indirectly offer, promise or give, or to authorise such actions. 

You must not Give something of value to any Third Party or any fellow Employee that is intended or could be seen to: 

a) influence or reward an official action or decision (e.g., by a Public Official); 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 b) enable or induce a Third Party or fellow Employee to perform their function improperly, or make any decision or take any
action favourable to the interests of the Company (or You) on an improper basis, or reward them for doing so; 
 c) provide incentive or reward to a Third Party for
past, present or future willingness to prescribe, administer, recommend, purchase, pay for, reimburse, authorise, approve, supply or use any Company Product or service; or 

d) obtain or retain improper business, or secure any improper professional or personal advantage. 

2.6 You must not Receive a Bribe. 
 Receive means to directly or indirectly
solicit, agree to receive or accept, or to authorise such actions. You must not Receive something of value from any Third Party or any fellow Employee that is intended or could be seen to: 

a) compromise Your independence or judgement; 
 b) enable or induce You to perform
Your function improperly, or make any decision or take any action favourable to the interests of the Third Party (or fellow Employee) on an improper basis, or reward You for doing so; or 

c) obtain or retain improper business, or secure any improper professional or personal advantage. 

3. ITEMS OF VALUE & HOSPITALITY 
 3.1 You must not Give or
Receive Items of Value or Hospitality that are intended or could be seen as improper influence. 
 To the extent appropriate, Business Units must establish
Relevant Procedures on actual or perceived value and frequency when Giving and Receiving Items of Value and Hospitality. These Relevant Procedures must include specific limits on value (modest) and frequency (occasional) and definitions for
“modest” and “occasional,” to guide Employees on appropriate value and frequency levels that would not create actual or perceived improper influence, taking into account local custom and practice (See paragraph 2.1 of the
Global Standard on Meetings). 
 To the extent appropriate, Business Units must establish Relevant Procedures to enable the Company to satisfy transparency
obligations, with respect to the Giving of Items of Value and Hospitality to External Stakeholders. 
 Items of Value and Hospitality that exceed Company limits,
either separately or in total, to or from the same individual or organisation, are prohibited. 
 Any Giving or Receiving of Items of Value or Hospitality that is
based upon a genuine personal relationship independent of the Company and that is personally funded by the individuals involved (without Company reimbursement) is permissible and is not restricted by this Policy, if it is not intended and
could not be seen as improper influence. 
 3.2 See Section 2 of this Policy and the Global Standard on Items of Value and Hospitality
for further requirements on Items of Value and Hospitality. 
 4. PRICING, DISCOUNTS & REBATES 

4.1 To the extent appropriate, Business Units must have an approved pricing model in place, based on objective criteria, to govern the pricing, rebates and discounts
(and other commercial advantages or favourable terms) that can be Given to Third Parties. 
 The pricing model must be reviewed on a regular basis by the head of
the relevant Business Unit or designee to ensure appropriateness and transparency. 

  
 4 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 These Business Units must document the purpose of any prices, rebates or discounts (or other commercial advantages or
favourable terms) Given to Third Parties that fall outside the approved pricing model, and this documented purpose must be approved by the head of the relevant Business Unit or designee to ensure appropriateness and transparency. 

4.2 See Section 2 of this Policy for further requirements on prices, discounts and rebates. 

5. CONTRIBUTIONS (DONATIONS, SPONSORSHIPS & PARTNERSHIPS) 
 5.1
The Company is committed to making a positive impact on Our local communities and supporting the work of others in the healthcare and scientific arenas. 

Contributions may be classified as Donations, Sponsorships or Partnerships, and may take the form of financial or non-financial support (e.g., funds or in-kind
assistance, such as resources, facilities or employee time). 
 Contributions may generally only be Given for legitimate scientific, educational and/or charitable
purposes to support the following: health or healthcare, medical or scientific education, advances in medical or scientific research and disaster relief. Contributions may also be Given for other purposes on an exceptional basis, only with senior
management approval, as set out in Relevant Procedures. 
 For the avoidance of doubt, this Section does not prohibit individual Employees from supporting charities
and other organisations in a purely personal capacity and without any involvement of the Company, if the support meets the requirements of Section 8 of this Policy. This Section 5 also does not prohibit Employees from organising charitable
efforts on the Company premises (such as a local food drive or book drive), with line manager approval, where Employees use only their personal funds and resources to participate, if the support meets the requirements of Section 8 of this
Policy. 
 Generally, Contributions to support a Meeting or other event must only be Given where the venue and location of the supported event are appropriate and
conducive to the intended purpose, and where any Meals or other Hospitality provided by the Company or by the recipient of the Contribution are modest and incidental to the purpose of the event. See the Global Standard on Contributions, the
Global Standard on Items of Value and Hospitality and the Global Standard on Meetings for specific requirements and exceptions. 
 Certain charitable
Donations, Sponsorships and Partnerships that meet the relevant criteria described in the Global Standard on Contributions and the Global Procedure and Guidance Community Investment specifically qualify as Community Investment
Contributions. 
 5.2 Contributions may only be given to reputable, recognised and independent institutions or other legitimate, established organisations, and
only for legitimate purposes. 
 The relevant Business Unit managing the Contribution must conduct appropriate due diligence on the proposed recipient of any
Contribution to establish that the proposed recipient satisfies the requirements of this Section 5.2 and to establish that Contribution will be well used. In addition, the relevant Business Unit may agree upfront with the recipient organisation
to conduct appropriate post-funding review (e.g., review of a summary of the completed projects or other results of the 

  
 5 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 In addition to the requirements of Section 2, a Contribution must not be Given for any other improper purpose or use,
including, but not limited to, the following: 
 a) to help offset an External Stakeholder’s cost of purchasing or reimbursing Company Products or to influence
any other decisions about listing, purchasing or reimbursing of Company Products; 
 b) to organisations or activities that are known to discriminate on any unlawful
basis; 
 c) to support programming or editorial content containing gratuitous violence or sexually explicit material or any activity that does not reflect the values
and/or mission of the Company, or could cause embarrassment to the Company; or d) to support any activities prohibited by Relevant Procedures. 
 Contributions that
might be considered as excessive or inappropriate in scale and/or affiliation are not permitted. 
 Contributions must not be Given to avoid the restrictions on
Giving Items of Value and Hospitality to Third Parties (See Section 3 and the Global Standard on Items of Value and Hospitality). 
 5.3 Contributions
must not be Given to any organisation for the personal benefit of any individual or Healthcare Professional (“HCP”) practice (i.e., a group of HCPs sharing premises or other resources) selected by the Company, or to disguise or conceal any
such personal benefit (except as permitted in paragraph 4.5 of the Global Standard on Contributions regarding Fellowships and Preceptorships for scientists to support research activities). 

Contributions must not be Given by the Company directly to an individual or HCP practice. 

For the avoidance of doubt, direct Company support for individual External Stakeholders to attend Meetings or independent congresses is not considered to be a
Contribution for purposes of this Policy and is permissible only in limited circumstances (See section 3 of the Global Standard on Meetings). 
 For the
avoidance of doubt, awards to individuals are not considered Contributions. See the Global Standard on Items of Value and Hospitality for requirements regarding awards and awards ceremonies. 

An individual who formally represents an organisation may request a Contribution from the Company on behalf of the organisation, and such request must be considered and
processed as required by Relevant Procedures. Contributions must not be Given to an organisation at the request of any other individual (e.g., to a Public Official’s preferred charity), except for Sympathy Gifts Given to a designated non-profit
organisation as a memorial in the event of a death, or Contributions Given at the request of an Employee as part of a Company matching fund programme. 

Contributions must not be Given to financially benefit HCPs or HCP practices by replacing any assets or funding any activities that they would be expected or required
to provide themselves to fulfil obligations they have under local law, contract or customary business practice. For example, Contributions must not be Given to improve business efficiencies or administrative processes of an HCP or HCP practice, such
as support for billing or taxes. For the avoidance of doubt, Contributions to support HCP education are permissible, in the interest of improving Patient care and/or Patient health. 

5.4 See Section 2 of this Policy and the Global Standard on Contributions for further requirements on Contributions. 

Contributions must not be Given by Third Parties on behalf of the Company, except for Company Product Donations (See the Global Procedure and Guidance Community
Investment and the Global Guidance for Product Donations). 
 For the avoidance of doubt, Contributions do not include Political Support or participation
in Political 

  
 6 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6. POLITICAL SUPPORT & POLITICAL ACTIVITIES 

6.1 Employees must not Give Political Support on behalf of the Company unless specifically authorised to do so by the Government Affairs function or the Reviewer.

 Third Parties must not Give Political Support on behalf of the Company under any circumstance. The Company will not reimburse in any way or form any Third
Party or non-authorised Employee for Giving Political Support. 
 Political Support may only be Given where it is expressly permitted by local law and where
acceptable as part of local custom and practice. 
 All Political Support must be Given directly to the recipient organisation or individual. The name of the
organisation or individual, purpose, nature and value of the Political Support and the date of the Political Support must be properly documented and recorded in the Company’s books and records, to enable public disclosure. 

The Government Affairs function will establish or approve Applicable Internal Review Procedures for the Giving of Political Support. 

6.2 Employees and Third Parties must not participate in Political Activities on behalf of the Company unless specifically authorised to do so by the Government
Affairs function or the Reviewer. 
 The Government Affairs function will establish or approve Applicable Internal Review Procedures for participation in
Political Activities. 
 6.3 The Company recognises the rights of Employees to use their own funds, time and other personal resources to Give Political Support or
to participate in Political Activities. 
 You must ensure that you do not act or appear to act as a representative of the Company when participating in Political
Activities or Giving Political Support in a personal capacity. You must make it clear that your views and actions are Your own, and that any Political Support You provide is Given on a personal basis, using Your own funds, time or other personal
resources. 
 6.4 See Section 2 of this Policy for further requirements on Political Support and Political Activities. 

7. PAYMENTS TO PUBLIC OFFICIALS & PUBLIC SECTOR ORGANISATIONS 

7.1 The Company does not permit Employees or Third Parties providing Services to Give Facilitation Payments, either directly or indirectly, to Public Officials
(including HCPs and other individuals employed by Public Sector Organisations), regardless of whether such payments are nominal in amount. 
 Employees and Third
Parties must not attempt to conceal or disguise Facilitation Payments to avoid the requirements of this Section. 
 The nature of the Company’s business involves
legitimate Interactions with a range of Public Officials. Examples include Public Officials responsible for issuing Company Product licences, making Company Product listing decisions, determining Company Product pricing and payment, providing
permits and regulatory Authorisations and conducting facility inspections. 
 You may Give payments to individual Public Officials where they are engaged to provide
legitimate Services (See Section 10). You must not Give any other payments to individual Public Officials unless such payments are required or otherwise expressly permitted by local law and not otherwise prohibited by this Policy. 

  
 7 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 You may Give legitimate and lawful payments to Public Sector Organisations with respect to taxes, permits, licences,
inspections and other fees required or otherwise expressly permitted by local law and not otherwise prohibited by this Policy. Official government receipts must be obtained to support all such payments. 

7.2 The Company recognises that, in exceptional circumstances, payments may be demanded under duress from Employees or Third Parties providing Services. It is
permissible for Employees and Third Parties to Give payments demanded under duress, where there is reasonable fear for personal safety. 
 Duress describes
situations of actual or threatened violence or imprisonment to force a person to act against their will. The Company is committed to ensuring the safety of its Employees and Third Parties and does not expect them to compromise their safety in such
situations. 
 Employees and Third Parties must promptly report in writing to their line manager all incidents where: 

a) Facilitation Payments are requested but not paid; or 
 b) payments are demanded
under duress, whether paid or not. 
 The line manager must then promptly inform the relevant Legal partner of such incidents in writing and ensure that any payments
actually made are properly documented and recorded in the Company’s books and records. The line manager must also consult with the relevant Legal partner regarding the reporting of such incidents to the relevant authorities and the steps to be
taken to prevent recurrence. 
 7.3 See Section 2 of this Policy for further requirements on payments to Public Officials and Public Sector Organisations.

 8. AVOIDING CONFLICTS OF INTEREST 
 8.1 You must ensure that Your
interests, activities and associations outside of the Company do not result in actual, apparent or potential Conflicts of Interest with Your professional duties and decisions as an Employee, by directly or indirectly compromising Your independence
or professional judgement, or creating an appearance of doing so. 
 You must not allow, or appear to allow, a personal relationship to influence Your
decision-making or judgement. You must ensure that the Company’s interests are paramount when business opportunities are assessed and commercial decisions are taken. 

You may make personal financial investments, pursue other business interests and maintain social relationships with people You meet through Your Employment, if all of
the relevant requirements of this Section of the Policy are met. You must ensure that these Interactions do not result in actual, apparent or potential Conflicts of Interest with the Company’s business activities. 

You must not use Company resources or your position as an Employee for Your own personal benefit or for the benefit of Your relatives, friends or other associates. 

8.2 You must inform Your line manager in writing of any actual, apparent or potential Conflicts of Interest at the time they become known. Engagement Owners must
also inform their line managers in writing of any actual, apparent or potential Conflicts of Interest of a Third Party providing Services, at the time they become known. 

Line managers must provide written direction on how to resolve or avoid the Conflict of Interest after obtaining any necessary advice from the relevant Legal and/or
Compliance partner. 

  
 8 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 If You, a relative or close friend has a financial or management interest in a Third Party (other than a nominal
shareholding interest through a publicly-available investment), You must disclose the situation as a potential Conflict of Interest to Your line manager. You must not participate in any purchasing or other Company decisions related to that Third
Party. 
 8.3 You must not do any volunteer or paid work outside of the Company related to Your Company work responsibilities or work product (e.g., speaking
engagement, authoring or publishing) unless You obtain written approval from Your line manager, on the basis that such work is unlikely to create an actual, apparent or potential Conflict of Interest and on the basis that any payment is not intended
and could not be seen as improper influence. 
 For all such work, You may Receive necessary and modest travel, accommodation, Meals and other directly related,
incidental expenses, with written line manager approval, on the basis that such expenses are not intended and could not be seen as improper influence. 
 8.4 You
must not accept any appointment to the Board of Directors of an external organisation in the healthcare or scientific arena, unless You obtain written approval from Your line manager. 

Approval should not normally be provided for directorships of Third Parties who are conducting, or may conduct, business directly within Your scope of responsibility or
where You will gain a financial benefit that could be open to question or misinterpretation if publicly disclosed. 
 8.5 You must not use non-public Company
information for personal gain. 
 You must not pass such information to anyone else (either inside or outside the Company), who does not have a legitimate need for
the information. 
 8.6 See Section 2 of this Policy for further requirements on Conflicts of Interest. 

9. MEETINGS 
 9.1 Organising or supporting Meetings with External
Stakeholders is part of Our business. Where doing so, You must follow the requirements listed in the Global Standard on Meetings. 
 The location, venue, conduct
and other arrangements made for Meetings must be modest, conducive and appropriate to the purpose of the Meeting. 
 9.2 Meetings must always have a scientific,
medical education and/or other legitimate business purpose, which must be clearly stated. 
 The Company may Give a Contribution (See Section 5) to a Meeting
organiser to support the conduct of a Meeting (e.g., a Sponsorship). Any such Contribution must meet the relevant requirements of both the Global Standard on Contributions and the Global Standard on Meetings, with respect to the
substance of the Meeting as well as the conduct and arrangements made for the Meeting. 
 9.3 See Section 2 of the Policy and the Global Standard on
Meetings for further requirements on Meetings. 
 The Global Standard on Meetings also includes specific requirements on Company support for
External Stakeholders to attend independent congresses. 

  
 9 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 10. ENGAGING THIRD PARTIES & ENSURING COMPLIANCE 

10.1 The Company is committed to engaging only those Third Parties who embrace standards of ethical behavior that are consistent with Our own. 

Engagement Owners are accountable for ensuring that the Third Party’s reputation and conduct are consistent with the Company’s ethical standards (See
Section 10.5). 
 For the avoidance of doubt, engagements do not include informal, routine business Interactions between Employees and Third Parties, where no
Services are provided and no payment is Given (e.g., informal discussions at professional Meetings or independent congresses for scientific exchange, or routine phone calls in the normal course of business). 

10.2 Engagement Owners must engage a Third Party only where there is a genuine business need for Third Party Services and must only engage the necessary and
appropriate Third Parties to provide those Services. 
 Engagement Owners must ensure that the selected Third Party has the relevant qualifications, expertise,
reputation, knowledge, experience and ability to fulfill the genuine business need, and is the most appropriate choice to provide the Services. 
 External
Stakeholders may be engaged by the Company (either directly or through a specifically authorised Third Party on the Company’s behalf) to provide Services. Such Services include, but are not limited to: providing input and information as an
Advisor or consultant, speaking at Meetings (e.g., a Promotional Speaker), acting as a clinical investigator or a study site, or educating or otherwise presenting to Representatives at Representative training or business cycle sessions. Patients and
Other Third Parties may also be engaged by the Company to provide Services. 
 Each engagement with an External Stakeholder or Patient for Services must be documented
in a signed contract. If the External Stakeholder or Patient is not accepting compensation, or payment or reimbursement of expenses, the requirement for a signed contract may be waived with documented line manager approval. 

Each engagement with Other Third Parties for Services must be documented in the format required for the particular Services to be provided, such as a contract,
Terms & Conditions, a Purchase Order or other required documentation of offer and acceptance of Services. 
 Third Parties must not provide any Service on
behalf of the Company, in connection with the execution of an engagement or otherwise, unless the Service has been specifically authorised in the signed contract (or other required documentation of the engagement) between the Company and the Third
Party, or has otherwise received appropriate documented approval. 
 You must not Give any Payments for Voluntary or Incidental Activities to any Third Party. 

10.3 Our Interactions and engagements with External Stakeholders and Patients must at all times be professional exchanges, designed to enhance the practice of
medicine, to benefit Patients, or to fulfill a genuine business need. 
 In no circumstances may the engagement of an External Stakeholder or Patient be used as a
means to gain access or to disguise Promotional Activities, or create an appearance of doing so. 
 10.4 To the extent appropriate, Business Units must establish
adequate Relevant Procedures to mitigate the risk of actual or apparent improper influence over individual External Stakeholders engaged to provide Services, and for monitoring compliance. 

To the extent appropriate, Business Units must establish Relevant Procedures that include Fair Market Value guidelines, as well as limits on aggregate compensation
provided to individual External Stakeholders and limits on frequency of engagement of individual External Stakeholders. The scope of such guidelines and limits ultimately established will vary, based upon locality and/or function. In developing Fair
Market Value guidelines, these Business Units must consider local established compensation levels, varying levels of expertise and/or prominence of Third Parties, varying types and durations of Services to be provided, and the spirit and principles
of this Policy. 

  
 10 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Third Parties must be paid compensation consistent with and no greater than Fair Market Value, taking into account
individual qualifications, experience, ability and reputation, and only for the Services actually provided, consistent with the terms of the engagement. 
 To the
extent appropriate, Business Units must establish Relevant Procedures to enable the Company to satisfy transparency obligations, with respect to payments made to External Stakeholders. 

10.5 Prior to the selection and engagement of a Third Party, Engagement Owners must conduct appropriate and proportionate risk assessments, as well as associated,
due diligence procedures (if necessary), according to Relevant Procedures. Engagement Owners must take these steps to ensure that the Third Party’s reputation and conduct relating to the execution of the engagement are consistent with the
Company’s ethical standards, with respect to all relevant areas of risk. 
 To the extent appropriate, Business Units must establish Relevant Procedures to
guide Engagement Owners on how to assess, develop, communicate, implement and enforce required compliance expectations for Third Parties. Required compliance expectations will vary, based upon the nature of the Third Party, the Services to be
provided and the nature of the associated risks. Based upon the risk assessment and outcomes for a particular Third Party, Engagement Owners may be required to implement one or more of the following actions with respect to that Third Party: 

a) improvement plans or action plans; 
 b) monitoring or auditing requirements; 

c) contractual obligations, including written assurances or commitments by the Third Party; 

d) provision of Global Policies, Global Standards, Relevant Procedures or other reference materials, and/or associated training; 

e) prior review of the engagement or aspects of the engagement or Services from the relevant Legal and/or Compliance partner; and/or 

f) other actions to mitigate identified areas of risk, such as contractual risk mitigation clauses. 

At a minimum, Engagement Owners must not engage a Third Party where it is known, or where there is a reason to believe, that the Third Party has Given or Received
Bribes, unless the Engagement Owner has documented his/her satisfaction with all of the following, in consultation with the relevant Legal and/or Compliance partner: 

a) the actions and improvements undertaken by the Third Party to remediate the concerns and/or behaviour; 

b) the current level of compliance by the Third Party; and 
 c) evidence of the
Third Party’s ability to provide strong governance and monitoring and to prevent future occurrences of such concerns and/or behaviour. 
 Engagement Owners, in
consultation with an appropriately senior level of management, must periodically reassess existing Third Party relationships, following the required timeframes outlined in the Relevant Procedures, and taking into account any unanticipated changes in
the conduct, reputation or risks related to the particular Third Party. 

  
 11 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 10.6 See Section 2 of this Policy for further requirements on Engaging Third Parties. Engagement Owners must also
refer to the Global Standard on Engaging Third Parties for further requirements, prior to entering into any engagement with a Third Party. 

11. PROMOTIONAL & NON-PROMOTIONAL ACTIVITIES & MATERIALS 

11.1 A key part of Our business is to provide information about Company Products and, where and when appropriate, to Promote their use. Promotional and
Non-Promotional Activities and Materials must always be accurate, fair and balanced and not misleading in their content. 
 The Company has a duty to support the
safe and effective use of Company Products. While the Company cannot provide medical advice to External Stakeholders or Patients, the Company may engage in Promotional and Non-Promotional Activities where this is appropriate and permitted by local
law. For example, Promotional and Non-Promotional Activities directed to Patients (i.e., “direct to consumer” activities) may only be undertaken where this is permitted by local law. 

Our activities must never undermine the relationship between HCPs and their Patients. All Promotional and Non-Promotional Activities and Materials directed to HCPs or
Patients must therefore support HCPPatient Interactions and must allow the therapeutic value of Company Products to be assessed by HCPs in the interest of Patient care. 

Promotional and Non-Promotional Materials about Company Products directed to Patients must be understandable, taking into account varying levels of education between
and within populations. These Materials must be educational, scientific and balanced, and should encourage the Patient to seek further information from the appropriate HCP. 

The Company may display Promotional or Non-Promotional exhibits, either in conjunction with a Meeting or as a stand-alone activity, according to the requirements
included in Relevant Procedures. See the Global Standard on Meetings for further requirements on exhibits (with or without a Meeting). 
 11.2 The Company
must only Promote Company Products once the time is right to do so (which will never be before the Company Product or Use has received the necessary Authorisation), and only consistent with the approved labeling. 

Promotional Activities and Promotional Materials must meet all of the following requirements: 

a) They must provide a fair balance between a Company Product’s benefits and its risks or limitations. They must not exaggerate the benefits or downplay the risks
or limitations; 
 b) They must not mislead by distortion, exaggeration, undue emphasis, omission or in any other way, and must not involve false or unapproved
statements about other companies’ products. Company Products must only be Promoted on their own proven merits; and 
 c) They must be capable of substantiation
by reference to the approved labeling or scientific evidence consistent with the approved labeling, and must not involve discussions of Unauthorised Company Products or Uses. 

Representatives and other Employees in customer-facing roles (e.g., public relations, telemarketing, Marketing, Medical) must be trained as appropriate to their role
and must do all of the following in an accurate, responsible manner: 
 a) They must possess sufficient Company Product and disease area knowledge to present
information to External Stakeholders or Patients, as appropriate to their role; and 
 b) They must be able to recognise inquiries regarding Unauthorised Company
Products or Uses and refer these inquiries to Scientifically Trained Personnel. 

  
 12 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 All training and educational materials must be approved through the Applicable Internal Review Procedures. 

Representatives and other Employees in customer-facing roles must have available a copy of the current, approved labeling for each Company Product or Use discussion
they initiate with External Stakeholders. 
 Any revisions to the approved labeling must be communicated to Representatives and other relevant customer-facing
Employees as soon as reasonably possible. 
 Promotional Activities that are directed to External Stakeholders must be confined to those individuals who are
recognised practitioners in the area of medicine concerning Authorised Company Products or Uses. 
 Promotional Activities and Promotional Materials must not be
directed to External Stakeholders who have requested that they not be sent such information. 
 11.3 Non-Promotional Activities and Materials (including those
regarding disease awareness programs) must not be used to Promote Company Products. Non-Promotional Activities and Materials must be presented in an objective, balanced manner, and must be scientific in tone, language, appearance and intent.

 Where local law allows the Company to respond to Company Product-related questions from Patients, any such response may only be made by Scientifically Trained
Personnel or other specifically authorised Employee or Third Party, according to Relevant Procedures. Patients communicating with the Company must not be given medical advice, but must instead be referred to their HCP. 

Specifically authorised Employees are permitted to proactively issue press releases or other Non-Promotional Materials, such as those relating to financial or investor
information. 
 Scientifically Trained Personnel are permitted to proactively present scientific data or findings regarding Authorised or Unauthorised Company
Products or Uses with a view to generating further scientific insight, supporting the medical community in learning about scientific/medical progress or sharing information on current medical practice, such as at scientific congresses or similar
events. 
 All inquiries concerning Unauthorised Company Products or Uses (whether from External Stakeholders or Patients) must be referred to Scientifically Trained
Personnel. All responses to such inquiries, either oral or written, must then come directly and only from such Scientifically Trained Personnel, and must meet all of the following requirements: 

a) Information must only be provided in response to unsolicited inquiries; 
 b)
Information must be accompanied by the approved labeling, as applicable; 
 c) All responses must be limited to the scope of the inquiry and must provide data which
are appropriate to the source of the inquiry; and 
 d) All responses must contain (as relevant) a statement that the information requested involves an Unauthorised
Company Product or Use and that the Company does not recommend Unauthorised Uses of the Company Product. 

  
 13 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 11.4 Promotional Materials and Non-Promotional Materials must be approved through the Applicable Internal Review
Procedures. Any modification to approved Promotional or Non-Promotional Materials must also be approved through the Applicable Internal Review Procedures. 
 You
must not create, use or provide “home-made” or other unapproved Promotional or Non-Promotional Materials on any topic. You must not alter any approved Promotional or Non-Promotional Materials in any way, unless such creation or alteration
is for the express purpose of submitting these Materials for review and approval. 
 Promotional and Non-Promotional Materials must be assigned an expiration date
upon approval, must be monitored for expiration date and must not be used after the expiration date specified in the original approval, unless they are formally re-approved through the Applicable Internal Review Procedures. 

Promotional and Non-Promotional Materials must be accompanied by the approved labeling where applicable, as required by Relevant Procedures. 

12. PRE-AUTHORISATION ACTIVITIES & MATERIALS 
 12.1 It is
permissible to engage in Pre-Authorisation Activities (i.e., Profiling, Market Access and Pre-Authorisation Training activities), and to use materials supporting such activities, to prepare for a successful commercial launch of a Company Product or
Use. Pre-Authorisation Activities must not be used to disguise Pre-Authorisation Company Product Promotion, or create an appearance of doing so. 
 Materials used
for Pre-Authorisation Activities must be approved through the Applicable Internal Review Procedures. 
 12.2 Relevant Employees (e.g., Employees in the Marketing,
Medical or Sales functions) and specifically authorised Third Parties may Profile customers prior to Authorisation of a new Company Product or Use, to assist in segmentation and targeting activities. 

Profiling Activities may only be conducted if all of the following requirements are met: 

a) Employees engaging in Profiling must use materials (e.g., scripts) that have been approved through the Applicable Internal Review Procedures; 

b) These materials must be structured to allow for a brief conversation to collect broad information about an External Stakeholder’s involvement in a disease area,
such as treatments and classes used (e.g., “What classes do you use to treat this disease state?”), as well as their needs and the needs of their Patients; 

c) These materials must contain clear instructions on proper execution. These materials must contain a clear, prominent prohibition against engaging in Promotional
Activities about the new Company Product or Use during a Profiling conversation; 
 d) These materials must not contain targeted questions that are specific or unique
to a Company Product or Use; 
 e) If asked by the External Stakeholder about the purpose of the Employee’s questions, Employees may objectively state that the
Company has submitted a Company Product or Use for regulatory Authorisation. Employees must not proactively discuss the Company Product or Use in any further detail; and 

f) In the event that the External Stakeholder asks for more details about the Company Product or Use during a Profiling discussion, Employees (other than those in the
Medical function) may provide appropriate contact information for the External Stakeholder to submit his/her own request for such information (i.e., a “professional information request”), but such Employees must not directly respond to the
request or submit the request on behalf of the External Stakeholder. Employees in the Medical function may directly respond to the request and may submit a professional information request on behalf of the External Stakeholder. 

  
 14 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 During, and in support of, internal Company segmentation and targeting activities, relevant Employees may share existing
knowledge and review and share prescribing data and other Company-purchased or publicly available information. 
 For the avoidance of doubt, Profiling activities are
also permitted after Authorisation of a new Company Product or Use. 
 12.3 Relevant Employees other than Representatives or their first line managers (e.g.,
Employees in the Market Access or Medical functions) and specifically authorised Third Parties may perform Market Access activities prior to Authorisation of a new Company Product or Use, by providing Company Product or relevant disease area
information to Healthcare Organisations (“HCOs”) (i.e., payers) or Public Officials to support regulatory Authorisation, pricing or reimbursement discussions. 

For the avoidance of doubt, Market Access activities are also permitted after Authorisation of a new Company Product or Use. 

12.4 Pre-Authorisation Training on Unauthorised Company Products or Uses may be initiated as necessary to allow for sufficient time to study and understand the new
information presented regarding the Company Product or Use, disease area, disease management, External Stakeholder and Patient needs and/or the current market, including the current state of medical practice, competitors and existing therapies, and
treatment protocols and Guidelines. 
 In making the determination of the timing and sequencing of Pre-Authorisation Training for a particular new Company Product
or Use (as a guideline, no longer than 60 days before the expected Authorisation date), the Reviewer must seek input from Employees in the Medical, Training, Commercial, Compliance and/or Legal functions (“contributing functions”), as
applicable, and must take into account all of the following considerations: 
 a) whether the training will involve a new or familiar disease area; 

b) whether the training will involve an Unauthorised Company Product or an Unauthorised Use of an Authorised Company Product; 

c) the likelihood of receiving significant changes and comments to the proposed labeling submitted to the regulatory agency responsible for Authorisation; 

d) the risks of pre-Authorisation Promotion arising from providing training on Unauthorised Company Products or Uses and/or Promotional messages; and 

e) other factors deemed relevant to the particular proposed training by the Reviewer and/or contributing functions, who are evaluating the training need and the
associated risks. 
 All Pre-Authorisation Training materials must be marked with a clear, prominent, appropriate disclaimer stating that the material is strictly for
internal purposes only (e.g., “For Internal Use Only”). These materials may include information on Unauthorised Company Products or Uses or relevant disease areas, and may include relevant reprints. These materials, or the information they
contain, must not be shown, discussed, or distributed outside the Company, except where an appropriate Third Party must also be trained (e.g., a contract sales force or sales force of a co-promotional partner). 

After the relevant Authorisation has been obtained, information included in Pre-Authorisation Training materials that is appropriate for discussion with External
Stakeholders or Patients may be included in Promotional and/or Non-Promotional Materials specifically designed and approved for those purposes. 

  
 15 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 13. NON-INTERVENTIONAL STUDIES 

13.1 Non-Interventional Studies (“NISs”) must address a scientifically and medically valid question to which the Company needs the answer. 

These may include: the effectiveness and/or safety of a Company Product, medical practice and drug utilisation characterisation, disease epidemiology and clinical
epidemiology, burden of disease (e.g., costs and quality of life) or other Patient-reported outcomes, and compliance/adherence to a therapeutic regimen. 
 13.2
The Company must not be involved in the decision to place a particular Patient on a specific Company Product. That decision is made solely by the Patient’s HCP. 

An NIS must not be used to induce the use or prescription of a Company Product or to train HCPs on the use of a particular therapy. 

Patients must not be given a Company Product or switched to a Company Product for the purpose of taking part in the study. 

13.3 NISs must be observational in nature and the collected data must undergo a formal analysis by the Company or by a Third Party on the Company’s behalf.

 Additional diagnostic or monitoring procedures must not be applied to the Patients, and epidemiological methods must be used for the analysis of collected
data. 
 13.4 See Section 2 of this Policy for further requirements on NISs. Employees must also refer to the Relevant Procedures (i.e., International
Procedures) for further requirements. 
 All NISs must be registered and their results posted according to the requirements of the Relevant Procedures. 

The decision to conduct an NIS and the selection, engagement and payment of NIS investigators must meet all of the relevant requirements of Section 10 of
this Policy and the Global Standard on Engaging Third Parties. 
 Support for NISs may be Given by specifically authorised Third Parties on behalf of the
Company according to the Relevant Procedures. 
 14. INVESTIGATOR SPONSORED STUDIES 

14.1 The Company recognises the importance of Investigator Sponsored Studies (“ISSs”) in expanding scientific knowledge related to potential Uses of
Company Products. 
 An ISS may be conducted with Authorised or Unauthorised Company Products or Uses. 

All ISSs supported by the Company must be consistent with the research strategy for the relevant Company Product. 

  
 16 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 14.2 The Company may provide support for an ISS, but must not be considered to be the sponsor or to have any partial
sponsorship role in the study in accordance with local law. 
 The decision to provide support for an ISS must be based on whether the study expands scientific
knowledge related to potential Uses of Company Products and/or associated disease area(s) through a properly conducted independent clinical study that will result in the publication of meaningful new data. 

14.3 See Section 2 of this Policy for further requirements on ISSs. Employees must also refer to the Relevant Procedures (i.e., International Procedures) for
further requirements. 
 A contract approved through the Applicable Internal Review Procedures must be negotiated and signed by authorised representatives of the
Company and the sponsor and, as applicable, the investigator, prior to study initiation. 
 The level of financial support that may be provided will vary among
countries. It must always be consistent with Fair Market Value for the activities to be conducted as part of the clinical trial, and payments must be milestone-driven. 

The Company must not provide Company Product Samples for use in ISSs. 
 Support for
ISSs may be Given by specifically authorised Third Parties on behalf of the Company according to the Relevant Procedures. 
 GLOSSARY 

Advisory Boards refers to internal Meetings organised by the Company where the Company engages External Stakeholders (i.e., “Advisors”) to
provide the Company with independent advice and input within their area of expertise. 
 Advisors refers to the definition provided within the definition of
Advisory Boards. 
 Applicable Internal Review Procedures refers to the review and approval requirements for Interactions and supporting materials, as set out
in Relevant Procedures. These requirements include, but are not limited to, review and approval by Nominated Signatories, Scientifically Trained Personnel, the Legal Department, other specialist functions (e.g., Procurement) or line managers, as
appropriate (i.e., “Reviewers”). Reviewers must take into account the substance, as well as the intended purpose and audience, when approving Interactions or supporting materials, and approval must be obtained in advance of any
Interaction or use of supporting materials. 
 Authorisation or Authorised refers to approval of a Company Product or Use by the relevant local
regulatory agency, to permit entry into the local market or to permit inclusion into the local approved labeling. 
 Bribe or Bribery refers to Giving
or Receiving of something of value that is intended or could be seen as an inducement or reward for improper behaviour (i.e., behaviour that is dishonest or illegal or a breach of duty of impartiality, trust or good faith), to influence any official
act or decision, or to obtain or retain business, favourable treatment or other advantage or benefit. Giving or Receiving of Bribes is a wellrecognised form of corruption (collectively referred to as “improper influence” through this
Policy). 
 Business Unit refers to a distinct section of the Company, such as a consolidated legal entity, a local marketing organisation, a Senior Executive
Team (“SET”) function, a department or operating entity within a SET function, or, in some cases, a cross-functional unit comprising Employees with common responsibilities. 

Community Investment Contributions refers to certain charitable Donations, Sponsorships or Partnerships Given by the Company to non-profit organisations that
meet the relevant criteria described in the Global Standard on Contributions and the Global Procedure and Guidance Community Investment. 

  
 17 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Company or Our refers to AstraZeneca PLC and its consolidated legal entities worldwide, including MedImmune.

 Company Product refers to any pharmaceutical or biological product or medical device that is developed and/or marketed by the Company, including
investigational products/devices and co-promoted products/devices. For purposes of this Policy, references to Company Products include both Authorised and Unauthorised Company Products, unless specifically noted. 

Conflicts of Interest refers to situations where personal, financial or other interests, activities or associations outside of the Company may influence or
compromise, or could be seen to influence or compromise, the professional duties and decisions of an Employee or Third Party providing Services. 
 Contributions
refers to financial or non-financial support (e.g., funds or in-kind assistance, such as resources, facilities or Employee time) Given by the Company to a Third Party. Contributions may be classified as either Donations, Sponsorships or
Partnerships. 
 Cultural Courtesy Gift refers to a personal Gift traditionally given to acknowledge a significant national, cultural or religious holiday or
event. 
 Donations refers to the type of Contributions Given by the Company to a non-profit or Public Sector Organisation, that may or may not be for a
designated pre-defined initiative. 
 Employee or You(r) refers to all Company full-time and part-time directors, officers, employees and temporary
staff worldwide. 
 Engagement Owners refers to Employees responsible for engaging with and managing the Services provided by a Third Party. 

External Stakeholders refers to the category of Third Parties who are external customers and other relevant stakeholders, including Healthcare Professionals
(“HCPs”) and Healthcare Organisations (“HCOs”), Scientifically Trained Personnel engaged by the Company to provide Services, Public Officials, Patient Groups and other relevant public and private organisations and groups. 

A Facilitation Payment (or “grease” payment) is an unofficial payment or anything else of value Given to Public Officials (including HCPs and other
individuals employed by Public Sector Organisations) to secure or speed up routine actions that the recipient has a duty to perform. Examples include additional payments required to issue permits or licences, speed passage through immigration
controls and release goods held at port or in customs. 
 Fair Market Value refers to the amount that a service or item would be worth to a typical buyer who
is under no duty to purchase and who receives no special advantage. Fair Market Value is determined by the home country of the relevant service provider (who receives payment for the service) or relevant buyer of the item. 

Fellowships and Preceptorships refer to programmes conducted at host institutions and designed to provide basic training (i.e., training necessary to
obtain a degree or licence) or advanced education to HCPs or scientists in a particular specialty, therapeutic area or field of research. 
 Gift refers to an
Item of Value that is provided as a mark of appreciation, commemoration or friendship. 
 Give, Giving or Given means to directly or indirectly offer,
promise or give, or to authorise such actions. 
 Global Policies refers to the mandatory documents that support the Company’s Code of Conduct by
setting out the compliance commitments of the Company and the key principles to be followed to meet those commitments. 

  
 18 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Global Standards refers to the mandatory documents that support the Global Policies by describing the compliance
rules to be followed to deliver the intent stated in the Global Policies or in the Company’s Code of Conduct. 
 Guidelines refers to any of the
following materials and may or may not relate to a specific disease state: practice guidelines, treatment guidelines, medication algorithms, disease definitions or Research & Development quality standards. Guidelines are not intended to
refer to treatment guidelines or protocols developed by HCOs, where such development is essential to the business of the HCO (such as a formulary or benefit administrator), or those developed by HCP practices. 

Healthcare Professionals (“HCPs”) and Healthcare Organisations (“HCOs”) refer to individuals or organisations, respectively, who may
or do prescribe, administer, recommend, purchase, pay for, reimburse, authorise, approve or supply any Company Product or service, including any members of the medical, dental, pharmacy or nursing professions, and relevant associated administrative
staff; and/or hospitals and other care organisations, health plans, health insurers, managed care organisations, pharmacies, formulary or benefit administrators and clinical research organisations, and relevant staff at such entities. 

Hospitality refers to Meals, travel/accommodation, and other directly related, incidental expenses, as well as invitations or tickets to social or entertainment
events. Entertainment events include sporting, theatre, music or recreational events. 
 Interactions refers to the business and personal interactions and
activities described in this Policy. 
 Interacts refers to the conduct of an Interaction. 

Investigator Sponsored Study (ISS) refers to a clinical study that is independently initiated, designed and conducted by an external investigator (who assumes
both the sponsor and principal investigator role) or medical institution, collaborative research group or academic research organisation (which assumes the sponsor role and appoints principal investigator(s) for the study). For purposes of this
Policy, sponsor/investigator is used as a generic term for both situations described above. 
 Item of Medical Utility refers to an Item of Value primarily
designed to educate External Stakeholders or Patients or help External Stakeholders educate Patients about disease management in disease state areas relevant to Authorised Company Products or Uses. 

Items of Value refers to Gifts, Items of Medical Utility, items used to assist in screening or diagnosis of Patients, items linked to the safe and effective
administration of Company Products, logistical items, Samples (including Samples vouchers or coupons), awards and Patient Programmes. 
 Market Access refers
to discussions with HCOs (i.e., payers) or Public Officials about regulatory Authorisation, pricing or reimbursement decisions. 
 Market Research refers to
the systematic gathering and interpretation of quantitative or qualitative data on the market environment from External Stakeholders or Patients using statistical and analytical methods to gain insight and support decision-making. It does not
include the gathering and interpretation of “real world evidence” or Company-purchased HCP-level data. 
 Meals refers to food and/or beverages. 

Meeting refers to a planned gathering of External Stakeholders, which the Company organises or supports, either financially or non-financially. Non-financial
support includes in-kind assistance, such as resources, facilities or Employee time. Meetings may be for an internal Employee audience, or for an external audience of External Stakeholders and may be held in-person or virtually. 

  
 19 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Non-Interventional Study (NIS) refers, in general terms, to a study where the assignment of the Patient to a
particular therapeutic strategy is not decided in advance by a study protocol but falls within the HCP’s current practice, and the prescription of the Company Product is clearly separated from the decision to include the Patient in the study.

 Non-Promotional Activity refers to any activity that is not a Promotional Activity that is intended to provide scientific or educational information about
Company Products, relevant disease areas or health and medicines generally. Non-Promotional Activities may be oral or written and may be conducted through any medium, including the Internet. Non-Promotional Activities may take a number of forms,
including, but not limited to, leaflets provided with Company Products, point of sale information, information regarding disease awareness programmes, responses to queries from External Stakeholders or Patients, information provided to inform the
development of Guidelines or other information contributing to scientific exchange. 
 Non-Promotional Materials refers to materials intended to be used during
Non-Promotional Activities or to support Non-Promotional Activities. 
 Our or Company refers to AstraZeneca PLC and its consolidated legal entities
worldwide, including MedImmune. 
 Other Third Parties refers to the category of Third Parties who are not External Stakeholders or Patients, including, but not
limited to, the media, suppliers, distributors, agents and joint venture, co-promotion, research and licensing partners. 
 Partnerships refers to the type of
Contributions Given by the Company in collaboration with a non-profit, for-profit or Public Sector Organisation for a pre-defined initiative, involving substantive, active Company participation and resulting in the delivery of specific, measurable
outcomes. For purposes of this Policy, Partnerships do not include research or commercial collaborations aimed at the development or marketing of Company Products or services for the Company’s benefit. 

Patient Groups refers to non-profit organisations formally representing the needs of Patients, their families and other caregivers. 

Patient Programmes refers to Items of Value, specifically vouchers, rebates, coupons, co-pay assistance cards, motivational information and other programmes and
materials designed to increase access and affordability of Company Products or to enhance therapy compliance. 
 Patients refers to the category of Third
Parties who are members of the general public and who use or may use Company Products. 
 Payments for Voluntary or Incidental Activities refers to any
compensation or expense reimbursement Given to an individual or organisation as a “thank you” for voluntary activities or for activities that are not necessary to address a genuine business need. They do not include payments made to Third
Parties for contracted Services that address a genuine business need. 
 Policy refers to this AstraZeneca Global Policy on Ethical Interactions. 

Political Activities refers to attendance or participation in public policy or other political activities, including participation in political conventions or
fundraising events for Political Organisations or individual Public Officials and their causes. 
 Political Organisations refers to political parties and
their employees, Political Action Committees (“PACs”) and other political organisations. Political Support is distinct from Company Contributions to Public Sector Organisations (See Section 5), as well as payments to Public Officials
or Public Sector Organisations (See Sections 7 and 10). 

  
 20 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Political Support refers to financial or non-financial support (e.g., funds or in-kind assistance, such as
resources, facilities or Employee time) Given to Political Organisations or individual Public Officials and their causes. 
 Pre-Authorisation Activities
refers to Profiling, Market Access and Pre-Authorisation Training activities undertaken by Employees in preparation for Authorisation of a new Company Product or Use. 

Pre-Authorisation Training refers to Company-provided education to Representatives and/or their first line managers in preparation for Authorisation of a new
Company Product or Use. 
 Preceptorships and Fellowships refer to programmes conducted at host institutions and designed to provide basic training
(i.e., training necessary to obtain a degree or licence) or advanced education to HCPs or scientists in a particular specialty, therapeutic area or field of research. 

Presentation refers to each segment of a Meeting, where a distinct speaker is used and/or distinct topic is discussed. 

Presentation Materials refers to all materials intended to be shown and/or distributed to the speaker or audience before, during or after a Presentation,
including but not limited to speaker briefing documents, written summaries of Presentation objectives, slides and reference documents. 
 Profiling (also known
as “disease insight visits”) refers to discussions with External Stakeholders to gain an understanding of their involvement in a disease area, including therapeutic options, medical gaps, External Stakeholder needs or the needs of
Patients. For the avoidance of doubt, Profiling is not considered Market Research. 
 Promote, Promotion or Promotional refers to the conduct of
Promotional Activities. 
 Promotional Activity refers to any activity that is intended or could be seen to Promote the prescription, administration,
recommendation, purchase, payment, reimbursement, authorisation, approval, supply or use of Company Products or services. Promotional Activities may be oral or written and may be conducted through any medium, including the Internet. 

Promotional Materials refers to materials intended to be used during Promotional Activities or to support Promotional Activities. 

Promotional Speaker Programmes refers to Promotional Meetings organised by the Company to Promote Authorised Company Products or Uses, where the Company engages
External Stakeholders 
 (i.e., “Promotional Speakers”) to speak to other External Stakeholders on behalf of the Company about such topics. 

Promotional Speakers refers to the definition provided within the definition of Promotional Speaker Programmes. 

Public Official refers to an individual who: 

	•	 	Holds a legislative, administrative or judicial position of any kind, whether appointed or elected, or is a candidate for such a position, or 

	•	 	Exercises a public function for a country or territory of a country, or for any Public Sector Organisation of a country or territory, at the national, regional or local level, 

	•	 	Acts as an official or agent of an international Public Sector Organisation, or 

	•	 	Is any other employee (including HCPs) of a Public Sector Organisation. 

 Public Sector Organisation refers to an
agency, enterprise, or other entity of a government that sets or administers public policy or exercises executive, political and/or sovereign power through customs, 

  
 21 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
institutions and laws within a country or territory of a country, at the national, regional or local level. It also includes state-owned and state-controlled entities, such as a state-owned or
state-controlled hospital, university, energy company, telecommunications company or other similar state-owned or statecontrolled enterprises. 
 Receive,
Receiving or Received means to directly or indirectly solicit, agree to receive or accept, or to authorise such actions. 
 Relevant Procedures
refers to the written local and/or functional policies, standards, procedures and guidelines that contain details, processes and controls for compliance with this Policy and the supporting Global Standards. 

Representatives refers to Employees who are members of any Commercial channel who Promote Company Products directly to External Stakeholders. Representatives may
be referred to as sales representatives, service team associates, inside sales agents, medical representatives or other titles, depending upon the relevant local marketing organisation. Representatives include any Third Parties fulfilling such
responsibilities on the Company’s behalf (i.e., a contract sales force). Representatives do not include other Employees, such as those performing marketing or market access activities. 

Reviewers refers to the definition provided within the definition of Applicable Internal Review Procedures. 

Sample refers to an Item of Value, specifically a unit of pharmaceutical Company Product that is not to be sold but is provided free of charge to an HCP to allow
the HCP and appropriate Patients to determine tolerability and effectiveness of the Company Product. 
 Scientifically Trained Personnel refers to individuals
employed or engaged by the Company who are highly-trained experts, who have relevant, specialised scientific and/or medical knowledge and whose responsibilities include the provision of scientific and/or medical information. This excludes anyone in
the Sales, Marketing or other non-Medical Commercial functions, even if they have scientific or medical training or backgrounds. 
 Section refers to Sections
1 through 14 of this Policy, listed in the Table of Contents. Each Section covers a category of Interactions. 
 Services refers to the activities performed by
a Third Party engaged by the Company. Services include activities performed on behalf of the Company, goods, services or information provided to the Company, or the activities performed in collaboration with the Company. 

Sponsorships refers to the type of Contributions Given by the Company to a non-profit, for-profit or Public Sector Organisation for a pre-defined initiative,
where the Company’s name is associated with the initiative and/or the Company receives other substantial recognition for the Sponsorship. 
 Sympathy Gift
refers to a personal Gift to express sympathy for bereavement or serious illness of the recipient or immediate family member. 
 Third Party(ies) refers to
any person or organisation who is not the Company or an Employee, with whom Employees Interact. The various types of Third Parties are categorised as either External Stakeholders, Patients, or Other Third Parties. Where a Third Party fits into more
than one category, the more restrictive rules apply. 
 Uses refers to the indications, dosing, populations and other uses of Company Products. For purposes of
this Policy, references to Uses include both Authorised and Unauthorised Uses of Company Products, unless specifically noted. 

  
 22 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Unauthorised refers to a Company Product or Use that has not yet received Authorisation from the relevant local
regulatory agency. An Unauthorised Company Product may also be referred to as “investigational.” An Unauthorised Use (i.e., an “off-label use”) is inconsistent with the local approved labeling for a Company Product. 

Voluntary or Incidental Activities refers to any voluntary activities or activities that are not necessary to address a genuine business need. 

You(r) or Employee refers to all Company full-time and part-time directors, officers, employees and temporary staff worldwide. 

REFERENCES 
 Global Standard on Items of Value and Hospitality 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/effective/Global%20Standard/LDMS_001_00145832.pdf

 Global Standard on Contributions 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/effective/Global%20Standard/LDMS_001_00145831.pdf

 Global Procedure and Guidance Community Investment 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/effective/Procedure/LDMS_001_00146359.pdf

 Global Guidance for Product Donations 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/Active/Guidance%20Materials/LDMS_001_00146361.pdf

 Global Standard on Meetings 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/effective/Global%20Standard/LDMS_001_00145768.pdf

 Global Standard on Engaging Third Parties 

http://portalapps.is.astrazeneca.net/azgard-components/ldms-documents/Global_Compliance/effective/Global%20Standard/LDMS_001_00145830.pdf

  
 23 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit G 

Initial Members of the JSC 

AstraZeneca 
 Fouzia
Laghrissi Thode, Vice President, Global Product Portfolio Strategy 
 Elisabeth Björk, Global Product Vice President, Global Medicines
Development 
 Howard Hutchinson, Vice President for Product Licensing, Global Medicines Development 

Peter Honig, VP Global Regulatory Affairs, Global Regulatory Affairs 

David Snow, President, China & Hong Kong, Global Commercial 

AstraZeneca Secretariat: Joseph McCullough 

FibroGen 
 Frank Valone

 Peony Yu 
 Al Lin 

Michael Lowenstein 
 Chris Chung

 FibroGen Secretariat: Kirara Tsuboi 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule G (a) 

Until the date when the JDC has been formed, the JSC delegates the following responsibilities to the Core Joint Project Team. Unless otherwise directed by
the JSC, the Core JPT shall: 
 (i)        provide regular reports to
the JSC regarding the development of the Product, and discuss, prepare and submit to the JSC for approval annual and interim amendments to the Development Plan (and the Development Budget) for each Product; 

(ii)      discuss and manage the implementation of the Initial Development Plan; 

(iii)     discuss the audited final report from the Carcinogenicity Studies, including
whether or not a Technical Product Failure has occurred, and provide input thereon to the JSC; 

(iv)      propose to the JSC particular studies to be conducted; 

(v)       create, propose for JSC review and approval, and implement the
Development Strategy for Development in the Territory and the design of all Clinical Trials and Nonclinical Studies conducted under each Development Plan, including Phase 4 Clinical Trials; 

(vi)      create and propose the CMC related development plan for JSC review and
approval, and oversee any CMC related development activities according to the plan, e.g. stability studies or packaging development, as well as other activities to prepare for supply of drug substance and finished Product for Commercialization,
including to oversee the selection process for, and select (pursuant to Section 6.4), a contract manufacturer to be used by FibroGen for commercial supplies; 

(vii)     allocate budgeted resources and determine priorities for each Clinical Trial and
Nonclinical Study under each Development Plan, including Phase 4 Clinical Trials; 

(viii)    supervise, with regular oversight by the JSC, the conduct of all Clinical Trials and
Nonclinical Studies under each Development Plan, including Phase 4 Clinical Trials; 

(ix)      endorse the selection of Third Party contractors to conduct Clinical Trials of
Products; 
 (x)       facilitate, with regular oversight by the JSC, the flow of
Information between the Parties with respect to the Development of Products, including Development Data and Astellas Data pursuant to Section 3.10, as well as any other Information related to the Astellas Collaboration that has a material
impact on AstraZeneca’s rights under this Agreement; 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (xi)       discuss the priority of life
cycle management Development of Products for other indications and propose any such indications to the JSC; 

(xii)       propose to the JSC for approval allocation of primary responsibility as
between the Parties for tasks relating to Development of Products where not already specified in the Development Plan; 

(xiii)      discuss the requirements for Regulatory Approval in the Territory and
oversee and coordinate regulatory matters with respect to Products in the Territory, including to review and approve material regulatory filings (other than the filing of an NDA in the U.S., which shall be approved by the JSC) prior to submission
thereof; 
 (xiv)      propose to the JSC for approval and implement a publication
strategy for publications and presentations related to Products in the Territory and review and approve all such publications in accordance with Section 12.5, provided that the responsibilities under this subsection (xvi) with respect to a
certain Product shall transition from the JDC to the JCC following the first NDA approval of such Product in the U.S., the more precise timing of such transition to be mutually agreed by the Parties; 

(xv)       facilitate the flow of Information between the Parties with respect to
obtaining Regulatory Approval for Products; and 
 (xvi)      perform such other
functions as may be appropriate to further the purposes of this Agreement, as directed by the JSC. 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule G (b) 

Until the date when the JCC has been formed, the JSC delegates the following responsibilities to Core Joint Project Team. Unless otherwise
directed by the JSC, the Core JPT shall: 
 (xvii)   regularly report to the JSC regarding the
Commercialization of the Products, and discuss, prepare and submit for approval to the JSC the U.S. Commercialization Plan for each Product in the U.S., including any amendments thereto; 

(xviii)  coordinate the Commercialization activities of FibroGen and AstraZeneca with respect to Products,
including pre-launch and post-launch activities; 
 (xix)    propose to the JSC for approval the
allocation of primary responsibility as between the Parties for tasks relating to Commercialization of Products in the U.S.; 

(xx)     propose to the JSC for approval the amount of Product to be distributed free of
charge annually for regulatory or marketing purposes or investigator-initiated trials (it being understood and agreed that neither Party shall have the right to distribute the Product as samples except pursuant to Section 5.7); and 

(xxi)    perform such other functions as appropriate to further the purposes of this Agreement, as
directed by the JSC. 

  
 4 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit H 

FG-4592 Initial Development Plan 

[*] 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit I 

U.S. Co-Commercialization Terms 

Unless the Parties agree in writing upon an alternate allocation of responsibility, the Parties shall have the following
rights and obligations with respect to the operational responsibilities for the Commercialization of Products in the U.S. under each U.S. Commercialization Plan, under the direction of the JCC as specified in Section 2.4 and Article 5. 

[*] 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit J 

Development Supply Terms 
 The supply from
FibroGen to AstraZeneca, or to FibroGen internally where FibroGen has been assigned (either by the JDC or under the terms of the Agreement) the lead responsibility for the conduct of a Clinical Trial for which the supply is intended, shall include
those GMP quantities of Product, and those development activities, in either case, approved by the JDC. As of the Effective Date, the JDC has not been convened. Therefore, the Parties have agreed that the following provisions shall govern the
manufacture and delivery of the supplies necessary to conduct the Clinical Trials under the Development Plan. 
 FibroGen shall manufacture and supply an
appropriate amount (currently estimated at up to approximately 3 million units of Product (i.e. 3 million tablets of active drug) and approximately 1.5 million tablets of placebo) for the conduct of the Phase 3 Clinical Trials
sponsored by AstraZeneca as well as the amount required to support FibroGen’s studies and regulatory submissions. The Parties shall agree upon more exact quantities as soon as possible. Such unit numbers shall include varying drug strengths for
the Clinical Trials and shall be delivered at least four (4) months ahead of the start of the Clinical Trials, subject to Section 6.2. 
 FibroGen
shall continue its already started development of a solid formulation, e.g. tablet, aimed at enabling attributes such as commercially viable shelf-life and use of standard primary packages, a dosage unit size to enable an attractive intake by
patients as well as deemed possible to manufacture by conventional manufacturing technology in a cost effective manner and that does not reduce the clinical effectiveness or increase a hypothetical adverse event profile of the Product. FibroGen
shall initiate in vivo testing as needed and according to timelines agreed by the JDC. 
 The supplies and activities set forth in this Exhibit J may
be amended from time to time by the JDC or the JSC. 
 FibroGen shall report the progress of the items listed above to AstraZeneca’s appointed
Pharmaceutical Development contacts on a regular and reasonable basis. FibroGen shall also consult AstraZeneca prior to making any critical decisions with material impact on further development, e.g. choice of solid state form, particle size control
methodology, choice of excipients, process technology and packaging materials, stability testing protocols, quality specifications and analytical testing methodology, choice of starting materials and sourcing. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit K 

Main Terms for Supply Agreement and Quality Agreement 

The Supply Agreement (“SA”) and Quality Agreement (“QA”) referenced at Section 6.3 of the Agreement
shall contain the following main terms and conditions. Capitalized terms used but not defined in this Exhibit K shall have the meaning ascribed to such terms in the Agreement. 

Supply 
  

	—	 	Effective Date of SA/QA: The SA and the QA will provide for an effective date which is earlier than the execution date, in case supply of Product is required prior to execution of the SA and the QA.

  

	—	 	Conflict:  In the event of a conflict between the Agreement and the SA or the QA, the SA once executed will control with respect to supply matters, and the QA, once executed, will control with respect
to quality matters. 

  

	—	 	Forecasting, Ordering and Delivery: Terms relating to forecasting and ordering shall be set forth in the SA. The Parties shall agree and include in the SA, a mechanism for defining the lead-times for all Products
ordered by AstraZeneca. Delivery of Product shall be EXW INCOTERMS 2010 to an address specified by AstraZeneca. Title shall pass to AstraZeneca on delivery to AstraZeneca or its designee. 

 

	—	 	Failure to Supply:  The SA will include remedies and other consequences for supply failure (to be defined in the SA) including: (i) rights for AstraZeneca to access relevant information in the
possession of FibroGen and its affiliates relating to the manufacturing processes for the Product; and (ii) rights for AstraZeneca to contact FibroGen’s suppliers (including suppliers of the active pharmaceutical ingredient for the
Product), both (i) and (ii) to assess the feasibility of (including contracting with) such suppliers manufacturing and supplying the Product to AstraZeneca, solely in the event of a supply failure by FibroGen. 

 

	—	 	Insurance and Risk:  The agreement will contain provisions requiring FibroGen to maintain insurance coverage of the types and in the amounts typically carried by providers of manufacturing services in
the pharmaceutical or chemical area. FibroGen shall bear the risk of loss of materials (including API) and Product while within FibroGen’s or its subcontractor’s control. 

 

	—	 	Subcontractors:  FibroGen may engage subcontractors (“Subcontractors”) that meet the quality standards agreed by the Parties. No such subcontract shall release FibroGen from any of its
obligations under the SA or the QA except to the extent such obligations are satisfactorily performed by such Subcontractor in accordance with the SA and the QA. To the extent that AstraZeneca has genuine concerns and can demonstrate with reasonable
documentation to FibroGen the basis for its concern with respect to the performance of the work for which the Subcontractor is to be engaged, the choice of such Subcontractor shall be subject to AstraZeneca’s approval. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	—	 	Formulation:  In the event the Parties decide that AstraZeneca will carry out formulation of the Product, such activities will be included in the SA and any applicable terms will be added to the SA to
account for AstraZeneca’s role in the formulation activities. 

  

	—	 	Non-Conforming Product:  The agreement will contain provisions relating to the determination and replacement of nonconforming product and the use of a Third Party testing laboratory to resolve disputes
relating to nonconforming product. 

  

	—	 	Shortfalls: The SA will include consequences relating to any failure or inability to supply full quantities of Product in compliance with the applicable product specifications ordered by AstraZeneca, including an
obligation that in the event of a shortage, FibroGen will allocate an amount of its remaining manufacturing capacity in an equitable manner to be set forth in the Supply Agreement. 

 

	—	 	Pricing and Payment:  The pricing provisions set out in Section 6.5 of the Agreement shall be incorporated into the terms of the SA. AstraZeneca shall pay invoices in accordance with the terms set
forth in the Agreement. 

  

	—	 	Legal and Regulatory Requirements:  Appropriate provisions shall be included in the SA to ensure that each Party complies with all relevant local, national and international legal or regulatory
requirements and other relevant requirements applicable to the manufacture, handing, transport and storage of all Products at all times. 

  

	—	 	Governance:  The SA will include governance and reporting provisions specific to the manufacturing activities, which governance provisions will be designed to provide AstraZeneca transparency into the
activities under such agreement, including subcontracting and CMO arrangements, and to facilitate effective management of the supply chain. 

  

	—	 	Health and Safety:  FibroGen shall be wholly accountable and liable for the safety, health and environmental aspects of all work performed on its or any of its subcontractor’s premises.

  

	—	 	AstraZeneca Policies:  The SA will include provisions required to comply with applicable AstraZeneca standard policies, including with respect to responsible procurement, product security and waste
handling. 

  

	—	 	Document Retention:  Appropriate provisions shall be included in the SA with regard to maintaining appropriate documentation for patent and regulatory purposes and in full compliance with all
applicable laws. 

  

	—	 	Technology Transfer:  The technology transfer provisions in the Agreement will remain in effect during the term of the SA (and any post-expiration or termination supply period, as described above in
Section 13.6(e) or (g)), even after the Agreement has terminated or expired. 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	—	 	Liability and Indemnity:  The SA will include provisions relating to liability and indemnification that are consistent with the principles of allocation of liability described in the Agreement.

  

	—	 	Warranties:  FibroGen will be required to provide customary representations and warranties within the SA, including (but not limited to) as to the following: 

(a)        that it has full power and authority, and has taken all necessary actions and has obtained
all necessary authorizations, licenses, consents and approvals required, to execute and perform the SA, and 

(b)        that its retention as a supplier by AstraZeneca and its performance of the SA do not, and
shall not, breach any agreement with any other third party. 
  

	—	 	Generally: 

  

	 	o	The SA shall include such terms as are reasonable and customary for similar supply agreements. 

  

	 	o	Each of the Parties agree and acknowledge that the SA will contain a number of provisions which shall be consistent with provisions in the body of the Agreement, including Confidentiality, Assignment, Governing Law and
Dispute Resolution. 

 Quality 
  

	—	 	General:  A Quality Agreement shall be negotiated in good faith between the Parties and shall include all appropriate provisions as would normally be contained in such an agreement. Any breach of the QA
shall be deemed a breach of the SA. 

  

	—	 	The QA shall include: 

  

	 	o	Notice to AstraZeneca of inspections by regulatory authorities and access to such inspections 

  

	 	o	Notice to AstraZeneca of and access to all investigations concerning the manufacture of Products 

  

	 	o	Provision by FibroGen of documentation required by AstraZeneca 

  

	 	o	Maintenance of a change control system which allows for the pre-approval of major changes 

  

	 	o	Rights for AstraZeneca to conduct quality audits on FibroGen or any Subcontractor 

  

	 	o	Agreed procedures on a product recall 

  

	—	 	Each of the Parties agrees and acknowledges that the Products must satisfy appropriate specifications and associated tests, details of which shall be set out in the QA, and a mechanism for handling any defective
products shall be agreed and included in the QA. 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit L 

Invoicing Requirements 

Subject to any separate instructions to be agreed between the Parties regarding payments to health care professionals or health care
organizations in the Territory, as required by applicable laws and regulations, invoices should be sent to: 
  

AstraZeneca AB 
 AstraZeneca
R&D Mölndal 
 Att. Christina Wågestrand 

CVGI iMed Strategy 
 431 83
Mölndal 
 Sweden 

Invoices shall contain the following information: 
  

	 	a.	 AstraZeneca’s Agreement ID: Elisabeth Björk, Global Product Vice President, Global Medicines Development, ECHO Project ID 10007956

	 	b.	 the number and date of invoice 

	 	c.	 the latest date of payment according to Agreement 

	 	d.	 description of services 

	 	e.	 name and address of FibroGen, Inc. 

	 	f.	 FibroGen, Inc. VAT registration number or EIN/TaxID, 

	 	g.	 AstraZeneca’s VAT registration number SE556011748201 (in EC), 

	 	h.	 VAT rate (%), if any, 

	 	i.	 taxable amount per VAT rate, if any, 

	 	j.	 VAT amount, if any 

	 	k.	 legal reference or explanation when VAT is excluded, 

	 	l.	 invoice amount and currency, 

	 	m.	 bank details, preferably IBAN code, otherwise account number and bank code, and 

	 	n.	 SWIFT-address. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit M 

Patents that may be Extended 

[*]. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit N 

ASTRAZENECA AND FIBROGEN COLLABORATE TO DEVELOP AND 

COMMERCIALISE FG-4592, A TREATMENT FOR ANAEMIA IN 

CHRONIC KIDNEY DISEASE AND END-STAGE RENAL DISEASE 

Collaboration to include US, China and selected other markets 

31 July 2013 
 AstraZeneca and FibroGen
today announced that they have entered into a strategic collaboration to develop and commercialise FG-4592, a first-in-class oral compound in late stage development for the treatment of anaemia associated with chronic kidney disease (CKD) and
end-stage renal disease (ESRD). 
 This broad collaboration focuses on the US, China and all major markets excluding Japan, Europe, the Commonwealth of
Independent States, the Middle East and South Africa, which are covered by an existing agreement between FibroGen and Astellas Pharma Inc. The AstraZeneca-FibroGen joint effort will be focused on the development of FG-4592 to treat anaemia in CKD
and ESRD, and may be extended to other anaemia indications. 
 FG-4592 is a small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase.
HIF is a protein that responds to oxygen changes in the cellular environment and meets the body’s demands for oxygen by inducing erythropoiesis, the process by which red blood cells are produced. FG-4592 has the potential to address the
considerable unmet medical need for an effective treatment for anaemia that offers the convenience of oral administration and an improved safety profile as compared to current standards of care. At present, treatment options involve a combination of
injectable erythropoiesis-stimulating agents (ESAs) and iron supplements. FG-4592 works through the body’s natural oxygen-sensing and response system to help produce red blood cells. This can be compared to the body’s natural response
to conditions at high altitude, where oxygen levels are low, which is to produce more red blood cells. 
 In Phase II clinical studies, FG-4592 met its primary objective of demonstrating anaemia correction in treatment-naïve CKD patients not on dialysis as well as maintenance of haemoglobin levels and anaemia correction in patients on dialysis. FG-4592 has demonstrated this efficacy combined with an acceptable safety profile in clinical trials, and has been shown to achieve anaemia correction in the absence of intravenous iron
supplementation. 
 The companies plan to undertake an extensive FG-4592 phase III development programme for the US, and to initiate phase III trials in
China, with anticipated regulatory filings in China in 2015 and in the US in 2017. 
 AstraZeneca will pay FibroGen committed upfront and subsequent
non-contingent payments totalling $350 million, as well as potential future development related milestone payments of up to $465 million, and potential future sales related milestone payments in addition to tiered royalty payments on future sales on
FG-4592 in the low 20% range. Additional development milestones will be payable for any subsequent indications which the companies choose to pursue. 

  
 1 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
AstraZeneca will be responsible for the US commercialisation of FG-4592, with FibroGen undertaking specified promotional activities in the ESRD segment in this market. The companies will also
co-commercialise FG-4592 in China where FibroGen will be responsible for clinical trials, regulatory matters, manufacturing and medical affairs, and AstraZeneca will oversee promotional activities and commercial distribution. 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our collaboration with FibroGen on FG-4592 is an important addition to AstraZeneca’s
growing late-stage portfolio in cardiovascular and metabolic disease, one of our core therapy areas. We know from our research into complications of renal disease that anaemia continues to be a challenge for patients with chronic kidney disease, due
in part to the inconvenience and complexity of existing injectable and intravenous therapies and the safety concerns associated with them. The science behind this compound is compelling. Through our collaboration with FibroGen we aim to offer a
first-in-class, convenient treatment option for doctors and patients.” 
 Thomas B. Neff, Chief Executive Officer, FibroGen, said: “FG-4592 has the
potential to offer anaemia patients an oral therapy that provides coordinated erythropoiesis, that increases natural erythropoietin within the normal physiological range, and that is effective without intravenous iron supplementation and without an
increased risk for hypertension. We are especially pleased that AstraZeneca will share our commitment to making China the first-to-launch country for FG-4592 and join our effort to bring important innovation in anaemia therapy to CKD and ESRD
patients in the US and other countries. This agreement secures proper development and commercialisation resources for FG-4592, and ensures US clinical trial efforts are fully funded.” 

– ENDS – 
 NOTES TO EDITORS 

About chronic kidney disease and anaemia 
 Diabetes, high
blood pressure, and other conditions can cause significant damage to the kidneys. If left untreated, those can result in chronic kidney disease and progress to kidney failure. Such deterioration can lead to patients needing a kidney transplant or
being placed on dialysis to remove excess fluid and toxins that build up in the body. The progression of CKD also increases the prevalence of anaemia, a condition associated with having fewer of the red blood cells that carry oxygen through the
body, and/or lower levels of haemoglobin, the protein that enables red blood cells to carry oxygen. As haemoglobin falls, the lower oxygen-carrying capacity of an anaemic patients’ blood results in various symptoms including fatigue, loss of
energy, breathlessness, and angina. Anaemia in CKD patients has been associated with increased hospitalisation rates, increased mortality, and reduced quality of life. 

CKD is a worldwide critical healthcare problem that affects millions of people and drives significant healthcare cost. In the US, prevalence of CKD has
increased dramatically in the past 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
20 years, from 10% of the adult population (or approximately 20 million US adults) as stated in the National Health and Nutrition Evaluation Survey (NHANES) 1988-1994, to 15% (or
approximately 30 million adults) in NHANES 2003-2006. In 2009, total Medicare costs for CKD patients were $34 billion. China has an estimated 125 million CKD patients, or 5 times the number of CKD patients in the US [Lancet April
2012]. 
 About FG-4592 
 FG-4592 is an orally
administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity, in development for the treatment of anaemia in patients with chronic kidney disease (CKD). HIF is a protein transcription factor that induces the
natural physiological response to conditions of low oxygen, “turning on” erythropoiesis (the process by which red blood cells are produced) and other protective pathways. FG-4592 has been shown to correct anaemia and maintain haemoglobin
levels without the need for supplementation with intravenous iron in CKD patients not yet receiving dialysis and in end-stage renal disease patients receiving dialysis. An Independent Data Monitoring Committee has found no signals or trends to date
to suggest that treatment with FG-4592 is associated with increased risk of cardiovascular events, thrombosis, or increases in blood pressure requiring initiation or intensification of antihypertensive medications. 

Under a licensing agreement between FibroGen, Inc. and Astellas Pharma Inc., Astellas is developing FG-4592 for the treatment of anaemia in CKD and ESRD
patients in Europe, Japan, the Commonwealth of Independent States, the Middle East, and South Africa. 
 About FibroGen 

FibroGen, Inc., is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of
fibrosis, anaemia, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 monoclonal antibody is in early-stage clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including
pancreatic cancer and liver fibrosis, and FG-4592 is a small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anaemia. FibroGen is also currently pursuing the use of
proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness. For more information please visit: www.fibrogen.com 

About AstraZeneca 
 AstraZeneca is a global, innovation-driven
biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and
neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 CONTACTS 
  

			
	Media Enquiries	  	
	  
 Ayesha Bharmal
	  	 +44 20 7604 8034 (UK/Global)

	 Esra Erkal-Paler
	  	 +44 20 7604 8030 (UK/Global)

	 Vanessa Rhodes
	  	 +44 20 7604 8037 (UK/Global)

	 Michele Meixell
	  	 +1 302 885 2677 (US)

	 Jacob Lund
	  	 +46 8 553 260 20 (Sweden)

		
	Investor Enquiries	  	
	  
 Ed Seage
	  	 +1 302 373 1361

	 Colleen Proctor
	  	 +1 302 357 4882

  
 4 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]